<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:72.8pt;left:39.8pt;line-height:6.0pt"><span style="font-family:SourceSansPro,serif;font-size:6.0pt">See discussions, stats, and author profiles for this publication at: </span><span style="font-family:SourceSansPro,serif;font-size:6.0pt;color:#3773a1">https://www.researchgate.net/publication/279966161</span></p>
<p style="top:94.1pt;left:39.8pt;line-height:13.3pt"><span style="font-family:Martel,serif;font-size:13.3pt">Enhanced analgesic activity by cyclodextrins - A systematic review and meta-</span></p>
<p style="top:112.6pt;left:39.8pt;line-height:13.3pt"><span style="font-family:Martel,serif;font-size:13.3pt">analysis</span></p>
<p style="top:145.8pt;left:39.8pt;line-height:6.6pt"><b><span style="font-family:SourceSansPro,serif;font-size:6.6pt;color:#212121">Article</span></b><span style="font-family:SourceSansPro,serif;font-size:6.6pt">&#xa0;&#xa0;</span><i><span style="font-family:SourceSansPro,serif;font-size:6.6pt;color:#606060">in</span></i><span style="font-family:SourceSansPro,serif;font-size:6.6pt">&#xa0;&#xa0;</span><span style="font-family:SourceSansPro,serif;font-size:6.6pt;color:#333333">Expert Opinion on Drug Delivery &#xb7; July 2015</span></p>
<p style="top:157.3pt;left:39.8pt;line-height:4.6pt"><span style="font-family:SourceSansPro,serif;font-size:4.6pt;color:#545454">DOI: 10.1517/17425247.2015.1046835&#xa0;&#xb7;&#xa0;Source: PubMed</span></p>
<p style="top:189.2pt;left:39.8pt;line-height:5.3pt"><span style="font-family:SourceSansPro,serif;font-size:5.3pt;color:#333333">CITATIONS</span></p>
<p style="top:197.7pt;left:39.8pt;line-height:8.0pt"><span style="font-family:SourceSansPro,serif;font-size:8.0pt">56</span></p>
<p style="top:189.2pt;left:297.5pt;line-height:5.3pt"><span style="font-family:SourceSansPro,serif;font-size:5.3pt;color:#333333">READS</span></p>
<p style="top:197.7pt;left:297.5pt;line-height:8.0pt"><span style="font-family:SourceSansPro,serif;font-size:8.0pt">425</span></p>
<p style="top:224.0pt;left:39.8pt;line-height:6.6pt"><b><span style="font-family:SourceSansPro,serif;font-size:6.6pt;color:#212121">5 authors</span></b><span style="font-family:SourceSansPro,serif;font-size:6.6pt;color:#333333">, including:</span></p>
<p style="top:379.0pt;left:39.8pt;line-height:6.6pt"><b><span style="font-family:SourceSansPro,serif;font-size:6.6pt;color:#212121">Some of the authors of this publication are also working on these related projects:</span></b></p>
<img style="position:absolute;transform:matrix(.11043058,0,-0,.11043058,-89.324428,383.31849)" src="data:image/png;base64,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">
<p style="top:405.5pt;left:78.2pt;line-height:6.6pt"><span style="font-family:SourceSansPro,serif;font-size:6.6pt;color:#333333">Vitiligo</span><span style="font-family:SourceSansPro,serif;font-size:8.0pt"> </span><span style="font-family:SourceSansPro,serif;font-size:6.6pt;color:#3773a1">View project</span></p>
<img style="position:absolute;transform:matrix(.11043058,0,-0,.11043058,-89.324428,423.0735)" src="data:image/png;base64,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">
<p style="top:435.3pt;left:78.2pt;line-height:6.6pt"><span style="font-family:SourceSansPro,serif;font-size:6.6pt;color:#333333">Phytol, a alcohol diterpene derived from chlorophyll A, attenuates adjuvant-induced arthritis in mice</span><span style="font-family:SourceSansPro,serif;font-size:8.0pt"> </span><span style="font-family:SourceSansPro,serif;font-size:6.6pt;color:#3773a1">View project</span></p>
<img style="position:absolute;transform:matrix(.41411469,0,-0,.41411469,34.258348,302.82554)" src="data:image/jpeg;base64,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">
<p style="top:241.8pt;left:66.3pt;line-height:6.6pt"><span style="font-family:SourceSansPro,serif;font-size:6.6pt;color:#3773a1">Renan Brito</span></p>
<p style="top:252.4pt;left:66.3pt;line-height:6.6pt"><span style="font-family:SourceSansPro,serif;font-size:6.6pt;color:#212121">Universidade Tiradentes</span></p>
<p style="top:264.9pt;left:66.3pt;line-height:6.0pt"><b><span style="font-family:SourceSansPro,serif;font-size:6.0pt">44</span></b><span style="font-family:SourceSansPro,serif;font-size:6.6pt"> </span><span style="font-family:SourceSansPro,serif;font-size:5.3pt;color:#333333">PUBLICATIONS</span><span style="font-family:SourceSansPro,serif;font-size:6.6pt">&#xa0;&#xa0;&#xa0;</span><b><span style="font-family:SourceSansPro,serif;font-size:6.0pt">815</span></b><span style="font-family:SourceSansPro,serif;font-size:6.6pt"> </span><span style="font-family:SourceSansPro,serif;font-size:5.3pt;color:#333333">CITATIONS</span><span style="font-family:SourceSansPro,serif;font-size:6.6pt">&#xa0;&#xa0;&#xa0;</span></p>
<p style="top:281.3pt;left:73.5pt;line-height:5.3pt"><span style="font-family:SourceSansPro,serif;font-size:5.3pt;color:#333333">SEE PROFILE</span></p>
<img style="position:absolute;transform:matrix(.41411469,0,-0,.41411469,377.9183,302.82554)" src="data:image/jpeg;base64,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">
<p style="top:241.8pt;left:324.0pt;line-height:6.6pt"><span style="font-family:SourceSansPro,serif;font-size:6.6pt;color:#3773a1">Adriano A S Ara&#xfa;jo</span></p>
<p style="top:252.4pt;left:324.0pt;line-height:6.6pt"><span style="font-family:SourceSansPro,serif;font-size:6.6pt;color:#212121">Universidade Federal de Sergipe</span></p>
<p style="top:264.9pt;left:324.0pt;line-height:6.0pt"><b><span style="font-family:SourceSansPro,serif;font-size:6.0pt">233</span></b><span style="font-family:SourceSansPro,serif;font-size:6.6pt"> </span><span style="font-family:SourceSansPro,serif;font-size:5.3pt;color:#333333">PUBLICATIONS</span><span style="font-family:SourceSansPro,serif;font-size:6.6pt">&#xa0;&#xa0;&#xa0;</span><b><span style="font-family:SourceSansPro,serif;font-size:6.0pt">5,835</span></b><span style="font-family:SourceSansPro,serif;font-size:6.6pt"> </span><span style="font-family:SourceSansPro,serif;font-size:5.3pt;color:#333333">CITATIONS</span><span style="font-family:SourceSansPro,serif;font-size:6.6pt">&#xa0;&#xa0;&#xa0;</span></p>
<p style="top:281.3pt;left:331.3pt;line-height:5.3pt"><span style="font-family:SourceSansPro,serif;font-size:5.3pt;color:#333333">SEE PROFILE</span></p>
<img style="position:absolute;transform:matrix(.41411469,0,-0,.41411469,34.258348,386.75279)" src="data:image/jpeg;base64,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">
<p style="top:304.8pt;left:66.3pt;line-height:6.6pt"><span style="font-family:SourceSansPro,serif;font-size:6.6pt;color:#3773a1">Jullyana Quintans</span></p>
<p style="top:315.4pt;left:66.3pt;line-height:6.6pt"><span style="font-family:SourceSansPro,serif;font-size:6.6pt;color:#212121">Universidade Federal de Sergipe</span></p>
<p style="top:327.8pt;left:66.3pt;line-height:6.0pt"><b><span style="font-family:SourceSansPro,serif;font-size:6.0pt">202</span></b><span style="font-family:SourceSansPro,serif;font-size:6.6pt"> </span><span style="font-family:SourceSansPro,serif;font-size:5.3pt;color:#333333">PUBLICATIONS</span><span style="font-family:SourceSansPro,serif;font-size:6.6pt">&#xa0;&#xa0;&#xa0;</span><b><span style="font-family:SourceSansPro,serif;font-size:6.0pt">4,592</span></b><span style="font-family:SourceSansPro,serif;font-size:6.6pt"> </span><span style="font-family:SourceSansPro,serif;font-size:5.3pt;color:#333333">CITATIONS</span><span style="font-family:SourceSansPro,serif;font-size:6.6pt">&#xa0;&#xa0;&#xa0;</span></p>
<p style="top:344.3pt;left:73.5pt;line-height:5.3pt"><span style="font-family:SourceSansPro,serif;font-size:5.3pt;color:#333333">SEE PROFILE</span></p>
<img style="position:absolute;transform:matrix(.41411469,0,-0,.41411469,377.9183,386.75279)" src="data:image/jpeg;base64,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">
<p style="top:304.8pt;left:324.0pt;line-height:6.6pt"><span style="font-family:SourceSansPro,serif;font-size:6.6pt;color:#3773a1">Kathleen Sluka</span></p>
<p style="top:315.4pt;left:324.0pt;line-height:6.6pt"><span style="font-family:SourceSansPro,serif;font-size:6.6pt;color:#212121">University of Iowa</span></p>
<p style="top:327.8pt;left:324.0pt;line-height:6.0pt"><b><span style="font-family:SourceSansPro,serif;font-size:6.0pt">349</span></b><span style="font-family:SourceSansPro,serif;font-size:6.6pt"> </span><span style="font-family:SourceSansPro,serif;font-size:5.3pt;color:#333333">PUBLICATIONS</span><span style="font-family:SourceSansPro,serif;font-size:6.6pt">&#xa0;&#xa0;&#xa0;</span><b><span style="font-family:SourceSansPro,serif;font-size:6.0pt">22,567</span></b><span style="font-family:SourceSansPro,serif;font-size:6.6pt"> </span><span style="font-family:SourceSansPro,serif;font-size:5.3pt;color:#333333">CITATIONS</span><span style="font-family:SourceSansPro,serif;font-size:6.6pt">&#xa0;&#xa0;&#xa0;</span></p>
<p style="top:344.3pt;left:331.3pt;line-height:5.3pt"><span style="font-family:SourceSansPro,serif;font-size:5.3pt;color:#333333">SEE PROFILE</span></p>
<p style="top:803.7pt;left:43.1pt;line-height:6.6pt"><span style="font-family:SourceSansPro,serif;font-size:6.6pt">All content following this page was uploaded by </span><span style="font-family:SourceSansPro,serif;font-size:6.6pt;color:#3773a1">Adriano A S Ara&#xfa;jo</span><span style="font-family:SourceSansPro,serif;font-size:6.6pt"> on 03 August 2015.</span></p>
<p style="top:820.0pt;left:43.1pt;line-height:5.3pt"><span style="font-family:SourceSansPro,serif;font-size:5.3pt">The user has requested enhancement of the downloaded file.</span></p>


<p style="top:148.8pt;left:81.4pt;line-height:8.0pt"><span style="font-family:AdvP6A46,serif;font-size:8.0pt">1.</span></p>
<p style="top:148.8pt;left:98.7pt;line-height:8.0pt"><span style="font-family:AdvP6A46,serif;font-size:8.0pt">Introduction</span></p>
<p style="top:163.8pt;left:81.4pt;line-height:8.0pt"><span style="font-family:AdvP6A46,serif;font-size:8.0pt">2.</span></p>
<p style="top:163.8pt;left:98.7pt;line-height:8.0pt"><span style="font-family:AdvP6A46,serif;font-size:8.0pt">Methods</span></p>
<p style="top:178.7pt;left:81.4pt;line-height:8.0pt"><span style="font-family:AdvP6A46,serif;font-size:8.0pt">3.</span></p>
<p style="top:178.7pt;left:98.7pt;line-height:8.0pt"><span style="font-family:AdvP6A46,serif;font-size:8.0pt">Results</span></p>
<p style="top:193.7pt;left:81.4pt;line-height:8.0pt"><span style="font-family:AdvP6A46,serif;font-size:8.0pt">4.</span></p>
<p style="top:193.7pt;left:98.7pt;line-height:8.0pt"><span style="font-family:AdvP6A46,serif;font-size:8.0pt">Discussion</span></p>
<p style="top:208.6pt;left:81.4pt;line-height:8.0pt"><span style="font-family:AdvP6A46,serif;font-size:8.0pt">5.</span></p>
<p style="top:208.6pt;left:98.7pt;line-height:8.0pt"><span style="font-family:AdvP6A46,serif;font-size:8.0pt">Conclusion</span></p>
<p style="top:223.6pt;left:81.4pt;line-height:8.0pt"><span style="font-family:AdvP6A46,serif;font-size:8.0pt">6.</span></p>
<p style="top:223.6pt;left:98.7pt;line-height:8.0pt"><span style="font-family:AdvP6A46,serif;font-size:8.0pt">Expert opinion</span></p>
<p style="top:42.1pt;left:515.5pt;line-height:15.9pt"><span style="font-family:AdvP45A506,serif;font-size:15.9pt">Review</span></p>
<p style="top:77.2pt;left:241.3pt;line-height:19.9pt"><span style="font-family:AdvP4B06EF,serif;font-size:19.9pt">Enhanced analgesic activity by</span></p>
<p style="top:101.1pt;left:241.3pt;line-height:19.9pt"><span style="font-family:AdvP4B06EF,serif;font-size:19.9pt">cyclodextrins</span><span style="font-family:AdvP4C4E59,serif;font-size:19.9pt"> --</span><span style="font-family:AdvP4B06EF,serif;font-size:19.9pt"> a systematic</span></p>
<p style="top:125.1pt;left:241.3pt;line-height:19.9pt"><span style="font-family:AdvP4B06EF,serif;font-size:19.9pt">review and meta-analysis</span></p>
<p style="top:156.5pt;left:241.3pt;line-height:10.5pt"><span style="font-family:AdvP5D8B,serif;font-size:10.5pt">Renan G Brito, Adriano AS Ara</span><span style="font-family:AdvP4C4E59,serif;font-size:10.5pt">&#xfffd;</span><span style="font-family:AdvP5D8B,serif;font-size:10.5pt">ujo, Jullyana SS Quintans,</span></p>
<p style="top:168.5pt;left:241.3pt;line-height:10.5pt"><span style="font-family:AdvP5D8B,serif;font-size:10.5pt">Kathleen A Sluka &amp; Lucindo J Quintans-J</span><span style="font-family:AdvP4C4E59,serif;font-size:10.5pt">&#xfffd;</span><span style="font-family:AdvP5D8B,serif;font-size:10.5pt">unior</span><sup><span style="font-family:AdvTIR,serif;font-size:7.4pt">&#x2020;</span></sup></p>
<p style="top:180.3pt;left:241.3pt;line-height:6.0pt"><span style="font-family:AdvTIR,serif;font-size:6.0pt">&#x2020;</span><span style="font-family:AdvP92E7,serif;font-size:8.5pt">Federal University of Sergipe, Department of Physiology, Sergipe, Brazil</span></p>
<p style="top:203.5pt;left:241.3pt;line-height:9.0pt"><span style="font-family:AdvP6A55,serif;font-size:9.0pt">Introduction:</span><span style="font-family:AdvP6A46,serif;font-size:9.0pt"> Analgesics can be ineffective in treating some types of pain,</span></p>
<p style="top:216.0pt;left:241.3pt;line-height:9.0pt"><span style="font-family:AdvP6A46,serif;font-size:9.0pt">hence, improved drug delivery systems could optimize their efficacy.</span></p>
<p style="top:228.4pt;left:241.3pt;line-height:9.0pt"><span style="font-family:AdvP6A55,serif;font-size:9.0pt">Area covered:</span><span style="font-family:AdvP6A46,serif;font-size:9.0pt"> The authors conducted a systematic review to evaluate the</span></p>
<p style="top:240.9pt;left:241.3pt;line-height:9.0pt"><span style="font-family:AdvP6A46,serif;font-size:9.0pt">analgesic activity of compounds complexed in cyclodextrins, analyzing</span></p>
<p style="top:253.3pt;left:241.3pt;line-height:9.0pt"><span style="font-family:AdvP6A46,serif;font-size:9.0pt">whether these complexes improved analgesic efficacy. The search terms</span></p>
<p style="top:265.8pt;left:241.3pt;line-height:9.0pt"><span style="font-family:AdvP6A46,serif;font-size:9.0pt">&#x2018;analgesics&#x2019;, &#x2018;cyclodextrins&#x2019; and &#x2018;drug effects&#x2019; were used to retrieve articles</span></p>
<p style="top:278.2pt;left:241.3pt;line-height:9.0pt"><span style="font-family:AdvP6A46,serif;font-size:9.0pt">in SCOPUS, PUBMED and EMBASE. A total of 22 papers were identified. In</span></p>
<p style="top:290.7pt;left:241.3pt;line-height:9.0pt"><span style="font-family:AdvP6A46,serif;font-size:9.0pt">the clinical studies, there was greater efficacy in the complexed drug when</span></p>
<p style="top:303.2pt;left:241.3pt;line-height:9.0pt"><span style="font-family:AdvP6A46,serif;font-size:9.0pt">compared with control groups, with differences ranging from 25 to 83%.</span></p>
<p style="top:315.6pt;left:241.3pt;line-height:9.0pt"><span style="font-family:AdvP6A46,serif;font-size:9.0pt">Through a meta-analysis, the preclinical studies showed that the complexed</span></p>
<p style="top:328.0pt;left:241.3pt;line-height:9.0pt"><span style="font-family:AdvP6A46,serif;font-size:9.0pt">drug had a significantly (p &lt; 0.01) greater effect than the non-complexed</span></p>
<p style="top:340.5pt;left:241.3pt;line-height:9.0pt"><span style="font-family:AdvP6A46,serif;font-size:9.0pt">drug.</span></p>
<p style="top:352.9pt;left:241.3pt;line-height:9.0pt"><span style="font-family:AdvP6A55,serif;font-size:9.0pt">Expert opinion:</span><span style="font-family:AdvP6A46,serif;font-size:9.0pt"> The use of cyclodextrins can improve the efficacy of analgesic</span></p>
<p style="top:365.4pt;left:241.3pt;line-height:9.0pt"><span style="font-family:AdvP6A46,serif;font-size:9.0pt">compounds, and they are an important tool in the search for greater analge-</span></p>
<p style="top:377.8pt;left:241.3pt;line-height:9.0pt"><span style="font-family:AdvP6A46,serif;font-size:9.0pt">sic effect. They may also be a way to reduce the therapeutic doses, and hence</span></p>
<p style="top:390.3pt;left:241.3pt;line-height:9.0pt"><span style="font-family:AdvP6A46,serif;font-size:9.0pt">increasing the potential of the drug.</span></p>
<p style="top:414.7pt;left:241.3pt;line-height:8.5pt"><span style="font-family:AdvP93EE,serif;font-size:8.5pt">Keywords:</span><span style="font-family:AdvP5D8B,serif;font-size:8.5pt"> analgesics, cyclodextrins, drug effects, meta-analysis, pain, systematic review</span></p>
<p style="top:436.7pt;left:241.3pt;line-height:8.5pt"><span style="font-family:AdvP92E7,serif;font-size:8.5pt">Expert Opin. Drug Deliv. [Early Online]</span></p>
<p style="top:459.9pt;left:241.3pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">1.</span><span style="font-family:AdvP4B06EF,serif;font-size:11.0pt"> Introduction</span></p>
<p style="top:482.0pt;left:241.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Pain is defined as an unpleasant sensory and emotional experience associated with</span></p>
<p style="top:493.9pt;left:241.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">actual or potential tissue damage, or described in terms as such damage. Pain is</span></p>
<p style="top:505.9pt;left:241.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">recognized as a public health problem with significant physical and psychological</span></p>
<p style="top:517.9pt;left:241.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">consequences</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [1]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. The average prevalence of acute and chronic pain in the adult pop-</span></p>
<p style="top:529.8pt;left:241.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">ulation ranges around 15%</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [2,3]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">, resulting in an annual spending, in the US alone, in</span></p>
<p style="top:541.8pt;left:241.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the order of US $ 635 billion</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [4]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">.</span></p>
<p style="top:553.7pt;left:251.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Pharmacotherapy is widely used in the treatment of pain. Several classes of drugs</span></p>
<p style="top:565.6pt;left:241.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">are common, including opioids, non-steroidal anti-inflammatories (NSAIDs), mus-</span></p>
<p style="top:577.6pt;left:241.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">cle relaxants, anticonvulsants and antidepressants are the most widely used</span></p>
<p style="top:589.6pt;left:241.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">drugs</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [5,6]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. However, 40</span><span style="font-family:AdvP4C4E59,serif;font-size:10.0pt"> --</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> 60% of patients do not respond appositely to the therapy,</span></p>
<p style="top:601.5pt;left:241.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">and may have partial reductions in pain or significant side effects</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [7,8]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. Thus, various</span></p>
<p style="top:613.5pt;left:241.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">types of drugs with an analgesic profile, such as NSAIDs, have been incorporated</span></p>
<p style="top:625.5pt;left:241.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">into drug delivery systems, such as cyclodextrins (CDs), to improve pharmacologi-</span></p>
<p style="top:637.4pt;left:241.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">cal properties</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [9]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">.</span></p>
<p style="top:649.4pt;left:251.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CDs have been known for over 100 years. They were first discovered in 1891 by</span></p>
<p style="top:661.3pt;left:241.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Villiers, a French scientist. He isolated about 3 g of a crystalline substance from</span></p>
<p style="top:673.3pt;left:241.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">1000 g of starch and determined its composition as (C</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt">6</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">H</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt">10</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">O</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt">5</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">)</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt">2</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">&#xb7;3H</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt">2</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">O</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [10]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. The</span></p>
<p style="top:685.2pt;left:241.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">first patent on CDs and their complexes was registered in 1953 in the US. However,</span></p>
<p style="top:697.2pt;left:241.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">until 1970 only small amounts of CDs were produced and high production costs</span></p>
<p style="top:709.1pt;left:241.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">prevented their widespread usage in pharmaceutical formulations. With recent</span></p>
<p style="top:752.1pt;left:171.4pt;line-height:7.0pt"><span style="font-family:AdvP45A506,serif;font-size:7.0pt">10.1517/17425247.2015.1046835</span><span style="font-family:AdvTT263d80c4,serif;font-size:7.0pt"> &#xa9;</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt"> 2015 Informa UK, Ltd. ISSN 1742-5247, e-ISSN 1744-7593</span></p>
<p style="top:750.5pt;left:558.5pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">1</span></p>
<p style="top:761.1pt;left:218.0pt;line-height:7.0pt"><span style="font-family:AdvP45A506,serif;font-size:7.0pt">All rights reserved: reproduction in whole or in part not permitted</span></p>
<p style="top:558.4pt;left:-0.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Nandini Loganathan on 07/10/15</span></p>
<p style="top:426.0pt;left:7.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">For personal use only.</span></p>
<img style="position:absolute;transform:matrix(1.3333334,0,-0,1.3333334,674.7067,1021.9347)" src="data:image/png;base64,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">


<p style="top:253.8pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">biotechnological advancements, the production of CDs has</span></p>
<p style="top:265.8pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">improved and production costs have been lowered</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [11]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">.</span></p>
<p style="top:277.8pt;left:59.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CDs are cyclic oligosaccharides consisting of six (</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">a</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD),</span></p>
<p style="top:289.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">seven (</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD), eight (</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">g</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD) or more glucopyranose units</span></p>
<p style="top:301.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">linked by</span><span style="font-family:AdvP697C,serif;font-size:10.0pt"> a</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">-(1,4) bonds. The sugar units adapt to a</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> </span><sup><span style="font-family:AdvP5D8B,serif;font-size:7.0pt">4</span></sup><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">C</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt">1</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> chain</span></p>
<p style="top:313.8pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">conformation and are orientated in such a way that the mole-</span></p>
<p style="top:325.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">cule forms a toroidal truncated cone structure</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [12,13]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. CDs are</span></p>
<p style="top:337.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">pharmaceutically useful due to the fact that they can interact</span></p>
<p style="top:349.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">with drug molecules to form inclusion complexes. In forming</span></p>
<p style="top:361.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">inclusion complexes, major changes in candidate drug proper-</span></p>
<p style="top:373.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">ties, including enhanced solubility, pharmacological bioavail-</span></p>
<p style="top:385.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">ability, chemical stability and physical profile, have been</span></p>
<p style="top:397.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">reported</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [14-16]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. Such changes have then resulted in a better</span></p>
<p style="top:409.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">biological performance, and thus in the use of CDs in various</span></p>
<p style="top:421.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">commercially successful pharmaceutical products</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [17,18]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">.</span></p>
<p style="top:433.7pt;left:59.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">In this context, the present study aimed to assess, through a</span></p>
<p style="top:445.6pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">systematic review and meta-analysis, the studies that evaluated</span></p>
<p style="top:457.6pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the analgesic activity of analgesic compounds complexed in</span></p>
<p style="top:469.6pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CDs, analyzing whether the drug encapsulation improves</span></p>
<p style="top:481.6pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the analgesic profile.</span></p>
<p style="top:509.0pt;left:49.0pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">2.</span><span style="font-family:AdvP4B06EF,serif;font-size:11.0pt"> Methods</span></p>
<p style="top:533.0pt;left:49.0pt;line-height:7.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:7.5pt">2.1</span><span style="font-family:AdvP4B06EF,serif;font-size:9.5pt"> Systematic review</span></p>
<p style="top:542.9pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">This systematic review was conducted in accordance with the</span></p>
<p style="top:554.9pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">guidelines of Transparent Reporting of Systematic Reviews</span></p>
<p style="top:566.9pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">and Meta-Analyses (PRISMA statement)</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [19]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. A literature</span></p>
<p style="top:578.9pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">search was performed in January 2014 and included articles</span></p>
<p style="top:590.9pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">published over a period of 14 years (January 2000 to January</span></p>
<p style="top:602.9pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">2014). This literature search was performed through special-</span></p>
<p style="top:614.9pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">ized databases (PUBMED, SCOPUS and EMBASE) using</span></p>
<p style="top:626.9pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">different</span></p>
<p style="top:626.9pt;left:93.5pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">combinations</span></p>
<p style="top:626.9pt;left:157.5pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">of</span></p>
<p style="top:626.9pt;left:176.8pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the</span></p>
<p style="top:626.9pt;left:200.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">following</span></p>
<p style="top:626.9pt;left:248.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">keywords:</span></p>
<p style="top:638.8pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">&#x2018;Analgesics&#x2019;, &#x2018;Cyclodextrins&#x2019; and &#x2018;Drug effects&#x2019; either as</span></p>
<p style="top:650.9pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">MeSH terms or as free-text words. The inclusion criteria</span></p>
<p style="top:662.9pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">used were: both preclinical and clinical studies that investi-</span></p>
<p style="top:674.8pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">gated analgesic action and the use of CDs to improve analge-</span></p>
<p style="top:686.9pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">sia, published between January 2000 and January 2014 and</span></p>
<p style="top:698.8pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">written in English.</span></p>
<p style="top:710.8pt;left:59.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">For the selection of the manuscripts, two independent</span></p>
<p style="top:722.8pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">investigators (R.G.B. and J.S.S.Q.) first selected the articles</span></p>
<p style="top:77.2pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">according to the title. The abstract was used to consider inclu-</span></p>
<p style="top:89.1pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">sion criteria, and then assessment of the full-text publication</span></p>
<p style="top:101.1pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">confirmed the inclusion criteria and extracted data. The</span></p>
<p style="top:113.1pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">disagreements, which happened two times, were resolved</span></p>
<p style="top:125.0pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">through consensus. The resulting articles were manually</span></p>
<p style="top:137.0pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">reviewed with the goal of identifying studies that met the</span></p>
<p style="top:149.0pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">inclusion criteria described above.</span></p>
<p style="top:175.2pt;left:303.0pt;line-height:7.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:7.5pt">2.2</span><span style="font-family:AdvP4B06EF,serif;font-size:9.5pt"> Risk of bias in clinical studies included</span></p>
<p style="top:185.1pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">In order to assess the &#x2018;risk of bias&#x2019;, clinical studies were judged</span></p>
<p style="top:197.0pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">on</span></p>
<p style="top:197.0pt;left:321.1pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the</span></p>
<p style="top:197.0pt;left:341.2pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">following</span></p>
<p style="top:197.0pt;left:385.7pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">items:</span></p>
<p style="top:197.0pt;left:416.9pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">random</span></p>
<p style="top:197.0pt;left:455.4pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">sequence</span></p>
<p style="top:197.0pt;left:497.8pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">generation,</span></p>
<p style="top:209.0pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">allocation, blinding, incomplete outcome data and sources</span></p>
<p style="top:221.0pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">of funding bias using criteria outlined by the Cochrane Col-</span></p>
<p style="top:232.9pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">laboration</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [20]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. The overall risk of bias in the seven clinical</span></p>
<p style="top:244.9pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">studies was classified as high, low or unclear.</span></p>
<p style="top:271.1pt;left:303.0pt;line-height:7.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:7.5pt">2.3</span><span style="font-family:AdvP4B06EF,serif;font-size:9.5pt"> Data analyses</span></p>
<p style="top:281.0pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Clinical Studies: The clinical studies did not have enough</span></p>
<p style="top:293.0pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">similar data to perform a meta-analysis as comparison groups</span></p>
<p style="top:304.9pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">were mixed. We determined the extent to which the CD-</span></p>
<p style="top:316.9pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">complexed drug improved the analgesia when compared</span></p>
<p style="top:328.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">with placebo, standard drug, vehicle, baseline or the drug</span></p>
<p style="top:340.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">alone by calculating the percentage of the analgesic improve-</span></p>
<p style="top:352.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">ment (AI). For those clinical studies with Visual Analog Scale</span></p>
<p style="top:364.7pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">(VAS) scores provided, the following formula was used to cal-</span></p>
<p style="top:376.7pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">culate the percentage improvement in pain: AI = ((Mean</span></p>
<p style="top:388.7pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">VAS</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt">Experimental</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> - Mean VAS</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt">Control</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">)/Mean VAS</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt">Control</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">))</span><span style="font-family:AdvP4C4E74,serif;font-size:10.0pt"> &#xfffd;</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> 100.</span></p>
<p style="top:400.6pt;left:312.9pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Preclinical studies: we performed a meta-analysis using the</span></p>
<p style="top:412.6pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">software Open Meta.[Analyst] 2013. The data from the pub-</span></p>
<p style="top:424.5pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">lished trials were divided into three groups and a separate</span></p>
<p style="top:436.5pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">analysis was performed for each one: thermal, chemical and</span></p>
<p style="top:448.5pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">nociceptive score. We extracted the sample size, means and</span></p>
<p style="top:460.4pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">standard deviations for each measure for the individual</span></p>
<p style="top:472.4pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">papers. When the same study had two or more assessments</span></p>
<p style="top:484.4pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">in the same group of animals, we used the assessment with</span></p>
<p style="top:496.3pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the greatest effect. For the meta-analyses, we only included</span></p>
<p style="top:508.3pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">studies that compared the drug complexed with CD to the</span></p>
<p style="top:520.2pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">drug alone. Three studies were, therefore, not included in</span></p>
<p style="top:532.2pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the meta-analysis as they compared the complexed drug to</span></p>
<p style="top:544.2pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the vehicle. Two additional studies were also excluded because</span></p>
<p style="top:556.1pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">we could not extract all data required for the meta-analysis.</span></p>
<p style="top:568.1pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">For all studies when multiple doses were tested, we extracted</span></p>
<p style="top:580.0pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">data from the dose with the greatest analgesic effect.</span></p>
<p style="top:605.0pt;left:303.0pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">3.</span><span style="font-family:AdvP4B06EF,serif;font-size:11.0pt"> Results</span></p>
<p style="top:627.1pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">This review searched studies that evaluated the effectiveness of</span></p>
<p style="top:639.1pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">substances complexed in CDs in the analgesic activity. The</span></p>
<p style="top:651.0pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">primary search identified 329 articles: 190 from PUBMED,</span></p>
<p style="top:663.0pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">81 from SCOPUS and 58 from EMBASE. After screening,</span></p>
<p style="top:675.0pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">47 articles met the inclusion criteria: 14 from PUBMED,</span></p>
<p style="top:686.9pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">14 from SCOPUS and 19 from EMBASE. Out of this total,</span></p>
<p style="top:698.9pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">25 were indexed in two or more databases and were consid-</span></p>
<p style="top:710.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">ered only once, resulting in 22 articles selected for final anal-</span></p>
<p style="top:722.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">ysis. Seven publications were clinical and 15 were preclinical.</span></p>
<p style="top:87.6pt;left:61.5pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">Article highlights.</span></p>
<p style="top:104.6pt;left:60.5pt;line-height:5.9pt"><span style="font-family:AdvPi1,serif;font-size:5.9pt">.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> Cyclodextrins (CDs) are one of the most interesting drug</span></p>
<p style="top:113.5pt;left:67.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">encapsulation systems for analgesic and</span></p>
<p style="top:123.5pt;left:67.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">anti-inflammatory drugs already used in medicine.</span></p>
<p style="top:134.5pt;left:60.5pt;line-height:5.9pt"><span style="font-family:AdvPi1,serif;font-size:5.9pt">.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> CDs can easily form complexes with analgesic drugs and</span></p>
<p style="top:143.4pt;left:67.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">they can improve the pharmacological efficacy.</span></p>
<p style="top:154.4pt;left:60.5pt;line-height:5.9pt"><span style="font-family:AdvPi1,serif;font-size:5.9pt">.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> CDs can act using decreasing doses of analgesic drugs,</span></p>
<p style="top:163.4pt;left:67.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">which may reduce any side effects.</span></p>
<p style="top:174.4pt;left:60.5pt;line-height:5.9pt"><span style="font-family:AdvPi1,serif;font-size:5.9pt">.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> There are few studies sufficiently providing evidence of</span></p>
<p style="top:183.3pt;left:67.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">why this improvement occurs.</span></p>
<p style="top:194.3pt;left:60.5pt;line-height:5.9pt"><span style="font-family:AdvPi1,serif;font-size:5.9pt">.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> Preclinical studies have a key role to understand how</span></p>
<p style="top:203.2pt;left:67.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">the CDs can advance analgesic profiles.</span></p>
<p style="top:225.3pt;left:60.5pt;line-height:7.0pt"><span style="font-family:AdvP45A506,serif;font-size:7.0pt">This box summarizes key points contained in the article.</span></p>
<p style="top:41.8pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">R. G. Brito</span><span style="font-family:AdvP47DAD7,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:749.3pt;left:49.0pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">2</span></p>
<p style="top:750.9pt;left:236.6pt;line-height:7.0pt"><span style="font-family:AdvP4194AB,serif;font-size:7.0pt">Expert Opin. Drug Deliv.</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt"> (2015)</span><span style="font-family:AdvP6A50,serif;font-size:7.0pt"> 12</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">(10)</span></p>
<p style="top:558.4pt;left:-0.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Nandini Loganathan on 07/10/15</span></p>
<p style="top:426.0pt;left:7.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">For personal use only.</span></p>
<img style="position:absolute;transform:matrix(1.3333334,0,-0,1.3333334,674.7067,1021.9347)" src="data:image/png;base64,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">


<p style="top:362.6pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">A flowchart illustrating the progressive study selection and</span></p>
<p style="top:375.1pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">numbers at each stage is shown in</span><span style="font-family:AdvP5D4A,serif;font-size:9.0pt"> Figure 1</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. The general char-</span></p>
<p style="top:387.6pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">acteristics of the clinical and preclinical studies identified by</span></p>
<p style="top:400.0pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">this systematic review are described in</span><span style="font-family:AdvP5D4A,serif;font-size:9.0pt"> Tables 1</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> and</span><span style="font-family:AdvP5D4A,serif;font-size:9.0pt"> 2</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">.</span></p>
<p style="top:412.0pt;left:81.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Using the assessment for risk of bias, sequence generation</span></p>
<p style="top:424.4pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">was judged to be adequate in six studies, incomplete outcome</span></p>
<p style="top:436.8pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">data were adequate in six studies, four had adequate assessor</span></p>
<p style="top:449.3pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">and participant blinding and the source of funding bias was</span></p>
<p style="top:461.8pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">clear in six. The allocation concealment was unclear in six</span></p>
<p style="top:474.2pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">studies and with high risk of bias in one.</span><span style="font-family:AdvP5D4A,serif;font-size:9.0pt"> Figure 2</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> provides</span></p>
<p style="top:486.7pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">details of the judgments about each methodological quality</span></p>
<p style="top:499.1pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">item for each study and</span><span style="font-family:AdvP5D4A,serif;font-size:9.0pt"> Figure 3</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> provides a summary of overall</span></p>
<p style="top:511.6pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">risk of bias in the seven studies as high, low or unclear.</span></p>
<p style="top:523.5pt;left:81.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">The seven clinical studies selected by this systematic review</span></p>
<p style="top:536.0pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">compared the use of NSAIDs complexed with CDs (</span><span style="font-family:AdvP5D4A,serif;font-size:9.0pt">Table 3</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">).</span></p>
<p style="top:548.5pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Among those, three were compared with placebo, two were</span></p>
<p style="top:560.9pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">compared with the CD-free drug, one was compared with</span></p>
<p style="top:573.4pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the baseline and one was compared with another NSAID,</span></p>
<p style="top:585.8pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">naproxen. Five of the seven studies provided VAS pain scores,</span></p>
<p style="top:598.2pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">for which we calculated percent reduction in pain. Of those</span></p>
<p style="top:610.7pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">that were compared with placebo, the CD-free drug, baseline</span></p>
<p style="top:623.2pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">or standard drug, there was (n = 5) a reduction in pain inten-</span></p>
<p style="top:635.6pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">sity between 25 and 83%. Two studies normalized VAS scores</span></p>
<p style="top:648.1pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">and provided total pain relief or pain intensity differences for</span></p>
<p style="top:660.5pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">each group, demonstrating an improvement in the analgesic</span></p>
<p style="top:673.0pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">effect by the complexed drug. One study did not find any dif-</span></p>
<p style="top:685.4pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">ference in the analgesic profile when compared with another</span></p>
<p style="top:697.9pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">NSAID. However, there were fewer side effects related to</span></p>
<p style="top:710.3pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">gastrointestinal tract, suggesting an improvement in the</span></p>
<p style="top:722.8pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">gastrointestinal tolerability to the complexed drug.</span></p>
<p style="top:77.2pt;left:335.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">The preclinical studies evaluated the analgesic effect of dif-</span></p>
<p style="top:89.2pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">ferent complexed drugs including NSAIDs, natural products,</span></p>
<p style="top:101.2pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">opioids, local anesthetic and antidepressants. The preclinical</span></p>
<p style="top:113.1pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">studies compared complexed drugs in CDs with the vehicle</span></p>
<p style="top:125.1pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">or the drug alone. Several analgesic protocols were used and</span></p>
<p style="top:137.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">classified into three broad categories: thermal, chemical and</span></p>
<p style="top:149.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">nociceptive score. Thermal tests included the tail-flick and</span></p>
<p style="top:161.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">hot-plate tests in uninjured animals. Chemical tests included</span></p>
<p style="top:172.9pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the acetic acid-induced abdominal constrictions and the for-</span></p>
<p style="top:184.9pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">malin. In the nociceptive score group, a subjective nociceptive</span></p>
<p style="top:196.9pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">assessment of animal response to injury was used (neuropathic</span></p>
<p style="top:208.8pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">pain). The meta-analysis from the chemical group demon-</span></p>
<p style="top:220.8pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">strated that the complexed drug significantly decreased (Over-</span></p>
<p style="top:232.7pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">all: 10.25; I^2 = 89%; p &lt; 0.001) the nociceptive behavior</span></p>
<p style="top:244.7pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">when compared with the drug alone (</span><span style="font-family:AdvP5D4A,serif;font-size:9.0pt">Figure 4A</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">). In the</span></p>
<p style="top:256.7pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">thermal group, the complexed drug increased significantly</span></p>
<p style="top:268.6pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">(Overall: -9.02; I^2 = 75%; p &lt; 0.01) the time on the hot-</span></p>
<p style="top:280.7pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">plate or tail-flick tests when compared with the drug alone</span></p>
<p style="top:292.6pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">(</span><span style="font-family:AdvP5D4A,serif;font-size:9.0pt">Figure 4B</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">). The nociceptive score group showed a significant</span></p>
<p style="top:304.6pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">(Overall: -1.5; I^2 = 97%; p &lt; 0.001) decrease in the pain</span></p>
<p style="top:316.5pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">score with the complexed drug compared to the drug alone</span></p>
<p style="top:328.5pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">(</span><span style="font-family:AdvP5D4A,serif;font-size:9.0pt">Figure 4C</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">). Thus, all conditions clearly show an enhanced</span></p>
<p style="top:340.5pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">relief of pain behaviors for the complexed drug when</span></p>
<p style="top:352.4pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">compared to the drug alone.</span></p>
<p style="top:364.4pt;left:335.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Some clinical and preclinical studies also reported an</span></p>
<p style="top:376.4pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">improvement in other aspects. Among the clinical studies,</span></p>
<p style="top:388.3pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">one study showed an increase in the time of action when the</span></p>
<p style="top:400.3pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">complexed</span></p>
<p style="top:400.3pt;left:375.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">and</span></p>
<p style="top:400.3pt;left:398.1pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">non-complexed</span></p>
<p style="top:400.3pt;left:466.6pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">drugs</span></p>
<p style="top:400.3pt;left:496.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">were</span></p>
<p style="top:400.3pt;left:522.5pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">compared;</span></p>
<p style="top:412.2pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">another one demonstrated an increase in the gastrointestinal</span></p>
<p style="top:424.2pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">tolerability when the complexed drug was compared with</span></p>
<p style="top:436.2pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the standard drug. In the preclinical studies, eight demon-</span></p>
<p style="top:448.1pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">strated an increase in the solubility, three in time of action,</span></p>
<p style="top:460.1pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">two in absorption, one in oral delivery, one in permeability,</span></p>
<p style="top:472.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">one in bioavailability and one in the drug release when com-</span></p>
<p style="top:484.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">pared with the drug alone. In addition, two preclinical studies</span></p>
<p style="top:496.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">showed a decrease in the cytotoxicity when the complexed</span></p>
<p style="top:507.9pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">drug was compared with the drug alone. The other improve-</span></p>
<p style="top:520.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">ment aspects are summarized in</span><span style="font-family:AdvP5D4A,serif;font-size:9.0pt"> Table 4</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">.</span></p>
<p style="top:545.2pt;left:325.3pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">4.</span><span style="font-family:AdvP4B06EF,serif;font-size:11.0pt"> Discussion</span></p>
<p style="top:567.2pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">The current systematic review showed that analgesics com-</span></p>
<p style="top:579.2pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">plexed with CDs were effective when compared with the</span></p>
<p style="top:591.2pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">drug alone, placebo or vehicle. Clinical studies have already</span></p>
<p style="top:603.1pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">tested the complexed-NSAIDs diclofenac (DF)</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [21,22]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">, piroxi-</span></p>
<p style="top:615.1pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">cam (PX)</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [23-26]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> and nimesulide (NM)</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [27]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. The clinical studies</span></p>
<p style="top:627.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">generally show good methodological quality and demonstrate</span></p>
<p style="top:639.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the effectiveness of CDs in a variety of pain conditions. The</span></p>
<p style="top:651.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">preclinical studies used complexes with natural products</span></p>
<p style="top:662.9pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">(</span><span style="font-family:AdvP92E7,serif;font-size:10.0pt">Lippia grata</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> essential oil [EO]</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [28]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">, (-)-linalool [LIN]</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [29]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">,</span></p>
<p style="top:674.9pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP92E7,serif;font-size:10.0pt">p</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">-cymene [pCM]</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [14]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">), NSAIDs (indomethacin</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [30]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">, acetyl</span></p>
<p style="top:686.9pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">salicylic acid</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [31]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">, etoricoxib</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [32]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">, meloxicam</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [33]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">, etodolac</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [34,35]</span></p>
<p style="top:698.8pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">and ketoprofen</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [36]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">), cannabinoids (MDA7</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [37]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">), steroids (allo-</span></p>
<p style="top:710.8pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">pregnanolone and alphaxalone</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [38]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">), local anesthetic (tetracaine</span></p>
<p style="top:722.8pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">(TTC)</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [39]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">), opioid (sufentanil (SUF)</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [40]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">) and antidepressant</span></p>
<img style="position:absolute;transform:matrix(.48030574,0,-0,.48004876,-60,-68.772)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.48030574,0,-0,.48029227,-60.479997,-68.212039)" src="data:image/png;base64,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">
<p style="top:107.9pt;left:96.7pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Identified studies: 329</span></p>
<p style="top:193.6pt;left:103.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Selected studies: 47</span></p>
<p style="top:246.1pt;left:159.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Duplicated: 25</span></p>
<p style="top:272.0pt;left:240.6pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Clinical: 7</span></p>
<p style="top:299.2pt;left:230.7pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Pre-Clinical: 15</span></p>
<p style="top:287.0pt;left:109.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Studies used: 22</span></p>
<p style="top:82.6pt;left:239.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Pubmed: 190</span></p>
<p style="top:106.1pt;left:243.7pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Scopus: 81</span></p>
<p style="top:132.1pt;left:242.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Embase: 58</span></p>
<p style="top:169.3pt;left:241.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Pubmed: 14</span></p>
<p style="top:193.7pt;left:243.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Scopus: 14</span></p>
<p style="top:222.2pt;left:242.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Embase: 19</span></p>
<p style="top:336.3pt;left:78.7pt;line-height:8.5pt"><span style="font-family:AdvP6A50,serif;font-size:8.5pt">Figure 1. Flow chart of the search and selection results.</span></p>
<p style="top:41.8pt;left:439.2pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">CDs improving analgesic drugs</span></p>
<p style="top:750.9pt;left:258.9pt;line-height:7.0pt"><span style="font-family:AdvP4194AB,serif;font-size:7.0pt">Expert Opin. Drug Deliv.</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt"> (2015)</span><span style="font-family:AdvP6A50,serif;font-size:7.0pt"> 12</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">(10)</span></p>
<p style="top:749.3pt;left:558.3pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">3</span></p>
<p style="top:558.4pt;left:-0.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Nandini Loganathan on 07/10/15</span></p>
<p style="top:426.0pt;left:7.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">For personal use only.</span></p>
<img style="position:absolute;transform:matrix(1.3333334,0,-0,1.3333334,674.7067,1021.9347)" src="data:image/png;base64,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">


<p style="top:436.8pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">(doxepin (DOX)</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [41]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">). A variety of pain measures were used</span></p>
<p style="top:448.9pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">including chemical, thermal and nociceptive score tests. In all</span></p>
<p style="top:461.1pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">cases, there was a significantly better analgesic effect of</span></p>
<p style="top:473.1pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD-complexed drugs when compared with the drug alone.</span></p>
<p style="top:507.7pt;left:49.0pt;line-height:7.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:7.5pt">4.1</span><span style="font-family:AdvP4B06EF,serif;font-size:9.5pt"> Clinical studies</span></p>
<p style="top:517.6pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Several NSAIDs, including DF, PX and NM, have been</span></p>
<p style="top:529.6pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">complexed with CDs to improve analgesic efficacy in clinical</span></p>
<p style="top:541.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">populations.</span></p>
<p style="top:541.7pt;left:105.7pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">This</span></p>
<p style="top:541.7pt;left:131.6pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">class</span></p>
<p style="top:541.7pt;left:157.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">of</span></p>
<p style="top:541.7pt;left:173.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">drugs</span></p>
<p style="top:541.7pt;left:203.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">has</span></p>
<p style="top:541.7pt;left:223.9pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">analgesic,</span></p>
<p style="top:541.7pt;left:268.9pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">anti-</span></p>
<p style="top:553.8pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">inflammatory and anti-pyretic profiles. DF and PX inhibit</span></p>
<p style="top:565.9pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">prostaglandin synthesis by inhibiting cyclooxygenase-1 and</span></p>
<p style="top:578.0pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">cyclooxygenase-2 enzymes</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [42]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">, whereas NM is a selective</span></p>
<p style="top:590.0pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">cyclooxygenase-2 inhibitor.</span></p>
<p style="top:602.0pt;left:59.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Gan</span><span style="font-family:AdvP92E7,serif;font-size:10.0pt"> et al.</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [21]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> demonstrated that DF complexed with DF-</span></p>
<p style="top:614.1pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">hydroxypropyl</span><span style="font-family:AdvP697C,serif;font-size:10.0pt"> b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD (DF-HP</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD) provided significantly</span></p>
<p style="top:626.1pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">greater analgesic efficacy than did the placebo after abdominal</span></p>
<p style="top:638.2pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">or pelvic surgery; the study was not empowered to discern</span></p>
<p style="top:650.3pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">significant</span></p>
<p style="top:650.3pt;left:98.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">differences</span></p>
<p style="top:650.3pt;left:148.9pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">between</span></p>
<p style="top:650.3pt;left:189.9pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the</span></p>
<p style="top:650.3pt;left:211.5pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">treatment</span></p>
<p style="top:650.3pt;left:258.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">groups.</span></p>
<p style="top:662.4pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Christensen</span><span style="font-family:AdvP92E7,serif;font-size:10.0pt"> et al.</span></p>
<p style="top:664.8pt;left:128.0pt;line-height:7.0pt"><span style="font-family:AdvP5D8B,serif;font-size:7.0pt">[22]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> showed a substantially lower DF-</span></p>
<p style="top:674.5pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">HP</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD dose than that previously thought as necessary</span></p>
<p style="top:686.6pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">(37.5 vs 75 mg) to sufficiently reduce moderate to severe</span></p>
<p style="top:698.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">acute pain following the extraction of the third molar with a</span></p>
<p style="top:710.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">more rapid onset of action by several measures when com-</span></p>
<p style="top:722.8pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">pared with ketorolac</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [43]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">.</span></p>
<p style="top:436.8pt;left:312.9pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">PX has been widely prescribed for the treatment of low</span></p>
<p style="top:449.3pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">back pain, even though gastrointestinal mucosal injury</span></p>
<p style="top:461.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">reduces</span></p>
<p style="top:461.8pt;left:341.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the</span></p>
<p style="top:461.8pt;left:363.1pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">incidence</span></p>
<p style="top:461.8pt;left:409.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">of</span></p>
<p style="top:461.8pt;left:426.9pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">favorable</span></p>
<p style="top:461.8pt;left:471.6pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">outcomes</span></p>
<p style="top:464.2pt;left:518.2pt;line-height:7.0pt"><span style="font-family:AdvP5D8B,serif;font-size:7.0pt">[44,45]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">.</span></p>
<p style="top:474.2pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Keles</span><span style="font-family:AdvP92E7,serif;font-size:10.0pt"> et al.</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [23]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> demonstrated that oral preemptive analgesia</span></p>
<p style="top:486.7pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">with PX complexed with</span><span style="font-family:AdvP697C,serif;font-size:10.0pt"> b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD (PX-</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD) decreased postop-</span></p>
<p style="top:499.1pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">erative pain and morphine consumption after functional</span></p>
<p style="top:511.6pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">endoscopic sinus surgery. Chang</span><span style="font-family:AdvP92E7,serif;font-size:10.0pt"> et al.</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [24,25]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> showed that</span></p>
<p style="top:524.0pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">PX-</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD yielded greater improvement in pain than did the</span></p>
<p style="top:536.5pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">same dose of PX alone in people with chronic low back</span></p>
<p style="top:548.9pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">pain. Pijak</span><span style="font-family:AdvP92E7,serif;font-size:10.0pt"> et al.</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [26]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> demonstrated that patients with chronic</span></p>
<p style="top:561.4pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">back pain receiving PX-</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD once daily for 40 days showed</span></p>
<p style="top:573.9pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">an AI higher than with other NSAIDs. In addition, the</span></p>
<p style="top:586.3pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">PX-</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD complexes considerably increase the water solubility</span></p>
<p style="top:598.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">as well as the rate of dissociation of poorly soluble PX, leading</span></p>
<p style="top:611.2pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">to a higher rate of gastrointestinal absorption than PX</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [46,47]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">.</span></p>
<p style="top:623.6pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Thus, the rapid onset of action, the long duration of activity,</span></p>
<p style="top:636.1pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the favorable risk-benefit ratio and less gastrointestinal injury</span></p>
<p style="top:648.6pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">are the major clinical advantages of PX-</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [12,48,49]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">.</span></p>
<p style="top:660.5pt;left:312.9pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">NM is commonly used for the treatment of acute pain and</span></p>
<p style="top:673.0pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">painful osteoarthritis, having a fast rate of oral absorption</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [50]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">.</span></p>
<p style="top:685.4pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Fioravanti</span><span style="font-family:AdvP92E7,serif;font-size:10.0pt"> et al.</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [27]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> showed that NM-</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD (400 mg, orally)</span></p>
<p style="top:697.9pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">showed efficacy similar to that of naproxen (500 mg, orally)</span></p>
<p style="top:710.3pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">with a 41% reduction of pain in people with osteoarthritis</span></p>
<p style="top:722.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">of the hip and/or knee. The gastrointestinal tolerability of</span></p>
<p style="top:78.0pt;left:49.0pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">Table 1. Description of the main aspects of the clinical studies included in the systematic review.</span></p>
<p style="top:102.3pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">Author (year)</span></p>
<p style="top:102.3pt;left:121.2pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">Substance</span></p>
<p style="top:102.3pt;left:174.9pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">CD</span></p>
<p style="top:114.3pt;left:171.7pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">type</span></p>
<p style="top:102.3pt;left:213.4pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">Doses</span></p>
<p style="top:102.3pt;left:343.5pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">Sample</span></p>
<p style="top:102.3pt;left:469.6pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">Assessment pain</span></p>
<p style="top:114.3pt;left:493.1pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">tools</span></p>
<p style="top:131.7pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Gan</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2012)</span></p>
<p style="top:142.4pt;left:49.0pt;line-height:7.5pt"><span style="font-family:AdvP45A506,serif;font-size:7.5pt">[21]</span></p>
<p style="top:131.7pt;left:121.2pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Diclofenac</span></p>
<p style="top:131.7pt;left:167.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">HP</span><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD 18.75 and</span></p>
<p style="top:141.6pt;left:199.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">37.5 mg</span></p>
<p style="top:131.7pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">265 adults between 18 and 65 years old scheduled</span></p>
<p style="top:141.6pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">undergoing abdominal or pelvic surgery. The first</span></p>
<p style="top:151.6pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">treatment was administrated 6 h after the surgery</span></p>
<p style="top:131.7pt;left:465.1pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">VAS, SPID and PID</span></p>
<p style="top:161.6pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Christensen</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:171.6pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(2011)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [22]</span></p>
<p style="top:161.6pt;left:121.2pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Diclofenac</span></p>
<p style="top:161.6pt;left:167.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">HP</span><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD 3.75, 9.4,</span></p>
<p style="top:171.6pt;left:199.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">18.75,</span></p>
<p style="top:181.5pt;left:199.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">37.5 and</span></p>
<p style="top:191.5pt;left:199.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">75 mg</span></p>
<p style="top:161.6pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">353 male and female subjects between 18 and</span></p>
<p style="top:171.6pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">75 years old undergoing surgical extraction of 1 or</span></p>
<p style="top:181.5pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">more third molar</span></p>
<p style="top:161.6pt;left:465.1pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CPIS, VAS, TPR,</span></p>
<p style="top:171.6pt;left:465.1pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">TSPR, PPR, SPID,</span></p>
<p style="top:181.5pt;left:465.1pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">PID, PPID, SPRID.</span></p>
<p style="top:201.5pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Keles</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:211.4pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(2010)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [23]</span></p>
<p style="top:201.5pt;left:121.2pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Piroxicam</span></p>
<p style="top:201.5pt;left:167.6pt;line-height:8.5pt"><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:201.5pt;left:199.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">20 and</span></p>
<p style="top:211.4pt;left:199.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">40 mg</span></p>
<p style="top:201.5pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">75 male and female subjects aged between</span></p>
<p style="top:211.4pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">18</span><span style="font-family:AdvP4C4E59,serif;font-size:8.5pt">--</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">65 years of age meeting physical status I or II of</span></p>
<p style="top:221.4pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">the American Society of Anesthesiologists and</span></p>
<p style="top:231.3pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">undergoing endoscopic sinus surgery. The subjects</span></p>
<p style="top:241.3pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">received the treatment before induction of general</span></p>
<p style="top:251.2pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">anesthesia</span></p>
<p style="top:201.5pt;left:465.1pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">VAS</span></p>
<p style="top:261.2pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Chang</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:271.2pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(2008)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [24]</span></p>
<p style="top:261.2pt;left:121.2pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Piroxicam</span></p>
<p style="top:261.2pt;left:167.6pt;line-height:8.5pt"><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:261.2pt;left:199.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">20 mg</span></p>
<p style="top:261.2pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">47 male and female subjects between the ages of</span></p>
<p style="top:271.2pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">20 and 75 years old, who had low back pain for more</span></p>
<p style="top:281.2pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">than 3 months</span></p>
<p style="top:261.2pt;left:465.1pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">VAS, ODI and the</span></p>
<p style="top:271.2pt;left:465.1pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">sway assessments</span></p>
<p style="top:291.1pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Chang</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:301.1pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(2008)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [25]</span></p>
<p style="top:291.1pt;left:121.2pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Piroxicam</span></p>
<p style="top:291.1pt;left:167.6pt;line-height:8.5pt"><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:291.1pt;left:199.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">20 mg</span></p>
<p style="top:291.1pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">47 subjects between 20 and 75 years with low back</span></p>
<p style="top:301.1pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">pain for more than 3 months</span></p>
<p style="top:291.1pt;left:465.1pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">VAS and ODI</span></p>
<p style="top:311.0pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Pijak</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2002)</span></p>
<p style="top:321.8pt;left:49.0pt;line-height:7.5pt"><span style="font-family:AdvP45A506,serif;font-size:7.5pt">[26]</span></p>
<p style="top:311.0pt;left:121.2pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Piroxicam</span></p>
<p style="top:311.0pt;left:167.6pt;line-height:8.5pt"><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:311.0pt;left:199.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">20 mg</span></p>
<p style="top:311.0pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">31 subjects of both sexes without age limitation that</span></p>
<p style="top:321.0pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">experienced back pain between the occipital region</span></p>
<p style="top:330.9pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">and gluteal fold, lasting during most days of the</span></p>
<p style="top:340.9pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">preceding 6 weeks</span></p>
<p style="top:311.0pt;left:465.1pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">VAS and PID</span></p>
<p style="top:350.9pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Fioravanti</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:360.8pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(2002)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [27]</span></p>
<p style="top:350.9pt;left:121.2pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Nimesulide</span></p>
<p style="top:350.9pt;left:167.6pt;line-height:8.5pt"><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:350.9pt;left:199.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">400 mg</span></p>
<p style="top:350.9pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">287 subjects aged 50</span><span style="font-family:AdvP4C4E59,serif;font-size:8.5pt"> --</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> 80 years with a diagnosis of</span></p>
<p style="top:360.8pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">osteoarthritis of the hip or knee according to the</span></p>
<p style="top:370.8pt;left:257.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">criteria of American College of Rheumatology</span></p>
<p style="top:350.9pt;left:465.1pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">VAS, Pain on</span></p>
<p style="top:360.8pt;left:465.1pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">movement</span></p>
<p style="top:392.0pt;left:49.0pt;line-height:7.0pt"><span style="font-family:AdvP697C,serif;font-size:7.0pt">b</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">CD:</span><span style="font-family:AdvP697C,serif;font-size:7.0pt"> b</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">-cyclodextrin; CD: Cyclodextrin; CPIS: Categorical pain intensity scale; HP</span><span style="font-family:AdvP697C,serif;font-size:7.0pt">b</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">CD: Hydroxypropyl</span><span style="font-family:AdvP697C,serif;font-size:7.0pt"> b</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">-cyclodextrin; ODI: Oswestry Disability Index; PID: Pain</span></p>
<p style="top:401.9pt;left:49.0pt;line-height:7.0pt"><span style="font-family:AdvP45A506,serif;font-size:7.0pt">intensity differences; PPID: Peak pain intensity difference; PPR: Peak pain relief; SPID: Sum of pain intensity differences; SPRID: Summed pain relief intensity</span></p>
<p style="top:411.9pt;left:49.0pt;line-height:7.0pt"><span style="font-family:AdvP45A506,serif;font-size:7.0pt">differences; TPR: Total pain relief; TSPR: Time-specific pain relief; VAS: Visual analog scale.</span></p>
<p style="top:41.8pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">R. G. Brito</span><span style="font-family:AdvP47DAD7,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:749.3pt;left:49.0pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">4</span></p>
<p style="top:750.9pt;left:236.6pt;line-height:7.0pt"><span style="font-family:AdvP4194AB,serif;font-size:7.0pt">Expert Opin. Drug Deliv.</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt"> (2015)</span><span style="font-family:AdvP6A50,serif;font-size:7.0pt"> 12</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">(10)</span></p>
<p style="top:558.4pt;left:-0.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Nandini Loganathan on 07/10/15</span></p>
<p style="top:426.0pt;left:7.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">For personal use only.</span></p>
<img style="position:absolute;transform:matrix(1.3333334,0,-0,1.3333334,674.7067,1021.9347)" src="data:image/png;base64,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">


<p style="top:635.6pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">NM-</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD was higher than that of naproxen during medium-</span></p>
<p style="top:647.6pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">term treatment on demand.</span></p>
<p style="top:676.7pt;left:71.3pt;line-height:7.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:7.5pt">4.2</span><span style="font-family:AdvP4B06EF,serif;font-size:9.5pt"> Preclinical studies</span></p>
<p style="top:688.9pt;left:71.3pt;line-height:7.5pt"><span style="font-family:AdvP3F5A6A,serif;font-size:7.5pt">4.2.1</span><span style="font-family:AdvP3F5A6A,serif;font-size:9.5pt"> Natural products</span></p>
<p style="top:698.8pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Several EOs or related compounds from medicinal plants</span></p>
<p style="top:710.8pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">have been used in preclinical studies for their analgesic profile.</span></p>
<p style="top:722.8pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">For instance, the EO obtained from</span><span style="font-family:AdvP92E7,serif;font-size:10.0pt"> Lippia grata</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> has anti-</span></p>
<p style="top:635.6pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">inflammatory and analgesic properties. Similarly, LIN and</span></p>
<p style="top:648.1pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">pCM, terpenes as main compounds of some EOs, have a</span></p>
<p style="top:660.5pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">diversity of pharmacological properties, including anticonvul-</span></p>
<p style="top:673.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">sant, anti-inflammatory and analgesic</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [51-56]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. The inclusion of</span></p>
<p style="top:685.4pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">volatile oils with</span><span style="font-family:AdvP697C,serif;font-size:10.0pt"> b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD can protect the EOs against oxidation,</span></p>
<p style="top:697.9pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">heat and light degradation, evaporation and moisture; it also</span></p>
<p style="top:710.3pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">turns liquid EOs into water-dispersible and easy-to-handle</span></p>
<p style="top:722.8pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">powders</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [57,58]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">.</span></p>
<p style="top:78.0pt;left:71.3pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">Table 2. Description of the main aspects of the preclinical studies included in the systematic review.</span></p>
<p style="top:102.3pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">Author (year)</span></p>
<p style="top:102.3pt;left:140.3pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">Substance</span></p>
<p style="top:102.3pt;left:215.5pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">CD type</span></p>
<p style="top:102.3pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">Doses</span></p>
<p style="top:102.3pt;left:314.6pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">N (per</span></p>
<p style="top:114.3pt;left:314.6pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">group)</span></p>
<p style="top:102.3pt;left:356.4pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">Route Animal</span></p>
<p style="top:102.3pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">Nociception protocols used</span></p>
<p style="top:131.7pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP4194AB,serif;font-size:8.5pt">Natural products</span></p>
<p style="top:141.6pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Siqueira-</span></p>
<p style="top:151.6pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Lima</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:161.6pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(2014)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [28]</span></p>
<p style="top:141.6pt;left:140.3pt;line-height:8.5pt"><span style="font-family:AdvP4194AB,serif;font-size:8.5pt">Lippia grata</span></p>
<p style="top:151.6pt;left:140.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">essential oil</span></p>
<p style="top:141.6pt;left:215.5pt;line-height:8.5pt"><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:141.6pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">6, 12 and</span></p>
<p style="top:151.6pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">24 kg/kg</span></p>
<p style="top:141.6pt;left:314.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">6</span></p>
<p style="top:141.6pt;left:356.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">p.o.</span></p>
<p style="top:141.6pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Male albino</span></p>
<p style="top:151.6pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Swiss mice</span></p>
<p style="top:141.6pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Formalin-, glutamate- and</span></p>
<p style="top:151.6pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">capsaicin induced nociception.</span></p>
<p style="top:171.6pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Quintans-</span></p>
<p style="top:181.5pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">J</span><span style="font-family:AdvP4C4E59,serif;font-size:8.5pt">&#xfffd;</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">unior</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:191.5pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(2013)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [29]</span></p>
<p style="top:171.6pt;left:140.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(-)-Linalool</span></p>
<p style="top:171.6pt;left:215.5pt;line-height:8.5pt"><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:171.6pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">20 and</span></p>
<p style="top:181.5pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">40 mg/kg</span></p>
<p style="top:171.6pt;left:314.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">6</span></p>
<p style="top:171.6pt;left:356.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">p.o.</span></p>
<p style="top:171.6pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Male albino</span></p>
<p style="top:181.5pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Swiss mice</span></p>
<p style="top:171.6pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Acetic acid-induced abdominal</span></p>
<p style="top:181.5pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">constrictions, formalin-,</span></p>
<p style="top:191.5pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">glutamate- and capsaicin-</span></p>
<p style="top:201.5pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">induced nociception and hot-</span></p>
<p style="top:211.4pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">plate test.</span></p>
<p style="top:221.4pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Quintans</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:231.3pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(2013)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [14]</span></p>
<p style="top:221.4pt;left:140.3pt;line-height:8.5pt"><span style="font-family:AdvP4194AB,serif;font-size:8.5pt">p</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">-Cymene</span></p>
<p style="top:221.4pt;left:215.5pt;line-height:8.5pt"><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:221.4pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">20 and</span></p>
<p style="top:231.3pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">40 mg/kg</span></p>
<p style="top:221.4pt;left:314.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">8</span></p>
<p style="top:221.4pt;left:356.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">p.o.</span></p>
<p style="top:221.4pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Male albino</span></p>
<p style="top:231.3pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Swiss mice</span></p>
<p style="top:221.4pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Acetic acid-induced abdominal</span></p>
<p style="top:231.3pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">constrictions and hot plate test.</span></p>
<p style="top:241.3pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP4194AB,serif;font-size:8.5pt">NSAIDs</span></p>
<p style="top:251.2pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">El-Feky</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:261.2pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(2013)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [30]</span></p>
<p style="top:251.2pt;left:140.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Indomethacin</span></p>
<p style="top:251.2pt;left:215.5pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">HP</span><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:251.2pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">15 and</span></p>
<p style="top:261.2pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">20 mg/kg</span></p>
<p style="top:251.2pt;left:314.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">6</span></p>
<p style="top:251.2pt;left:356.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">p.o.</span></p>
<p style="top:251.2pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Albino rats</span></p>
<p style="top:251.2pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Tail-flick test</span></p>
<p style="top:271.2pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Dolita (2012)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [31]</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> Acetyl salicylic acid</span><span style="font-family:AdvP697C,serif;font-size:8.5pt"> b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:271.2pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">30 mg/kg</span></p>
<p style="top:271.2pt;left:314.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">6</span></p>
<p style="top:271.2pt;left:356.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">p.o.</span></p>
<p style="top:271.2pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Female albino</span></p>
<p style="top:281.2pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Swiss mice</span></p>
<p style="top:271.2pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Acetic acid-induced abdominal</span></p>
<p style="top:281.2pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">constrictions</span></p>
<p style="top:291.1pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Singh</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:301.1pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(2011)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [32]</span></p>
<p style="top:291.1pt;left:140.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Etoricoxib</span></p>
<p style="top:291.1pt;left:215.5pt;line-height:8.5pt"><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD and</span></p>
<p style="top:301.1pt;left:215.5pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">HP</span><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:291.1pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">6 mg/kg</span></p>
<p style="top:291.1pt;left:314.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">6</span></p>
<p style="top:291.1pt;left:356.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">i.p.</span></p>
<p style="top:291.1pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Rats</span></p>
<p style="top:291.1pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Tail-flick test and Eddy&#x2019;s hot-</span></p>
<p style="top:301.1pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">plate apparatus</span></p>
<p style="top:311.0pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Janovsky</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:321.0pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(2010)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [33]</span></p>
<p style="top:311.0pt;left:140.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Meloxicam</span></p>
<p style="top:311.0pt;left:215.5pt;line-height:8.5pt"><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:311.0pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">3, 7,</span></p>
<p style="top:321.0pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">10 and</span></p>
<p style="top:330.9pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">15 mg/kg</span></p>
<p style="top:311.0pt;left:314.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">6</span></p>
<p style="top:311.0pt;left:356.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">p.o.</span></p>
<p style="top:311.0pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Rats and mice Plantar test and writhing test</span></p>
<p style="top:340.9pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Sinha and Goel</span></p>
<p style="top:350.9pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(2010)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [34]</span></p>
<p style="top:340.9pt;left:140.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Etodolac</span></p>
<p style="top:340.9pt;left:215.5pt;line-height:8.5pt"><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:340.9pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">10 mg/kg</span></p>
<p style="top:340.9pt;left:314.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">6</span></p>
<p style="top:340.9pt;left:356.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">p.o.</span></p>
<p style="top:340.9pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">LACA mice</span></p>
<p style="top:340.9pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Tail-flick test, Acetic acid-</span></p>
<p style="top:350.9pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">induced abdominal constrictions</span></p>
<p style="top:360.8pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Capello</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:370.8pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(2009)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [35]</span></p>
<p style="top:360.8pt;left:140.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Etodolac</span></p>
<p style="top:360.8pt;left:215.5pt;line-height:8.5pt"><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD,</span></p>
<p style="top:370.8pt;left:215.5pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">HP</span><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD and</span></p>
<p style="top:380.8pt;left:215.5pt;line-height:8.5pt"><span style="font-family:AdvP697C,serif;font-size:8.5pt">g</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:360.8pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">3.5 mg/kg</span></p>
<p style="top:360.8pt;left:314.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">6</span></p>
<p style="top:360.8pt;left:356.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">p.o.</span></p>
<p style="top:360.8pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Male Swiss</span></p>
<p style="top:370.8pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">mice</span></p>
<p style="top:360.8pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Acetic acid-induced abdominal</span></p>
<p style="top:370.8pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">constrictions</span></p>
<p style="top:390.8pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Lu</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2004)</span></p>
<p style="top:401.5pt;left:71.3pt;line-height:7.5pt"><span style="font-family:AdvP45A506,serif;font-size:7.5pt">[36]</span></p>
<p style="top:390.8pt;left:140.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Ketoprofen</span></p>
<p style="top:390.8pt;left:215.5pt;line-height:8.5pt"><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:390.8pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">4, 8 and</span></p>
<p style="top:400.7pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">16 mg/kg</span></p>
<p style="top:390.8pt;left:314.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">15</span></p>
<p style="top:390.8pt;left:356.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">p.o.</span></p>
<p style="top:390.8pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Kun-Ming</span></p>
<p style="top:400.7pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">mice</span></p>
<p style="top:390.8pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Acetic acid-induced abdominal</span></p>
<p style="top:400.7pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">constrictions</span></p>
<p style="top:410.7pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP4194AB,serif;font-size:8.5pt">Canabinoid</span></p>
<p style="top:420.6pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Astruc-Diaz</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:430.6pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(2013)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [37]</span></p>
<p style="top:420.6pt;left:140.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">MDA7</span></p>
<p style="top:420.6pt;left:215.5pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">HP</span><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:420.6pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">10 mg/kg</span></p>
<p style="top:420.6pt;left:314.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">3</span></p>
<p style="top:420.6pt;left:356.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">i.v.</span></p>
<p style="top:420.6pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Male</span></p>
<p style="top:430.6pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Sprague-Daw-</span></p>
<p style="top:440.5pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">ley rats</span></p>
<p style="top:420.6pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Spinal nerve ligation neuropathic</span></p>
<p style="top:430.6pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">pain model and von Frey</span></p>
<p style="top:440.5pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">filaments</span></p>
<p style="top:450.5pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP4194AB,serif;font-size:8.5pt">Steroids</span></p>
<p style="top:460.5pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Svensson</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:470.4pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(2013)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [38]</span></p>
<p style="top:460.5pt;left:140.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Allopregnanolone,</span></p>
<p style="top:470.4pt;left:140.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">alphaxalone</span></p>
<p style="top:460.5pt;left:215.5pt;line-height:8.5pt"><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:460.5pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">10</span><span style="font-family:AdvOT35fdff1a,serif;font-size:8.5pt"> &#xb5;</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">l</span></p>
<p style="top:460.5pt;left:314.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">6</span></p>
<p style="top:460.5pt;left:356.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">i.t.</span></p>
<p style="top:460.5pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Adult male</span></p>
<p style="top:470.4pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">rats</span></p>
<p style="top:480.4pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(Holtzman)</span></p>
<p style="top:460.5pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Unilateral intraplantar delivery of</span></p>
<p style="top:470.4pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">carrageenan, Hargreaves system</span></p>
<p style="top:480.4pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">and von Frey filaments.</span></p>
<p style="top:490.4pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP4194AB,serif;font-size:8.5pt">Local anesthetics</span></p>
<p style="top:500.3pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Franco de</span></p>
<p style="top:510.3pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Lima</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:520.2pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(2012)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [39]</span></p>
<p style="top:500.3pt;left:140.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Tetracaine</span></p>
<p style="top:500.3pt;left:215.5pt;line-height:8.5pt"><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD and</span></p>
<p style="top:510.3pt;left:215.5pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">HP</span><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:500.3pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">0.5%</span></p>
<p style="top:500.3pt;left:314.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">7</span></p>
<p style="top:500.3pt;left:356.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">i.n.</span></p>
<p style="top:500.3pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Male Wistar</span></p>
<p style="top:510.3pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">rats</span></p>
<p style="top:500.3pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Infraorbital nerve blockade</span></p>
<p style="top:510.3pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">technique</span></p>
<p style="top:530.2pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP4194AB,serif;font-size:8.5pt">Opioid</span></p>
<p style="top:540.2pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Volobuef</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:550.1pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(2012)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [40]</span></p>
<p style="top:540.2pt;left:140.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Sufentanil</span></p>
<p style="top:540.2pt;left:215.5pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">HP</span><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:540.2pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">1</span><span style="font-family:AdvOT35fdff1a,serif;font-size:8.5pt"> &#xb5;</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">g/kg</span><sup><span style="font-family:AdvP45A506,serif;font-size:6.0pt">-1</span></sup></p>
<p style="top:540.2pt;left:314.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">7</span></p>
<p style="top:540.2pt;left:356.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">i.m.</span></p>
<p style="top:540.2pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Male Wistar</span></p>
<p style="top:550.1pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">rats</span></p>
<p style="top:540.2pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Tail-flick test</span></p>
<p style="top:560.1pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP4194AB,serif;font-size:8.5pt">Antidepressants</span></p>
<p style="top:570.1pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Sammeta</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:580.0pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(2010)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [41]</span></p>
<p style="top:570.1pt;left:140.3pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Doxepin</span></p>
<p style="top:570.1pt;left:215.5pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">HP</span><span style="font-family:AdvP697C,serif;font-size:8.5pt">b</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">CD</span></p>
<p style="top:570.1pt;left:264.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">5%</span></p>
<p style="top:570.1pt;left:314.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">3</span></p>
<p style="top:570.1pt;left:356.4pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">t.o.</span></p>
<p style="top:570.1pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Male hairless</span></p>
<p style="top:580.0pt;left:386.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">rats</span></p>
<p style="top:570.1pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Pain avoiding response using a</span></p>
<p style="top:580.0pt;left:443.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">blunt needle.</span></p>
<p style="top:601.1pt;left:71.3pt;line-height:7.0pt"><span style="font-family:AdvP697C,serif;font-size:7.0pt">b</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">CD:</span><span style="font-family:AdvP697C,serif;font-size:7.0pt"> b</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">-Cyclodextrin;</span><span style="font-family:AdvP697C,serif;font-size:7.0pt"> g</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">CD:</span><span style="font-family:AdvP697C,serif;font-size:7.0pt"> g</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">-Cyclodextrin; CD: Cyclodextrin; HP</span><span style="font-family:AdvP697C,serif;font-size:7.0pt">b</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">CD: Hydroxypropyl</span><span style="font-family:AdvP697C,serif;font-size:7.0pt"> b</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">-cyclodextrin; i.m.: Intramuscular; i.n.: Infraorbital notch; i.p.: Intraperitoneal;</span></p>
<p style="top:611.1pt;left:71.3pt;line-height:7.0pt"><span style="font-family:AdvP45A506,serif;font-size:7.0pt">i.t.: Intrathecal; i.v.: Intravenous; p.o.: Oral administration; t.o.: Topically.</span></p>
<p style="top:41.8pt;left:439.2pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">CDs improving analgesic drugs</span></p>
<p style="top:750.9pt;left:258.9pt;line-height:7.0pt"><span style="font-family:AdvP4194AB,serif;font-size:7.0pt">Expert Opin. Drug Deliv.</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt"> (2015)</span><span style="font-family:AdvP6A50,serif;font-size:7.0pt"> 12</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">(10)</span></p>
<p style="top:749.3pt;left:558.3pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">5</span></p>
<p style="top:558.4pt;left:-0.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Nandini Loganathan on 07/10/15</span></p>
<p style="top:426.0pt;left:7.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">For personal use only.</span></p>
<img style="position:absolute;transform:matrix(1.3333334,0,-0,1.3333334,674.7067,1021.9347)" src="data:image/png;base64,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">


<img style="position:absolute;transform:matrix(.48025484,0,-0,.47846053,137.69,171.90796)" src="data:image/jpeg;base64,
/9j/7gAOQWRvYmUAZIAAAAAB/9sAhAASDg4OEA4VEBAVHhMREx4jGhUVGiMiGBga
GBgiJx4iISEiHicnLjAzMC4nPj5CQj4+REREREREREREREREREREARQTExYZFhsX
FxsaFhoWGiEaHR0aITEhISQhITE+LScnJyctPjg7MzMzOzhERD4+RERERERERERE
RERERERERET/wAARCAEjAgYDASIAAhEBAxEB/8QBPwAAAQUBAQEBAQEAAAAAAAAA
AwABAgQFBgcICQoLAQABBQEBAQEBAQAAAAAAAAABAAIDBAUGBwgJCgsQAAEEAQMC
BAIFBwYIBQMMMwEAAhEDBCESMQVBUWETInGBMgYUkaGxQiMkFVLBYjM0coLRQwcl
klPw4fFjczUWorKDJkSTVGRFwqN0NhfSVeJl8rOEw9N14/NGJ5SkhbSVxNTk9KW1
xdXl9VZmdoaWprbG1ub2N0dXZ3eHl6e3x9fn9xEAAgIBAgQEAwQFBgcHBgU1AQAC
EQMhMRIEQVFhcSITBTKBkRShsUIjwVLR8DMkYuFygpJDUxVjczTxJQYWorKDByY1
wtJEk1SjF2RFVTZ0ZeLys4TD03Xj80aUpIW0lcTU5PSltcXV5fVWZnaGlqa2xtbm
9ic3R1dnd4eXp7fH/9oADAMBAAIRAxEAPwDuEkkklKSSSSUpJJJJSkkkklKSSSSU
pJJJJSkkkklKSSSSUpJJJJSkkkklKSSSSUpJJJJSkkkklKSSSSU819Ya3fb8Rzbb
KyQ8fo3uZwPJUfTu/wC5eT/29Z/etL6wf03D/t/9SqKq5pSEqBI0a+WUhLQkI/Tu
/wC5eT/29Z/el6d3/cvJ/wC3rP70RJRe5P8AeP2sfHLuUfp3f9y8n/t6z+9L07v+
5eT/ANvWf3oiSXuT/eP2q45dyiox3WdRqa/JyDLHmfWfu0jgytX9nN/7k5X/ALEW
f3qhif8AKdX/ABdn/fVuKrzGbKJACch6ehbmDXGCddS0v2c3/uTlf+xFn96X7Ob/
ANycr/2Is/vV1JQ/eM3+cn/jM1Ds0v2c3/uTlf8AsRZ/el+zm/8AcnK/9iLP71dS
S+8Zv85P/GVQ7PPZmO6rqDGsyMgTUSXes8u+k3vKXp3f9ysn/t6z+9H6h/ymz/iX
f9U1QV7HkmYRJlLWPdo5pETIBIR+nd/3Lyf+3rP70vTu/wC5WT/29Z/eiJJ3uT/e
P2sfHL94o/Tu/wC5WT/29Z/elsu/7l5P/b1n96Ikl7k/3j9quOXctO5lv2mj9ZyC
SXam55I9p4Mqx6d3/cvJ/wC3rP70K7+lY/xd/wBSVZTjOdD1Hburjl3KP07v+5WT
/wBvWf3pend/3Lyf+3rP70RJN9yf7x+1XHLuUfp3f9ysn/t6z+9L07v+5eT/ANvW
f3oiSXuT/eP2q45fvFpWMt+2U/rORJa/3es/cIjgyrPp3f8AcrJ/7es/vQrP6bR/
Vs/grKJnPT1Hburjl3KPZd/3Lyf+3rP70vTu/wC5eT/29Z/eiJIe5P8AeP2q45dy
j9O7/uXk/wDb1n96Wy7/ALl5P/b1n96Ikl7k/wB4/arjl+8Wm5lv21g+05Emt3u9
Z+7lveVY9O7/ALlZP/b1n96E7+nM/wCLd+VqspxnPT1Hburjl3KPZd/3Lyf+3rP7
0vTu/wC5WT/29Z/eiJJvuT/eP2q45dyj9O7/ALl5P/b1n96Xp3f9y8n/ALes/vRE
kvcn+8ftVxy/eLUtZb69P6zkEkugm15I9p4M6JIl39Io+Lv+pKSfxyr5j8v7U8cq
3O37XtkkklcbakkkklKSSSSUpJJJJSkkkklKSSSSUpJJJJSkkkklKSSSSUpJJJJS
kkkklKSSSSUpJJJJSkkkklPPfWD+m4f9v/qVRV76wf03D/t/9SqKqZ/n+jWy/MpJ
JJQsSkkkklL4n/KdX/F2f99W4sTE/wCU6v8Ai7P++rbhU+Z+cf3Q3+X/AJseZWTp
QUoUDMpMnhKCkpxeof8AKbP+Jd/1TVBT6gP8p1/8S7/qmqC0Mf8ANw/uufn/AJyS
kkkk9iUkkkkprXf0rH+Lv+pKsqvd/Ssf4u/6kqwidh5ftUpJJJBSkkoSSU1rP6bR
/Vs/grKrWf02j+rZ/BWUT08ldlJJJJqlJJJJKazv6cz/AIt35Wqyq7v6cz/i3fla
rCcenkpSSUJIKUkkkkpBd/SKPi7/AKkpJXf0ij4u/wCpKSf+j/gf90np9P2vbJJJ
K83VJJJJKUkkkkpSSSSSlJJJJKUkkkkpSSSSSlJJJJKUkkkkpSSSSSlJJJJKUkkk
kpSSSSSlJJJJKeY+suLRbnYhsZuJDwTLhoBI4KzP2bhf6L/pP/8AJLZ+sH9Nw/7f
/UqiquckT0JGjWykiWhan7Nwv9F/0n/+SS/ZuF/ov+k//wAkraSh4pdz9rHxHuWp
+zcL/Rf9J/8A5JL9m4X+i/6T/wDyStpJcUu5+1XEe5auN03Bd1Cqt1UsLHkjc/kR
/KWv+xemf6D/AKdn/klTxP8AlOr/AIuz/vq3FV5jJMTFSkPSOrdwa4xeupc/9i9M
/wBB/wBOz/ySX7F6Z/oP+nZ/5JaCSg93J+/P/GLNQ7Of+xemf6D/AKdn/kkv2L0z
/Qf9Oz/yS0Ekvdyfvz/xiqh2eazumYLM9lbaoaanEjc/nc3+Uofs3C/0X/Sf/wCS
V7qH/KbP+Jd/1TVBX8c5cEPUfl7tHMSMhotT9m4X+i/6T/8AySX7Nwv9F/0n/wDk
lbSTuKXc/axcR7lqfs3C/wBF/wBJ/wD5JL9m4X+i/wCk/wD8kraSXFLuftVxHuXN
twMMZFDRXo4ukbndm/FH/ZuF/ov+k/8A8kpXf0rH+Lv+pKspxlKhqdu6uI9y1P2b
hf6L/pP/APJJfs3C/wBF/wBJ/wD5JW0k3il3P2q4j3LU/ZuF/ov+k/8A8kl+zcL/
AEX/AEn/APklbSS4pdz9quI9y5r8DEGXU0V+1zXkjc7tHmj/ALNwv9F/0n/+SUrP
6bR/Vs/grKcZS01O3dXEe5an7Nwv9F/0n/8Akkv2bhf6L/pP/wDJK2km8Uu5+1XE
e5an7Nwv9F/0n/8Akkv2bhf6L/pP/wDJK2klxS7n7VcR7lzXYGH9sYz0/aa3GNzu
QR5o/wCzcL/Rf9J//klJ39OZ/wAW78rVZTjKWmp27q4j3LU/ZuF/ov8ApP8A/JJf
s3C/0X/Sf/5JW0k3il3P2q4j3LU/ZuF/ov8ApP8A/JJfs3C/0X/Sf/5JW0kuKXc/
ariPcufZgYguqaK9HF24bndmk+KSs3f0ij4u/wCpKSfxSrc/L/3SeI1udv2vbJJJ
K63FJJJJKUkkkkpSSSSSlJJJJKUkkkkpSSSSSlJJJJKUkkkkpSSSSSlJJJJKUkkk
kpSSSSSlJJJJKee+sH9Nw/7f/Uqir31g/puH/b/6lUVUz/P9Grl+ZSSSShY1JJJJ
KXxP+U6v+Ls/76txYmJ/ynV/xdn/AH1bcFU+Z+cf3Q3+X/mx5lSSUFKCq7MpJKCl
BSU4vUP+U2f8S7/qmqCn1D/lNn/Eu/6pqgtHH/Nw/uufn/nJKSSST2JSSSSSmtd/
Ssf4u/6kqyq139Kx/i7/AKkqyidh5ftUpJJJBSkkkklNaz+m0f1bP4Kyq1n9No/q
2fwVlE9PJXZSSSSapSSSSKms7+nM/wCLd+Vqsqu7+nM/4t35WqwienkpdJIJ9E1L
FJOUySEF39Io+Lv+pKSV39Io+Lv+pKSk/R/wP+6T0+n7XtkkklebqkkkklKSSSSU
pJJJJSkkkklKSSSSUpJJJJSkkkklKSSSSUpJJJJSkkkklKSSSSUpJJJJSkkkklPM
fWXGrtzsQuLwSHg7XubwJ7FZn7Po/ft/7df/AHrZ+sH9Nw/7f/UqiquckT0PRrZS
RLdqfs+j9+3/ALdf/el+z6P37f8At1/96tpKHil3LHxHu1P2fR+/b/26/wDvS/Z9
H79v/br/AO9W0kuKXcq4j3auN0+h3UKmF9sFjzIteDpHeVr/ALIxf9Jf/wBv2/8A
klTxP+U6v+Ls/wC+rcVXmMkxMVIj0hu4NcYvuXP/AGRi/wCkv/7ft/8AJJfsjF/0
l/8A2/b/AOSWgkoPdyfvS+1moOf+yMX/AEl//b9v/kkv2Pi/6S//ALft/wDJLQSS
93J+9L7VUHms7p1DM9jA+0g1OMm15P0m9yVD9n0fv2/9uv8A71e6h/ymz/iXf9U1
QV/HOXBDU/K0cxIyGmp+z6P37f8At1/96X7Po/ft/wC3X/3q2kncUu5YuI92p+z6
P37f+3X/AN6X7Po/ft/7df8A3q2klxS7lXEe7m24NIyKG7rIcXT+kfP0e2qP+z6P
37f+3X/3qV39Kx/i7/qSrKcZSoanZXEe7U/Z9H79v/br/wC9L9n0fv2/9uv/AL1b
STeKXcq4j3an7Po/ft/7df8A3pfs+j9+3/t1/wDeraSXFLuVcR7ua/BpGXU3dZBa
8n9I+dI7yj/s+j9+3/t1/wDepWf02j+rZ/BWCnGUtNTsniPdq/s+j9+3/t1/96X7
Po/ft/7df/erMppQ4pdyqz3a/wCz6P37f+3X/wB6X7Po/ft/7df/AHq0CnQ4pdyj
iPdzXYNP2xjd1kGtx/nHzyO8o/7Po/ft/wC3X/3qTv6cz/i3flarKcZS01OyuI92
p+z6P37f+3X/AN6X7Po/ft/7df8A3q2km8Uu5VxHu1P2fR+/b/26/wDvS/Z9H79v
/br/AO9W0kuKXcq4j3c+zCpF1TQ6yHF0zY+dGk6apKzd/SKPi7/qSkn8Rrf9H/uk
8Rrfp+17ZJJJXW4pJJJJSkkkklKSSSSUpJJJJSkkkklKSSSSUpJJJJSkkkklKSSS
SUpJJJJSkkkklKSSSSUpJJJJTz31g/puH/b/AOpVFXvrB/TcP+3/ANSqKqZ/n+jW
y/MpJJJQsSkkkklL4n/KdX/F2f8AfVuLDxP+U6v+Ls/76ttU+Z+cf3Q3uX/mx5ld
JJJQM6kkkklOL1D/AJTZ/wAS7/qmqCn1D/lNn/Eu/wCqaoLQx/zcP7rn5/5ySkkk
k9iUkkkkprXf0rH+Lv8AqSrKrXf0rH+Lv+pKsonYeX7VKSSSQUpJJJJTWs/ptH9W
z+CsFV7P6bR/Vs/grBCJ6eSeyMlNKkWpbUUrhTUQFJNKC1nf05n/ABbvytVlVnf0
5n/Fu/K1WUT08kKSSSQUpJJJJSC7+kUfF3/UlJK7+kUfF3/UlJP/AEf8D/uk9Pp+
17ZJJJXm6pJJJJSkkkklKSSSSUpJJJJSkkkklKSSSSUpJJJJSkkkklKSSSSUpJJJ
JSkkkklKSSSSUpJJJJTzH1loNmdiH1bGSHiGOgCBMjRZn2I/9yb/APPH9y2frB/T
cP8At/8AUqiquckT+jWyk8TU+xH/ALk3/wCeP7kvsR/7k3/54/uVtJQ8RY+ItX7E
f+5N/wDnj+5N9iP/AHJv/wA8f3K2klxFXEWtjYTndQqZ9pvEsedweNwiPJa37Md/
3Nyv+3B/5FU8T/lOr/i7P++rcVXmMkhMUf0R0buDXGL7lz/2Y7/ublf9uD/yKX7M
d/3Nyv8Atwf+RWgkoPdn3/AM1Of+zHf9zcr/ALcH/kUv2Y7/ALm5X/bg/wDIrQSS
9yff8Aqnms7Cc3PYz7Te6anHc54LvpN04UPsR/7k3/54/uV7qH/KbP8AiXf9U1QV
/HI8EP7rRzEjIWp9iP8A3Jv/AM8f3JfYj/3Jv/zx/craSdxFi4i1PsR/7k3/AOeP
7kvsR/7k3/54/uVtJLiKuIubbiEZFA+0XHcXalwke3toj/Yj/wByb/8APH9yld/S
sf4u/wCpKspxkaHkriLU+xH/ALk3/wCeP7kvsR/7k3/54/uVtJN4iriLU+xH/uTf
/nj+5L7Ef+5N/wDnj+5W0kuIq4i5GVQ+vKpDci07mv1LtREcaJend/3Ju/zv9iNn
f0zH/q2fwTKSzQ8nd+HYMWTlxKcIyPHIWQi9O7/uTd/nf7EvTu/7k3f53+xFSQst
77py/wDmofYi9O7/ALk3f53+xL07v+5N3+d/sRUkrKvunL/5qH2NQtu+1tb9ot+g
fdu15Hkjend/3Ju/zv8AYoH+mt/4t35QrCJJ08lkeVwer9VDSXZF6d3/AHJu/wA7
/Yl6d3/cm7/O/wBiKkhZX/dOX/zUPsRend/3Ju/zv9iXp3f9ybv87/YipJWVfdOX
/wA1D7Gs5lvqsBvtPMEu1GnbRJEf/PV/P8iSfen+D+1h+7YOOvbh/OVt04L/ADfR
kkklacdSSSSSlJJJJKUkkkkpSSSSSlJJJJKUkkkkpSSSSSlJJJJKUkkkkpSSSSSl
JJJJKUkkkkpSSSSSnnvrB/TcP+3/ANSqKvfWD+m4f9v/AKlUVUz/AD/Rq5fmUkkk
oWNSSSSSl8T/AJTq/wCLs/76txYeJ/ynV/xdn/fVuKnzPzj+6G9y/wDNjzKkkklA
zqSSSSU4vUP+U2f8S7/qmqCn1D/lNn/Eu/6pqgtDH/Nw/uufn/nJKSSST2JSSSSS
mtd/Ssf4u/6kqyq139Kx/i7/AKkqyidh5ftUpJJJBSkkkklOdnf0zH/q2fwTJ87+
mY/9Wz+CZSdI+T0fwr/cw/vyUkkkg6CkkkklNc/01v8AxbvyhWFXP9Nb/wAW78oV
hOPTyWQ3l/e/YpJJPITV6ySSSSkT/wCer+f5Ekn/AM9X8/yJJ/T/AAf2sH6f/Vv/
AFG+jJJJK24KkkkklKSSSSUpJJJJSkkkklKSSSSUpJJJJSkkkklKSSSSUpJJJJSk
kkklKSSSSUpJJJJSkkkklPMfWSq1+diFtzqwQ8ANDTBjnULM+y5P/cuz/Nr/APIr
Z+sH9Nw/7f8A1KoqrnJE/p2a2U+pqfZcn/uXZ/m1/wDkUvsuT/3Ls/za/wDyKtpK
HiPh9gY7Ph9jV+y5P/cuz/Nr/wDIpvsuT/3Ls/za/wDyKtpJcR8PsCrPh9jWxsXJ
PUKmjMsa4seQ8NrkRGn0VrfYcz/ywu/zKf8AyCp4n/KdX/F2f99W4qvMTImPl+Uf
ohu8vrjHmXP+w5n/AJYXf5lP/kEvsOZ/5YXf5lP/AJBaCSg9yX9X/Fj/AAZqc/7D
mf8Alhd/mU/+QS+w5n/lhd/mU/8AkFoJJe5L+r/ix/gqnms7FyW57GuzLHO9IneW
1zG5umjVD7Lk/wDcuz/Nr/8AIq91D/lNn/Eu/wCqaoK/jkeCG3y9g0cxrIWp9lyf
+5dn+bX/AORS+y5P/cuz/Nr/APIq2kncR8PsDFZ8Psan2XJ/7l2f5tf/AJFL7Lk/
9y7P82v/AMiraSXEfD7Aqz4fY5tuPeMigHKeSS6DtZp7f6qP9lyf+5dn+bX/AORU
rv6Vj/F3/UlWU4yNDbbsFWfD7Gp9lyf+5dn+bX/5FL7Lk/8Acuz/ADa//Iq2km8R
8PsCrPh9jU+y5P8A3Ls/za//ACKX2XJ/7l2f5tf/AJFW0kuI+H2BXEfD7HGzKLhl
UA5D3EtfDiGSOPAJvQu/7kP+5n9ys539Mx/6tn8Eyk4jQ227PQfDIiXLAm/nlsSP
ya/oXf8Ach/3M/uS9C7/ALkP+5n9ysJIcR8Psb/tx/rf40v4tf0Lv+5D/uZ/cl6F
3/ch/wBzP7lYSS4j4fYr24/1v8aX8WgabftbR67p2E7obPI04R/Qu/7kP+5n9yR/
prf+Ld+UKwnEnTbbstjjjcvm+b949vNr+hd/3If9zP7kvQu/7kP+5n9ysJJvEfD7
F3tx/rf40v4tf0Lv+5D/ALmf3Jehd/3If9zP7lYSS4j4fYr24/1v8aX8Wo6m0WsH
ruJMwYbp+CSM/wDnq/n+RJPs1/g9vFh4Bx/pfzv7x/cfRkkklacNSSSSSlJJJJKU
kkkkpSSSSSlJJJJKUkkkkpSSSSSlJJJJKUkkkkpSSSSSlJJJJKUkkkkpSSSSSnnv
rB/TcP8At/8AUqir31g/puH/AG/+pVFVM/z/AEauX5lJJJKFjUkkkkpfE/5Tq/4u
z/vq3Fh4n/KdX/F2f99W2qfM/OP7ob3L/wA2PMrpJJKBnUkkkkpxeof8ps/4l3/V
NUFPqH/KbP8AiXf9U1QWhj/m4f3XPz/zklJJJJ7EpJJJJTWu/pWP8Xf9SVZVa7+l
Y/xd/wBSVZROw8v2qUkkkgpSSSSSnOzv6Zj/ANWz+CZPnf0zH/q2fwTKTpHyej+F
f7mH9+SkkkkHQUkkkkprn+mt/wCLd+UKwq5/prf+Ld+UKwnHp5LIby/vfsUkkkmr
1JJJJKRP/nq/n+RJJ/8APV/P8iSf0/wf2sH6f/Vv/Ub6MkkkrbgqSSSSUpJJJJSk
kkklKSSSSUpJJJJSkkkklKSSSSUpJJJJSkkkklKSSSSUpJJJJSkkkklKSSSSU8r9
aX5LMzENRYAQ+A4EmY1mCFj/AGjqH71P+a7/AMktr61f0rC/t/8AUrGVbN823R0O
V5TBlx8eSHFLiIuyt9o6h+9T/mu/8kl9o6h+9T/mu/8AJJ0lH9A2f9Hcr/m/+cVv
tHUf3qf813/kkvtHUP3qf813/kk6SH0Cv9Hcr/m/+cUbM7qFWbW4Gov2PAlrtsGJ
/OV79sdW/wCA/wAx/wD5NZj/AOm1f1XfwVlCcIGiYxOnZUOTwDiAjQEtPUeza/a/
Vv8AgP8AMf8A+TS/bHVv+A/zH/8Ak1VSTfax/uR+xk+6Yf3T/jFtftjq3/Af5j//
ACaX7X6t/wAB/mP/APJqqkl7WP8Acj9ivumH90/4xTUv6j1DP1fTW9lR12PLY3N7
blf/AGZ1P/uRR/22/wD8mq3Rf+Un/wDEn/qmro1XzZZQkIxoARGlBys+DGMsxw7F
xf2Z1P8A7kUf9tv/APJpfszqf/cij/tt/wD5NbKdRfeMncf4oYvZx/uhxf2Z1P8A
7kUf9tv/APJpfszqf/cij/tt/wD5NbSSX3jJ3H+KFezj/dDzd+B1BuXjMN9Jc4u2
kVvgQ08+9Wv2Z1P/ALkUf9tv/wDJq3lf8oYfxf8A9QVfT5Z8lQ1Gsf3R3KBhx/uu
L+zOp/8Acij/ALbf/wCTS/ZnU/8AuRR/22//AMmtpJM+8ZO4/wAUJ9nH+64v7M6n
/wByKP8Att//AJNL9mdT/wC5FH/bb/8Aya2kkvvGTuP8UK9nH+6HkOp4udRlY4fb
U5zmv2lrHADiZlyr7c39+v8AzXf+SWv17+mYv9Wz+CoK9imZY4k1ZHbxdTkscRho
WPWdi19ub+/X/mu/8kltzf36/wDNd/5JWEk+/L7G3wDvL/GLX25v79f+a7/ySW3N
/fr/AM13/klYSSvy+xXAO8v8YtAty/tbffXv2HXa6IkeaPtzf36/813/AJJI/wBN
b/xbvyhWE4nbbZbCAuWsvm/ePZr7c39+v/Nd/wCSS25v79f+a7/ySsJJt+X2LuAd
5f4xa+3N/fr/AM13/kktub+/X/mu/wDJKwklfl9iuAd5f4xabm5fqsl9e7WDtdH5
Ukd/89X8/wAiSfenT5f2sPAOPeX873P7j6MkkkrThqSSSSUpJJJJSkkkklKSSSSU
pJJJJSkkkklKSSSSUpJJJJSkkkklKSSSSUpJJJJSkkkklKSSSSU8v9av6Thf2/8A
qVjLZ+tX9Kwv7f8A1KxlWzfN9HY+H/zJ/vlSSSSibqkkkklNZ/8ATav6rv4Kyqz/
AOm1f1XfwVlE9PJZDef979gUkkkgvUkkkkpudF/5Sf8A8Sf+qaujXOdG/wCUn/8A
En/qmro1Q5r+c/wQ4/Mfz0/P9iySSSgYV0kydJTQyv8AlDD+L/8AqCr6oZX/AChh
/F//AFBV9PntD+7+0oHVSSSSYlSSSSSnn+vf0zF/q2fwVBX+vf0zF/q2fwVBaWH+
ah5H83T5L+aP98qSSSUjbUkkkkprn+mt/wCLd+UKwq5/prf+Ld+UKwnHp5LIby/v
fsWTpJJq9SSSSSkT/wCer+f5Ekn/AM9X8/yJJ/T/AAf2sH6f/Vv/AFG+jJJJK24K
kkkklKSSSSUpJJJJSkkkklKSSSSUpJJJJSkkkklKSSSSUpJJJJSkkkklKSSSSUpJ
JJJSkkkklPK/WlmS/MxBUGQA+C4uGsazAWP9n6j+7T/nP/8AIrofrB/TcP8At/8A
UqiquaVS+iPvefF6McuGO+wcz7P1H92n/Of/AORS+z9R/dp/zn/+RWmkouLwCv8A
SPNf5z/mhzPs/UfCn/Of/wCRS+z9R/dp/wA5/wD5FaaSXF4BX+kea/zn/NDksweo
W5tbQKQ/Y8iXO2wIn81Xv2P1b/uv/nP/APIqzif8p1f8XZ/31bir5s84yAHD8vZs
4ebzyhxGepJvQPNfsfq3/df/ADn/APkUv2P1b/uv/nP/APIrpE6i+9ZP6v2Mv3nN
++fsDzX7H6t/3X/zn/8AkUv2P1b/ALr/AOc//wAiulTJfesn9X7Ffec375+wPL0s
6j0/P1ZTZY+o6b3hu3c3+Sr/AO0+p/6Cj/tx/wD5BLqH/KbP+Jd/1TVBWAIzjGco
gkx8XPz8xk9yWt/Rn+0+p/6Cj/tx/wD5BL9p9T/0FH/bj/8AyCgkl7WP9wfixfeM
nf8ABn+0+p/6Cj/tx/8A5BL9p9T/ANBR/wBuP/8AIKCSXtY/3B+KvvGTv+CC/P6g
7LxnmmkOaXbQHvgy08+xWv2n1P8A0FH/AG4//wAgqd39Kx/i7/qSrKJx46j6Bt49
1e/k7/gz/afU/wDQUf8Abj//ACCX7T6n/oKP+3H/APkFBJD2sf7g/FX3jJ3H2M/2
n1P/AEFH/bj/APyCX7T6n/oKP+3H/wDkFBJL2sf7g/FX3jJ3/BodQtz8rKo3V0sc
1r9sPeQRpM+1D+z9R/dp/wA5/wD5FWrP6bR/Vs/grKlFREQAAKZYc9zEBUZ0N9g5
n2fqP7tP+c//AMil9n6j+7T/AJz/APyK00kuLwC7/SPNf5z/AJocz7P1H92n/Of/
AORS+z9R/dp/zn/+RWmklxeAV/pHmv8AOf8ANDinHzvtbdKt5Y6BudESP5KP9n6j
+7T/AJz/APyKtO/pzP8Ai3flarKJltoNlD4hzI2nvr8ocz7P1H92n/Of/wCRS+z9
R/dp/wA5/wD5FaaSHF4BX+kea/zn/NDmfZ+o+FP+c/8A8il9n6j+7T/nP/8AIrTS
S4vAK/0jzX+c/wCaHIfRnC2uRVuMhsOdHE6+1JaF39Io+Lv+pKSfxabD5f8Aukff
+Y349fm2G/y/k9skkkri5SSSSSlJJJJKUkkkkpSSSSSlJJJJKUkkkkpSSSSSlJJJ
JKUkkkkpSSSSSlJJJJKUkkkkpSSSSSnnvrB/TcP+3/1Koq99YP6bh/2/+pVFVM/z
/Rq5fmUkkkoWNSSSSSl8T/lOr/i7P++rcWHif8p1f8XZ/wB9W4qfM/OP7ob3L/zY
8ypJJJQM6kkydJTi9Q/5TZ/xLv8AqmqCn1D/AJTZ/wAS7/qmqC0Mf83D+65+f+ck
pJJJPYlJJJJKa139Kx/i7/qSrKrXf0rH+Lv+pKsonYeX7VKSSSQUpJJJJTWs/ptH
9Wz+CsqtZ/TaP6tn8FZRPTyV2UkkkgpSSSSSms7+nM/4t35Wqyqzv6cz/i3flarK
J6eSlJJJIKUkkkkpBd/SKPi7/qSkld/SKPi7/qSkn/o/4H/dJ6fT9r2ySSSvN1SS
SSSlJJJJKUkkkkpSSSSSlJJJJKUkkkkpSSSSSlJJJJKUkkkkpSSSSSlJJJJKUkkk
kpSSSSSnG6v0zOzcqizHsrrZUHTvaXGXDycFU/YXVf8AuVR/20//ANKLpEk0wiTZ
FrTGJ1Ieb/YXVf8AuVR/20//ANKJfsLqv/cqj/tp/wD6UXSJIe1D90I9uHYPN/sL
qv8A3Ko/7af/AOlEv2F1X/uVR/20/wD9KLpEkvbh+6Fe3DsHmmdE6xXlMubkUHa1
zZNb4G6O3qK59h63/wByMb/tqz/0otlJNly+KRswBXx9IoaBxvsPW/8AuRjf9tWf
+lEvsPW/+5GN/wBtWf8ApRbKSb91wf5uKeI93G+w9b/7kY3/AG1Z/wClEvsPW/8A
uRjf9tWf+lFspJfdcH+biriPd5q7ovWLsptrsigQwt3Ct8akGI9TyT/sLqv/AHKo
/wC2n/8ApRdIknjFjAAERosMYk2RZeb/AGF1X/uVR/20/wD9KJfsLqv/AHKo/wC2
n/8ApRdIkj7UP3Qj24dg83+wuq/9yqP+2n/+lEv2F1X/ALlUf9tP/wDSi6RJL24f
uhXtw7B5az6vdWddU/7RQdk6+m4RIjjfqi/sLqv/AHKo/wC2n/8ApRdIkl7cP3Qr
24dg83+wuq/9yqP+2n/+lEv2F1X/ALlUf9tP/wDSi6RJL2ofuhXtw7B5v9hdV/7l
Uf8AbT//AEol+wuq/wDcqj/tp/8A6UXSJJe3D90K9uHYPLO+r3VjkV2faKPaHCfT
dA3R23ov7C6r/wByqP8Atp//AKUXSJJe3D90K9uPYPN/sLqv/cqj/tp//pRL9hdV
/wC5VH/bT/8A0oukSS9uH7oV7cOweb/YXVf+5VH/AG0//wBKJfsLqv8A3Ko/7af/
AOlF0iSXtw/dCvbh2Dyx+r3VjkNs+0UaNI3em6NSNI3ov7C6r/3Ko/7af/6UXSJJ
e3D90K9uPYPN/sLqv/cqj/tp/wD6US/YXVf+5VH/AG0//wBKLpEkvbh+6Fe3DsHm
/wBhdV/7lUf9tP8A/SiX7C6r/wByqP8Atp//AKUXSJJe3D90K9uHYPLv+r/VTbW7
7RQdpOvpuESI436pLqEkvbj2CeCPZSSruzsNri11rQRyE37Qwv8ATNTuKPcK4o9x
9rZSVb9oYX+mal+0ML/TNS4o9wrij3H2tlJVv2hhf6ZqX7Qwv9M1Lij3CuKPcfa2
UlGuyu1u+twc09wpIrlJJJJKUkkkkpSSSSSlJJJJKUkkkkpSSSSSlJJJJKUkkkkp
SSSSSlJJJnODRLjASJAFnRS6Sh61X7wS9ar94Jnu4/34f4wTR7M0lD1qv3gl61X7
wS93H+/D/GCqPZmkoetV+8E4trJgOBKXuY+k4/aFUezJJJJPQpJJJJSkkkklKSSS
SUpJJJJSkkkklKSSSSUpJJJJSkkkklKSSSSUpJJJJSklUd1Tp7SWm9gI0IlN+1en
f9yGfehxDuF/tZP3J/4pbiSp/tXp3/chn3pftXp3/chn3pcQ7hPtZP3J/wCKW4kq
f7V6d/3IZ96X7V6d/wByGfelxDuFe1k/cn/iluJKNdjLGB7CHNdqCFJFjUkkkkp5
F303fE/lTJ3fTd8T+VMs47loqSSSSUpJJJJT0HR/6H/acr6odI/of9pyvq9j+SPk
3IfKPJSSSSeuUkkkkpSSSSSlJJJJKUkkkkpSSSSSlJJJJKUkkkkpSSSSSlIGV/Nj
4o6BlfzY+Kg5r+Yyf3Ux3DUSSSWEzKSTJ0lKUq/pt+IUVKv6bfiE6HzR/vBBdBJJ
JdEwqSSSSUpJJJJSkkkklKSSSSUpJJJJSkkkklKSSSSUpJJJJSkkkklKUbf5p/8A
VP5FJRt/mn/1T+RJI3DwA4SSHCSovSKSSSSUpJJJJT2XRf8Akyn4H/qir6odF/5M
p+B/6oq+rkflHkHn8/8AO5P78vzUkkknMTyLvpu+J/KmTv8Apu+J/KmWcdy0VJJJ
JKUkkkkp6Do/9D/tOV9UOj/0P+05X1ex/JHybkPlHkpJJJPXKSSSSUpJJJJSkkkk
lKSSSSUpJJJJSkkkklKSSSSUpJJJJSkDK/mx8UdAyv5sfFQc1/MZP7qY7hqJJJLC
ZlJJJJKUpV/Tb8QoqVf02/EJ0Pmj/eCC6CSSS6JhUkkkkpSSSSSlJJJJKUkkkkpS
SSSSlJJJJKUkkkkpSSSSSlJJJJKUo2/zT/6p/IpKNv8ANP8A6p/Ikkbh8/HCdIcJ
Ki9IpJJJJSkkkklPZdF/5Mp+B/6oq+qHRf8Akyn4H/qir6uR+UeQefz/AM7k/vy/
NSSSScxPJ2R6juOTxPio6eX4rzxJUDudml9j6Hp5filp5fivPEkPsU+h6eX4paeX
4rzxJL7FPsfSf6GP6x4V5eHJK9D5I+Tbh8o8n3FJeHJJy59xSXhySSn3FJeHJJKf
cUl4ckkp9xSXhySSn3FJeHJJKfcUl4ckkp9xSXhySSn3FJeHJJKfcUHK/mx8V4ok
oeY/mZ7fL1THcPr+iWi8gSWJ/iMz6/okvIEkv8RD6/opVxvb8QvHkk6Hzx+T5gov
uKS8OSW+wvuKS8OSSU+4pLw5JJT7ikvDkklPuKS8OSSU+4pLw5JJT7ikvDkklPuK
S8OSSU+4pLw5JJT7ikvDkklPuKjZ/Nu+B/IvEEkkjd7I7ZP0fluj5Je3y/6S41JU
noht+k9l7fL/AKSXt8v+kuNSSV/jPZe3y/6Sb2+X/SXHJJK/xn2Po8fs6mIiDxMf
SPiry8OSVyPyjycDN/OT/vy3833FJeHJIsb/AP/Z">
<p style="top:187.8pt;left:222.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Gan </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. (2012)</span></p>
<p style="top:176.9pt;left:376.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Blinding (outcome assessor)</span></p>
<p style="top:176.9pt;left:358.6pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Blinding (participant)</span></p>
<p style="top:176.9pt;left:341.4pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Source of funding bias</span></p>
<p style="top:176.9pt;left:324.4pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Incomplete outcome data</span></p>
<p style="top:176.9pt;left:306.7pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Allocation concealment</span></p>
<p style="top:176.9pt;left:290.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Random sequence generation</span></p>
<p style="top:210.7pt;left:218.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Keles </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. (2010)</span></p>
<p style="top:223.1pt;left:210.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Chang </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. (2008a)</span></p>
<p style="top:234.8pt;left:210.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Chang </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. (2008b)</span></p>
<p style="top:246.3pt;left:220.7pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Pijak </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. (2002)</span></p>
<p style="top:257.7pt;left:203.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Fioravanti </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. (2002)</span></p>
<p style="top:292.5pt;left:181.6pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">Low risk of bias</span></b></p>
<p style="top:279.2pt;left:210.8pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">+</span></p>
<p style="top:257.7pt;left:293.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">+</span></p>
<p style="top:234.8pt;left:293.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">+</span></p>
<p style="top:223.1pt;left:293.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">+</span></p>
<p style="top:199.3pt;left:293.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">++</span></p>
<p style="top:187.8pt;left:293.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">+</span></p>
<p style="top:234.8pt;left:327.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">+</span></p>
<p style="top:223.1pt;left:327.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">+</span></p>
<p style="top:199.3pt;left:327.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">++</span></p>
<p style="top:187.8pt;left:327.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">+</span></p>
<p style="top:234.8pt;left:344.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">+</span></p>
<p style="top:223.1pt;left:344.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">+</span></p>
<p style="top:199.3pt;left:344.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">++</span></p>
<p style="top:187.8pt;left:344.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">+</span></p>
<p style="top:199.3pt;left:361.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">++</span></p>
<p style="top:187.8pt;left:361.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">+</span></p>
<p style="top:199.3pt;left:379.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">++</span></p>
<p style="top:187.8pt;left:379.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">+</span></p>
<p style="top:257.7pt;left:327.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">+</span></p>
<p style="top:257.7pt;left:344.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">+</span></p>
<p style="top:257.7pt;left:361.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">+</span></p>
<p style="top:257.7pt;left:379.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">+</span></p>
<p style="top:279.2pt;left:372.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:246.3pt;left:379.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:246.3pt;left:361.4pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:234.8pt;left:379.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:234.8pt;left:361.4pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:223.1pt;left:379.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:223.1pt;left:361.4pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:246.3pt;left:309.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:246.3pt;left:293.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;</span></p>
<p style="top:279.2pt;left:289.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">?</span></p>
<p style="top:257.7pt;left:309.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">?</span></p>
<p style="top:234.8pt;left:309.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">?</span></p>
<p style="top:223.1pt;left:309.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">?</span></p>
<p style="top:199.3pt;left:309.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">??</span></p>
<p style="top:187.8pt;left:309.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">?</span></p>
<p style="top:246.3pt;left:327.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">?</span></p>
<p style="top:246.3pt;left:344.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">?</span></p>
<p style="top:292.5pt;left:262.4pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">Unclear risk of bias</span></b></p>
<p style="top:292.5pt;left:346.2pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">High risk of bias</span></b></p>
<p style="top:199.3pt;left:195.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Christensen </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. (2011)</span></p>
<p style="top:324.0pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP6A50,serif;font-size:8.5pt">Figure 2. Methodological quality summary for clinical trials: review of authors&#x2019; judgments about each methodological</span></p>
<p style="top:335.0pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP6A50,serif;font-size:8.5pt">quality item for each study included.</span></p>
<p style="top:612.0pt;left:49.0pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">Table 3. Summary of the results of the clinical studies included in the systematic review.</span></p>
<p style="top:636.3pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">Author (year)</span></p>
<p style="top:636.3pt;left:167.8pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">Complexed substance</span></p>
<p style="top:636.3pt;left:268.7pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">Analgesia</span></p>
<p style="top:636.3pt;left:331.8pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">Comparison</span></p>
<p style="top:636.3pt;left:412.7pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">Protocol assessed</span></p>
<p style="top:653.7pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Gan</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2012)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [21]</span></p>
<p style="top:653.7pt;left:167.8pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Diclofenac</span></p>
<p style="top:653.7pt;left:268.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">433%</span></p>
<p style="top:653.7pt;left:331.8pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">vs placebo</span></p>
<p style="top:653.7pt;left:412.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Pain intensity differences from VAS</span></p>
<p style="top:663.7pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Christensen</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2011)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [22]</span></p>
<p style="top:663.7pt;left:167.8pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Diclofenac</span></p>
<p style="top:663.7pt;left:268.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">451%</span></p>
<p style="top:663.7pt;left:331.8pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">vs placebo</span></p>
<p style="top:663.7pt;left:412.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Total pain relief from VAS</span></p>
<p style="top:673.7pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Keles</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2010)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [23]</span></p>
<p style="top:673.7pt;left:167.8pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Piroxicam</span></p>
<p style="top:673.7pt;left:268.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">83%</span></p>
<p style="top:673.7pt;left:331.8pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">vs placebo</span></p>
<p style="top:673.7pt;left:412.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">VAS score</span></p>
<p style="top:683.6pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Chang</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2008)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [24]</span></p>
<p style="top:683.6pt;left:167.8pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Piroxicam</span></p>
<p style="top:683.6pt;left:268.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">25%</span></p>
<p style="top:683.6pt;left:331.8pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">vs piroxicam alone</span></p>
<p style="top:683.6pt;left:412.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">VAS score</span></p>
<p style="top:693.6pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Chang</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2008)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [25]</span></p>
<p style="top:693.6pt;left:167.8pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Piroxicam</span></p>
<p style="top:693.6pt;left:268.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">42%</span></p>
<p style="top:693.6pt;left:331.8pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">vs piroxicam alone</span></p>
<p style="top:693.6pt;left:412.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">VAS score</span></p>
<p style="top:703.5pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Pijak</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2002)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [26]</span></p>
<p style="top:703.5pt;left:167.8pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Piroxicam</span></p>
<p style="top:703.5pt;left:268.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">66%</span></p>
<p style="top:703.5pt;left:331.8pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">vs baseline</span></p>
<p style="top:703.5pt;left:412.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">VAS score</span></p>
<p style="top:713.5pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Fioravanti</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2002)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [27]</span></p>
<p style="top:713.5pt;left:167.8pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Nimesulide</span></p>
<p style="top:713.5pt;left:268.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">No difference</span></p>
<p style="top:713.5pt;left:331.8pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">vs naproxen</span></p>
<p style="top:713.5pt;left:412.7pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">VAS score</span></p>
<img style="position:absolute;transform:matrix(.48006679,0,-0,.47928358,67.16669,396.70796)" src="data:image/jpeg;base64,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">
<p style="top:378.8pt;left:153.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Random sequence generation</span></p>
<p style="top:395.3pt;left:178.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Allocation concealment</span></p>
<p style="top:410.9pt;left:166.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Incompleate outcome data</span></p>
<p style="top:427.1pt;left:180.6pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Source of funding bias</span></p>
<p style="top:443.2pt;left:187.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Blinding (participant)</span></p>
<p style="top:459.3pt;left:159.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Blinding (outcome assessor)</span></p>
<p style="top:484.8pt;left:260.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">0%</span></p>
<p style="top:528.0pt;left:161.5pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">Low risk of bias</span></b></p>
<p style="top:528.0pt;left:241.4pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">Unclear risk of bias</span></b></p>
<p style="top:528.0pt;left:340.7pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">High risk of bias</span></b></p>
<p style="top:484.8pt;left:290.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">20%</span></p>
<p style="top:484.8pt;left:322.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">40%</span></p>
<p style="top:484.8pt;left:356.4pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">60%</span></p>
<p style="top:484.8pt;left:389.8pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">80%</span></p>
<p style="top:484.8pt;left:416.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">100%</span></p>
<p style="top:559.5pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP6A50,serif;font-size:8.5pt">Figure 3. Methodological quality graph for clinical studies: review of authors&#x2019; judgments about each methodological quality</span></p>
<p style="top:570.4pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP6A50,serif;font-size:8.5pt">item presented as percentages across all studies included.</span></p>
<p style="top:41.8pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">R. G. Brito</span><span style="font-family:AdvP47DAD7,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:749.3pt;left:49.0pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">6</span></p>
<p style="top:750.9pt;left:236.6pt;line-height:7.0pt"><span style="font-family:AdvP4194AB,serif;font-size:7.0pt">Expert Opin. Drug Deliv.</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt"> (2015)</span><span style="font-family:AdvP6A50,serif;font-size:7.0pt"> 12</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">(10)</span></p>
<p style="top:558.4pt;left:-0.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Nandini Loganathan on 07/10/15</span></p>
<p style="top:426.0pt;left:7.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">For personal use only.</span></p>
<img style="position:absolute;transform:matrix(1.3333334,0,-0,1.3333334,674.7067,1021.9347)" src="data:image/png;base64,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">


<p style="top:558.9pt;left:81.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Siqueira-Lima</span><span style="font-family:AdvP92E7,serif;font-size:10.0pt"> et al.</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [28]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> demonstrated that the treatment</span></p>
<p style="top:571.4pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">with</span><span style="font-family:AdvP92E7,serif;font-size:10.0pt"> L. grata</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> EO complexed with</span><span style="font-family:AdvP697C,serif;font-size:10.0pt"> b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD induced a significant</span></p>
<p style="top:583.8pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">antinociceptive effect in the orofacial formalin-, capsaicin-</span></p>
<p style="top:596.3pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">and glutamate-induced pain tests. Quintans-J</span><span style="font-family:AdvP4C4E59,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">unior</span><span style="font-family:AdvP92E7,serif;font-size:10.0pt"> et al.</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [29]</span></p>
<p style="top:608.7pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">showed that the LIN and LIN</span><span style="font-family:AdvP697C,serif;font-size:10.0pt"> b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD complex (LIN-</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD)</span></p>
<p style="top:621.2pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">reduced glutamate-induced nociceptive behavior and inflam-</span></p>
<p style="top:633.6pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">matory cytokines in the carrageenan-induced peritonitis</span></p>
<p style="top:646.1pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">model. LIN-</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD when compared with LIN alone also</span></p>
<p style="top:658.6pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">showed enhanced water solubility, improved dissolution rate</span></p>
<p style="top:671.0pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">and enhanced stability of LIN</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [59,60]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. Quintans</span><span style="font-family:AdvP92E7,serif;font-size:10.0pt"> et al.</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [14]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> dem-</span></p>
<p style="top:683.5pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">onstrated the antinociceptive effect of pCM and pCM-</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD</span></p>
<p style="top:695.9pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">complexed in the acetic acid-induced abdominal constrictions</span></p>
<p style="top:708.3pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">and hot-plate tests, and the anti-inflammatory property</span></p>
<p style="top:720.8pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">through the carrageenan-induced paw edema in mice. The</span></p>
<p style="top:558.9pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">study showed that pCM-</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD inhibited nociceptive behavior</span></p>
<p style="top:571.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">for 8 h when compared with pCM alone, which showed 2 h</span></p>
<p style="top:583.1pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">of inhibition in the acetic acid-writhing test. Thus, these stud-</span></p>
<p style="top:595.1pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">ies show enhanced and prolonged analgesia and increased bio-</span></p>
<p style="top:607.2pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">availability with CD-complexed EOs.</span></p>
<p style="top:640.4pt;left:325.3pt;line-height:7.5pt"><span style="font-family:AdvP3F5A6A,serif;font-size:7.5pt">4.2.2</span><span style="font-family:AdvP3F5A6A,serif;font-size:9.5pt"> NSAIDs</span></p>
<p style="top:650.3pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">The NSAIDs are clinically used in different diseases, to reduce</span></p>
<p style="top:662.4pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">fever, pain, stiffness and swelling</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [30,61-69]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. That class of drugs</span></p>
<p style="top:674.5pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">has been complexed in CDs and tested in different experi-</span></p>
<p style="top:686.6pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">mental models to optimize their pharmacological effects.</span></p>
<p style="top:698.7pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">When complexed with CDs, indomethacin, etoricoxib and</span></p>
<p style="top:710.7pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">etodolac show enhanced efficacy in the tail-flick test and</span></p>
<p style="top:722.8pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">hot-plate test</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [30,32,34]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. Similarly, in the acetic acid-writhing</span></p>
<p style="top:76.7pt;left:98.9pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">A.</span></b></p>
<p style="top:88.7pt;left:98.9pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">Studies</span></b></p>
<p style="top:88.7pt;left:234.6pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Estimate (95% C.I.)</span></p>
<p style="top:236.0pt;left:98.9pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">B.</span></b></p>
<p style="top:248.0pt;left:98.9pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">Studies</span></b></p>
<p style="top:248.0pt;left:234.6pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Estimate (95% C.I.)</span></p>
<p style="top:374.7pt;left:98.9pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">C.</span></b></p>
<p style="top:386.7pt;left:98.9pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">Studies</span></b></p>
<p style="top:386.7pt;left:234.6pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Estimate (95% C.I.)</span></p>
<p style="top:109.5pt;left:98.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Dolita 2012</span></p>
<p style="top:120.3pt;left:98.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Quintans-Junior </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. 2013</span></p>
<p style="top:276.8pt;left:98.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Quintans-Junior </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. 2013</span></p>
<p style="top:267.9pt;left:98.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">El-feky </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. 2013</span></p>
<p style="top:130.5pt;left:98.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Quintans </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. 2012</span></p>
<p style="top:286.5pt;left:98.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Quintans </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. 2013</span></p>
<p style="top:409.0pt;left:98.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Lima </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. 2012</span></p>
<p style="top:420.7pt;left:98.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Sammeta </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. 2010</span></p>
<p style="top:140.3pt;left:98.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Janovysky </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. 2010</span></p>
<p style="top:160.5pt;left:98.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Capello </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. 2009</span></p>
<p style="top:170.4pt;left:98.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Lu </span><i><span style="font-family:Arial,serif;font-size:8.0pt">et al</span></i><span style="font-family:Arial,serif;font-size:8.0pt">. 2004</span></p>
<p style="top:191.5pt;left:98.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Overall (I</span><sup><span style="font-family:Arial,serif;font-size:5.6pt">2 </span></sup><span style="font-family:Arial,serif;font-size:8.0pt">= 89% , p &lt; 0.001)</span></p>
<p style="top:315.6pt;left:98.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Overall (I</span><sup><span style="font-family:Arial,serif;font-size:5.6pt">2 </span></sup><span style="font-family:Arial,serif;font-size:8.0pt">= 75% , p = 0.007)</span></p>
<p style="top:442.2pt;left:98.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Overall (I</span><sup><span style="font-family:Arial,serif;font-size:5.6pt">2 </span></sup><span style="font-family:Arial,serif;font-size:8.0pt">= 97% , p = 0.001)</span></p>
<p style="top:149.8pt;left:98.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Sinha &amp; Goel 2010</span></p>
<p style="top:297.5pt;left:98.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">Sinha &amp; Goel 2010</span></p>
<p style="top:315.6pt;left:217.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;9.021</span></p>
<p style="top:442.2pt;left:217.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;1.527</span></p>
<p style="top:191.5pt;left:215.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">10.352</span></p>
<p style="top:109.5pt;left:219.7pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">6.000</span></p>
<p style="top:109.5pt;left:258.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">(2.884, 9.116)</span></p>
<p style="top:119.4pt;left:254.4pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">(0.986, 10.614)</span></p>
<p style="top:129.7pt;left:245.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">(&#x2013;16.024, 20.024)</span></p>
<p style="top:139.5pt;left:254.4pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">(2.334, 11.666)</span></p>
<p style="top:149.2pt;left:250.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">(22.568, 33.432)</span></p>
<p style="top:159.5pt;left:250.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">(&#x2013;2.714, 16.714)</span></p>
<p style="top:171.0pt;left:250.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">(&#x2013;5.804, 36.404)</span></p>
<p style="top:267.9pt;left:250.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">(&#x2013;2.975, &#x2013;0.025)</span></p>
<p style="top:276.8pt;left:245.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">(&#x2013;25.786, &#x2013;3.814)</span></p>
<p style="top:286.5pt;left:250.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">(&#x2013;17.987, 1.387)</span></p>
<p style="top:297.5pt;left:245.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">(&#x2013;32.443, &#x2013;3.557)</span></p>
<p style="top:315.6pt;left:245.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">(&#x2013;17.435, &#x2013;0.607)</span></p>
<p style="top:191.5pt;left:254.4pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">(3.184, 17.521)</span></p>
<p style="top:130.5pt;left:219.7pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">2.000</span></p>
<p style="top:140.3pt;left:219.7pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">7.000</span></p>
<p style="top:160.5pt;left:219.7pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">7.000</span></p>
<p style="top:170.4pt;left:215.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">15.300</span></p>
<p style="top:267.9pt;left:215.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;1.500</span></p>
<p style="top:276.8pt;left:210.8pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;14.800</span></p>
<p style="top:286.5pt;left:215.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;8.300</span></p>
<p style="top:297.5pt;left:210.8pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;18.000</span></p>
<p style="top:409.0pt;left:254.4pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">(&#x2013;0.653, 0.453)</span></p>
<p style="top:419.9pt;left:250.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">(&#x2013;3.905, &#x2013;2.095)</span></p>
<p style="top:442.2pt;left:254.4pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">(&#x2013;4.369, 1.315)</span></p>
<p style="top:482.8pt;left:402.0pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">Mean Difference</span></b></p>
<p style="top:352.1pt;left:394.0pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">Mean Difference</span></b></p>
<p style="top:225.8pt;left:395.4pt;line-height:8.0pt"><b><span style="font-family:Arial,serif;font-size:8.0pt">Mean Difference</span></b></p>
<p style="top:469.2pt;left:321.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;4</span></p>
<p style="top:469.2pt;left:361.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;3</span></p>
<p style="top:469.2pt;left:400.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;2</span></p>
<p style="top:469.2pt;left:439.9pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;1</span></p>
<p style="top:469.2pt;left:481.5pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">0</span></p>
<p style="top:469.2pt;left:519.4pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">1</span></p>
<p style="top:339.3pt;left:325.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;30</span></p>
<p style="top:214.3pt;left:503.4pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">30</span></p>
<p style="top:339.3pt;left:359.0pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;25</span></p>
<p style="top:339.7pt;left:390.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;20</span></p>
<p style="top:214.3pt;left:463.2pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">20</span></p>
<p style="top:339.3pt;left:421.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;15</span></p>
<p style="top:339.3pt;left:488.6pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;5</span></p>
<p style="top:339.3pt;left:453.8pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;10</span></p>
<p style="top:214.3pt;left:421.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">10</span></p>
<p style="top:214.3pt;left:334.8pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;10</span></p>
<p style="top:339.3pt;left:524.1pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">0</span></p>
<p style="top:214.3pt;left:380.4pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">0</span></p>
<p style="top:409.0pt;left:215.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;0.100</span></p>
<p style="top:420.7pt;left:215.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">&#x2013;3.000</span></p>
<p style="top:149.8pt;left:215.3pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">28.000</span></p>
<p style="top:119.4pt;left:219.7pt;line-height:8.0pt"><span style="font-family:Arial,serif;font-size:8.0pt">5.800</span></p>
<p style="top:514.3pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP6A50,serif;font-size:8.5pt">Figure 4. Effects of the meta-analysis of 12 studies comparing the change in the mean analgesic effect in the complexed drug</span></p>
<p style="top:525.2pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP6A50,serif;font-size:8.5pt">group and the drug-alone group in different types of protocols. A</span><span style="font-family:AdvP6A46,serif;font-size:8.5pt">. Chemical protocols,</span><span style="font-family:AdvP6A50,serif;font-size:8.5pt"> B</span><span style="font-family:AdvP6A46,serif;font-size:8.5pt">. thermal protocols and</span></p>
<p style="top:536.2pt;left:71.3pt;line-height:8.5pt"><span style="font-family:AdvP6A50,serif;font-size:8.5pt">C</span><span style="font-family:AdvP6A46,serif;font-size:8.5pt">. nociception score.</span></p>
<p style="top:41.8pt;left:439.2pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">CDs improving analgesic drugs</span></p>
<p style="top:750.9pt;left:258.9pt;line-height:7.0pt"><span style="font-family:AdvP4194AB,serif;font-size:7.0pt">Expert Opin. Drug Deliv.</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt"> (2015)</span><span style="font-family:AdvP6A50,serif;font-size:7.0pt"> 12</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">(10)</span></p>
<p style="top:749.3pt;left:558.3pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">7</span></p>
<p style="top:558.4pt;left:-0.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Nandini Loganathan on 07/10/15</span></p>
<p style="top:426.0pt;left:7.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">For personal use only.</span></p>
<img style="position:absolute;transform:matrix(1.3333334,0,-0,1.3333334,674.7067,1021.9347)" src="data:image/png;base64,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">


<p style="top:326.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">test, meloxicam, etodolac, ketoprofen and acetyl salicylic acid</span></p>
<p style="top:338.8pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">showed a greater reduction in nociception when complexed in</span></p>
<p style="top:350.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CDs than when administered alone</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [31,33-36]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. Furthermore,</span></p>
<p style="top:362.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CDs improved the solubility of indomethacin</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [30]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">, enhanced</span></p>
<p style="top:374.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the solubility, dissolution and permeability of meloxi-</span></p>
<p style="top:386.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">cam</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [70,71]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">, and enhanced absorption of etodolac</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [34]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. For</span></p>
<p style="top:398.6pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">instance, Sinha and Goel</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [34]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> showed an increase in the</span><span style="font-family:AdvP92E7,serif;font-size:10.0pt"> t</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt">1/2</span></p>
<p style="top:410.7pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">and decrease in the elimination rate for CD-complexed etodo-</span></p>
<p style="top:422.6pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">lac compared to the drug alone. In addition, lower ulcero-</span></p>
<p style="top:434.6pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">genic activity occurs with CD-complexed etodolac alone as</span></p>
<p style="top:446.6pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the average number of ulcerations was reduced in approxi-</span></p>
<p style="top:458.6pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">mately 50% in the presence of the CDs examined. Thus,</span></p>
<p style="top:470.5pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the NSAIDs complexed to CDs show enhanced analgesia,</span></p>
<p style="top:482.5pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">improved bioavailability and reduced side effects when com-</span></p>
<p style="top:494.5pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">pared with the drug alone.</span></p>
<p style="top:521.3pt;left:49.0pt;line-height:7.5pt"><span style="font-family:AdvP3F5A6A,serif;font-size:7.5pt">4.2.3</span><span style="font-family:AdvP3F5A6A,serif;font-size:9.5pt"> Other analgesic drugs</span></p>
<p style="top:531.2pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Drugs from a variety of different classes have also been tested</span></p>
<p style="top:543.1pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">in the complexed form to check for a possible improvement in</span></p>
<p style="top:555.1pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">their analgesic activity. Those include studies with cannabi-</span></p>
<p style="top:567.1pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">noids, steroids, local anesthetics, opioids and antidepressants.</span></p>
<p style="top:579.0pt;left:59.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">MDA7, a selective CB</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt">2</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> agonist, suppresses allodynia in rats</span></p>
<p style="top:591.0pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">with spinal nerve ligation or paclitaxel-induced neuropathic</span></p>
<p style="top:603.0pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">pain</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [72,73]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. In animals with neuropathic pain induced by spi-</span></p>
<p style="top:615.0pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">nal nerve ligation, MDA7 formulated in HP</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD produces a</span></p>
<p style="top:627.0pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">greater reduction in mechanical hyperalgesia when compared</span></p>
<p style="top:639.0pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">with the vehicle</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [37]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">.</span></p>
<p style="top:650.9pt;left:59.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Allopregnanolone and alphaxalone are neurosteroids that</span></p>
<p style="top:662.9pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">probably</span></p>
<p style="top:662.9pt;left:91.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">facilitate</span></p>
<p style="top:662.9pt;left:132.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">activation</span></p>
<p style="top:662.9pt;left:177.7pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">by</span></p>
<p style="top:662.9pt;left:195.1pt;line-height:10.0pt"><span style="font-family:AdvP697C,serif;font-size:10.0pt">g</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">-amino</span></p>
<p style="top:662.9pt;left:235.9pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">butyric</span></p>
<p style="top:662.9pt;left:271.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">acid</span></p>
<p style="top:674.8pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">(GABA) of the GABA</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt">A</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> chloride ionophore and at higher con-</span></p>
<p style="top:686.9pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">centrations by directly activating the ionophore, promoting</span></p>
<p style="top:698.8pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the channel open state</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [74-76]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. Svensson</span><span style="font-family:AdvP92E7,serif;font-size:10.0pt"> et al.</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [38]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> showed that</span></p>
<p style="top:710.8pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the intrathecal delivery of 5</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">a</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">-reduced neurosteroid agonist</span></p>
<p style="top:722.8pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">allopregnanolone and alphaxalone in a CD-water-based</span></p>
<p style="top:326.7pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">vehicle shows a greater reduction in thermal and mechanical</span></p>
<p style="top:338.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">hyperalgesia in the unilateral intraplantar delivery of carra-</span></p>
<p style="top:350.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">geenan model when compared with the vehicle.</span></p>
<p style="top:362.7pt;left:312.9pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">TTC is a member of the ester class of local anesthetics that</span></p>
<p style="top:374.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">is used to anesthetize nasal tissues before diagnostic and surgi-</span></p>
<p style="top:386.7pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">cal procedures</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [77]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. Lima</span><span style="font-family:AdvP92E7,serif;font-size:10.0pt"> et al.</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [39]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> evaluated the antinocicep-</span></p>
<p style="top:398.7pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">tive</span></p>
<p style="top:398.7pt;left:325.4pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">effect</span></p>
<p style="top:398.7pt;left:354.7pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">induced</span></p>
<p style="top:398.7pt;left:394.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">by</span></p>
<p style="top:398.7pt;left:412.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">TTC</span></p>
<p style="top:398.7pt;left:441.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">complexes</span></p>
<p style="top:398.7pt;left:489.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">through</span></p>
<p style="top:398.7pt;left:528.9pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the</span></p>
<p style="top:410.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">infraorbital nerve blockade test in rats and showed that the</span></p>
<p style="top:422.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">complexation with HP</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD and</span><span style="font-family:AdvP697C,serif;font-size:10.0pt"> b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD increased the analgesic</span></p>
<p style="top:434.7pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">duration and intensity induced by TTC alone. The authors</span></p>
<p style="top:446.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">also demonstrated that the treatment of 3T3 cultured cells</span></p>
<p style="top:458.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">with TTC showed an increase in the LD</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt">50</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> following com-</span></p>
<p style="top:470.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">plexation, reflecting a reduction in the cytotoxicity of TTC</span></p>
<p style="top:482.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">upon the complexation of either</span><span style="font-family:AdvP697C,serif;font-size:10.0pt"> b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD or HP</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD.</span></p>
<p style="top:506.7pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">and</span><sup><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">SUF is a synthetic opioid of the 4-anilidopiperidine group</span></sup></p>
<p style="top:506.7pt;left:325.6pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">is</span></p>
<p style="top:506.7pt;left:339.6pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">commonly</span></p>
<p style="top:506.7pt;left:389.5pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">used</span></p>
<p style="top:506.7pt;left:415.1pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">in</span></p>
<p style="top:506.7pt;left:431.1pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the</span></p>
<p style="top:506.7pt;left:451.5pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">surgical</span></p>
<p style="top:506.7pt;left:489.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">room</span></p>
<p style="top:509.1pt;left:518.2pt;line-height:7.0pt"><span style="font-family:AdvP5D8B,serif;font-size:7.0pt">[78,79]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">.</span></p>
<p style="top:518.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Volobuef</span><span style="font-family:AdvP92E7,serif;font-size:10.0pt"> et al.</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [40]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> demonstrated that the latency to the</span></p>
<p style="top:530.7pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">tail-flick was increased after the complexation of SUF with</span></p>
<p style="top:542.7pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">HP</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD when compared with the free drug. SUF-HP</span><span style="font-family:AdvP697C,serif;font-size:10.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CD</span></p>
<p style="top:554.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">also changed hemolytic concentrations, which is possible</span></p>
<p style="top:566.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">because the CDs change the drug permeation across the</span></p>
<p style="top:578.7pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">membranes or its distribution, prolonging the effects,</span></p>
<p style="top:590.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">decreasing the plasmatic levels and reducing the systemic</span></p>
<p style="top:602.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">toxicity</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [79,80]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">.</span></p>
<p style="top:626.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">as</span><sup><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">DOX, a member of tricyclic antidepressant family, is used</span></sup></p>
<p style="top:626.8pt;left:319.7pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">analgesic</span></p>
<p style="top:626.8pt;left:363.1pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">in</span></p>
<p style="top:626.8pt;left:380.4pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">addition</span></p>
<p style="top:626.8pt;left:422.4pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">to</span></p>
<p style="top:626.8pt;left:439.7pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">depression</span></p>
<p style="top:626.8pt;left:489.7pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">and</span></p>
<p style="top:626.8pt;left:513.5pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">anxiety</span></p>
<p style="top:638.7pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">disorders</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [81-83]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">. Sammeta</span><span style="font-family:AdvP92E7,serif;font-size:10.0pt"> et al.</span><span style="font-family:AdvP5D8B,serif;font-size:7.0pt"> [41]</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt"> demonstrated that the</span></p>
<p style="top:650.7pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">electroporation of CD-complexed DOX resulted in the</span></p>
<p style="top:662.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">retention of significant amounts of drug in epidermis and</span></p>
<p style="top:674.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">sustained drug release from the epidermis. In the study, a</span></p>
<p style="top:686.7pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">prolonged analgesic activity measured with the pain avoiding</span></p>
<p style="top:698.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">response using a blunt needle model was observed in the</span></p>
<p style="top:710.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">CDs group of rats when compared with the pure drug solu-</span></p>
<p style="top:722.8pt;left:303.0pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">tion group.</span></p>
<p style="top:78.0pt;left:49.0pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">Table 4. Summary of the results of the preclinical studies included in the systematic review.</span></p>
<p style="top:102.3pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">Author (year)</span></p>
<p style="top:102.3pt;left:242.9pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">Complexed substance</span></p>
<p style="top:102.3pt;left:404.6pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">Other aspects improved</span></p>
<p style="top:119.8pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP4194AB,serif;font-size:8.5pt">Clinical</span></p>
<p style="top:129.7pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Christensen</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2011)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [22]</span></p>
<p style="top:129.7pt;left:242.9pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Diclofenac</span></p>
<p style="top:129.7pt;left:404.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Time action</span></p>
<p style="top:139.7pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Fioravanti</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2002)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [27]</span></p>
<p style="top:139.7pt;left:242.9pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Nimesulide</span></p>
<p style="top:139.7pt;left:404.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Gastrointestinal tolerability</span></p>
<p style="top:149.6pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP4194AB,serif;font-size:8.5pt">Preclinical</span></p>
<p style="top:159.6pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Siqueira-Lima</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2014)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [28]</span></p>
<p style="top:159.6pt;left:242.9pt;line-height:8.5pt"><span style="font-family:AdvP4194AB,serif;font-size:8.5pt">Lippia grata</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> essential oil</span></p>
<p style="top:159.6pt;left:404.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Solubility</span></p>
<p style="top:169.5pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Quintans-J</span><span style="font-family:AdvP4C4E59,serif;font-size:8.5pt">&#xfffd;</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">unior</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2013)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [29]</span></p>
<p style="top:169.5pt;left:242.9pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">(-)-Linalool</span></p>
<p style="top:169.5pt;left:404.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Solubility</span></p>
<p style="top:179.5pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Quintans</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2013)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [14]</span></p>
<p style="top:179.5pt;left:242.9pt;line-height:8.5pt"><span style="font-family:AdvP4194AB,serif;font-size:8.5pt">p</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt">-Cymene</span></p>
<p style="top:179.5pt;left:404.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Solubility and time action</span></p>
<p style="top:189.5pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">El-Feky</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2013)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [30]</span></p>
<p style="top:189.5pt;left:242.9pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Indomethacin</span></p>
<p style="top:189.5pt;left:404.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Solubility and oral delivery</span></p>
<p style="top:199.5pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Dolita (2012)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [31]</span></p>
<p style="top:199.5pt;left:242.9pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Acetyl salicylic acid</span></p>
<p style="top:199.5pt;left:404.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Permeability and solubility</span></p>
<p style="top:209.4pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Singh</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2011)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [32]</span></p>
<p style="top:209.4pt;left:242.9pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Etoricoxib</span></p>
<p style="top:209.4pt;left:404.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Solubility</span></p>
<p style="top:219.4pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Sinha and Goel (2010)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [34]</span></p>
<p style="top:219.4pt;left:242.9pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Etodolac</span></p>
<p style="top:219.4pt;left:404.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Bioavailability and absorption</span></p>
<p style="top:229.4pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Capello</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2009)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [35]</span></p>
<p style="top:229.4pt;left:242.9pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Etodolac</span></p>
<p style="top:229.4pt;left:404.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Gastrolesivity reduction and solubility</span></p>
<p style="top:239.3pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Lu</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2004)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [36]</span></p>
<p style="top:239.3pt;left:242.9pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Ketoprofen</span></p>
<p style="top:239.3pt;left:404.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Solubility and absorption</span></p>
<p style="top:249.3pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Astruc-Diaz</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2013)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [37]</span></p>
<p style="top:249.3pt;left:242.9pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">MDA7</span></p>
<p style="top:249.3pt;left:404.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Solubility</span></p>
<p style="top:259.2pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Franco de Lima</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2012)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [39]</span></p>
<p style="top:259.2pt;left:242.9pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Tetracaine</span></p>
<p style="top:259.2pt;left:404.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Time action and cytotoxicity decrease</span></p>
<p style="top:269.2pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Volobuef</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2012)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [40]</span></p>
<p style="top:269.2pt;left:242.9pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Sufentanil</span></p>
<p style="top:269.2pt;left:404.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Time action and cytotoxicity decrease</span></p>
<p style="top:279.1pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Sammeta</span><span style="font-family:AdvP4194AB,serif;font-size:8.5pt"> et al.</span><span style="font-family:AdvP45A506,serif;font-size:8.5pt"> (2010)</span><span style="font-family:AdvP45A506,serif;font-size:7.5pt"> [41]</span></p>
<p style="top:279.1pt;left:242.9pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Doxepin</span></p>
<p style="top:279.1pt;left:404.6pt;line-height:8.5pt"><span style="font-family:AdvP45A506,serif;font-size:8.5pt">Drug release</span></p>
<p style="top:41.8pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">R. G. Brito</span><span style="font-family:AdvP47DAD7,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:749.3pt;left:49.0pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">8</span></p>
<p style="top:750.9pt;left:236.6pt;line-height:7.0pt"><span style="font-family:AdvP4194AB,serif;font-size:7.0pt">Expert Opin. Drug Deliv.</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt"> (2015)</span><span style="font-family:AdvP6A50,serif;font-size:7.0pt"> 12</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">(10)</span></p>
<p style="top:558.4pt;left:-0.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Nandini Loganathan on 07/10/15</span></p>
<p style="top:426.0pt;left:7.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">For personal use only.</span></p>
<img style="position:absolute;transform:matrix(1.3333334,0,-0,1.3333334,674.7067,1021.9347)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAG4AAAAOCAYAAADOrymhAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAH9UlEQVR4nO2YWWxVVRSG74tPDjFGExLjgAoqEQVnBQeMBkckouA8
YQgag0DQBwkIqIAFyyCDZaaMIhVMcUARSiljqRVaWqGUwqUFSulMgU4sz7du12X3
3HNLoj744Ep2zrD3XvP61z4nJP/Tf5L2FZbJvCWZsnB5luTkHY2ZD9XXN0l1zRmp
qY2MU6cbpLn5bFyGDY3Ncjb+tO6tb2jS0dTUHHcdc+48POPx5r3xtBFPx8am5vOu
cfkyzkdt8TE7zrblFB8vdy336BAkY/2mQhk7eYNMnJ4u2TlHWs2F3vtotXTpMUU6
PzBZOt4zUbo9OVNeGrBMtmeFYxitTM2RB55JkpTU3Ji5E+V1Mmbib9L79WRd8/Cz
s+T5txfrHj+VnTgprwxcLgOHrdZEgb5ZvVt69J4tqWvzW609XnZS+cCv16sL5emX
F8h9T8yQD0f92Godxk+ZtVnXPNgrSR7y1vftvySGnxEJu3zVLpm9aIdUVJ0KXAP9
WXBc5nqZH5T12btLZP7SnbJg2U5ZszZPdaiqPi0r1+RI+taimPXMJX+TJb+l79dn
5OLLOYt3SFG4Qt8VFpXL4OGpUlB0Qp/TNhfK+KlpGrw9e0ujvEJPvjhfrukyXh35
eeJ6ebzfPLn0+tHy1qBvYwSPnrhOLmg3XEYlrIuZGzn+F7n42k+k+1MzZeykDTJk
xBq5tusXmhQE1aW8faWaJLc+NFmOldbqu+Gfr5WLrhmpe13COPQiIFfdNk5uvPdL
6f/BSpmVvL3VuszsYrnipk81ASdM26g6drh7gjz7WnJgNtedatCg4ZCjpTUx80Yb
MgrV7nUbC2Lmfvg1Xysi4auNes3NL5Ujx6r1PsnTz1+Eh0uqNAhLVmZLXV2DXuH9
47o/db6q5rT0eXOxtOv0mWzJPBTdl7YlErzJSRmyd3+ZvgvhkPZ3fCG/pkUUmzF/
q1zS/hOtOj+hEMHxOxfq985SFbg05Q99zth2UKsCB1pVGSGcgBK8d4et0qBRUVd2
HqtOCCKyGz2p6CB425l9WOV3fnCSBmPa3K0y6ONUWfXDnkB+6EQlJc7cJMeO1wau
gagcEgfY8tPP6/eqQ6m6L2ekawVTOciftzQzJnAlR6tl0teb1Mf0rnFT0hQRWEdy
DRiaojbcfH9iDOLhz6mzt8jMBduk8GC5hMjI6+9MkHt6TpeefefJ7Y9MlVu6Two0
+HyBw/EYiJPhR3DuemyaFJdUt1pL4Lr2mBqVC6x16paoFRUvcH/kRgIHbAb1E4JJ
ENADO4B8Ku7RPnMCK8oChyP/SeCYozqWeUEjeL9s2KeVES9wzDGQS9ANUmkfIBDo
FxQ4bKC1kLgfjfrpXMX1fGGuvO3BI44E4sBdP6HkhVeP0KufgK/LOoyRoR5Ehour
1BBgjeAAES7RN0gOAnvwcATbqc7LOoxWY4KI5oxRz72xKBD64PmEB/tUGff0Efhj
S07+sZj1Fjiqg2oNF1eqnv4D1cYtB9oMHH2dREUGuid+naE84R0UuAnT0mWJh0ph
TxaoQKKyH/r+pzy5zosFCecGjt745vvfyuUdx2iCZ2wvkhDGUilpmw/oIho8fQwH
+IneQcUFVQVQi6Pa35GgfQYBJAR8/I6mAZNdHDKs/+EcAkc2BtGuPUedioudp2o4
3BBceDNuuCtBezenZT+dPtOoPQ5nYw8OBbrskGC0ecdB1Y1eF2SzBQ4bgUyCBq/k
FVkx66ka5lZ8vzviBw/ysJc9JBuETrQQCxyHqP6DU7QoQMNtOyPvQyhGpGmWEIpT
LTTaIOeQgfGgpbSsVmGD8mdQJUH9CCMzvSx3T2oYBe/yirqY9WqAd7xHaWvOQVRe
eUrl0w9Ufu4RNTweUe17vINSnjM4tLhEgEEQ849LJARzrIGoDKqWEWQHdtM2KirP
nWI5fOFzS2AqHr+BCPiOEyaHLjdoUAjhCOQ0BFwQlKrqM3oMD7coweCeEyBCcTIK
Hy5pPdiL81CagTLAg82jdNQwbw5cV97Fkb0VlXXK27+We/jAE738cm2w12SbfOyK
tx6Z8HOHqy+DZxIyiA/v4GF77JlhdrgDO/xz3PPO/I8OUO3JenlnSIoiHOjh73ka
ODMAQxlkgRnOlWebc50Sna88N+8Ol49/L3uC9tk7kiSIp1++XzeXZ0Vla/ltPcez
w+Th4Lg6qC1x/BUgM8iuEy2JTBFBnDb5DgUmg2A6hIOALBf+gAs7uXGlbO2Zcm9s
OveHg9I2eAEyDnlZ48JMY0uzJysNxyH+1riQ4e4BpoGxM/URCKLxGxzZXxQj90+P
6WrPwKQL1fBwn0/W1UcPI+wxGS7xng/fA4fKo3Bpf4eMkGPP8KN6zF+8d2Xiq7b+
KLly26IQX+ZgrPUCMue7NbnRkyBf8HwohlueWUtTNkXpS9argBQ75FDqK1bvijZ7
DE9auF3hAMIZdppyifXwdA3m45dA6316gWTtKo7K4PQbdnTlOG5O42+G9QXWLlrx
u/ZWtdOrCtbawYV19kfDJdaR/QTVbIaHnTLtD8ymbUVROejb1JLc6EDvhEA1Prbd
oP9dClGiOL6mNlKiZCzfTPbMz06cRXaa8FznUEEgrOLISPoVxH6UtsDxVwA5VmVc
qUI/4SCCypwFwK2+/ILSaFUjF4fbQYBraUuPgNCTkxvEfvjaN6VVtlUZMlxEMEIF
EgI7LJGQj18gEAWdzE4CVhQuj1ZVroNmBJVq/DfoL39Pn0NQAB/pAAAAAElFTkSu
QmCC">


<p style="top:81.9pt;left:71.3pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">5.</span><span style="font-family:AdvP4B06EF,serif;font-size:11.0pt"> Conclusion</span></p>
<p style="top:104.0pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">This systematic review found clinical and preclinical studies</span></p>
<p style="top:116.0pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">that tested a variety of drugs complexed with different types</span></p>
<p style="top:127.9pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">of CDs. Clinical studies showed greater efficacy of NSAIDs</span></p>
<p style="top:139.9pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">complexed with CDs in a variety of conditions. The preclini-</span></p>
<p style="top:151.8pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">cal studies demonstrated that the CD complexions were capa-</span></p>
<p style="top:163.8pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">ble of producing analgesic profile in several animal models of</span></p>
<p style="top:175.7pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">nociception, having better effects than the drugs alone. These</span></p>
<p style="top:187.7pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">preclinical studies also showed greater bioavailability of the</span></p>
<p style="top:199.6pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">drug and reduced side effects. Thus, complexation of drugs</span></p>
<p style="top:211.6pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">with CD may be an important delivery method to improve</span></p>
<p style="top:223.6pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">analgesic efficacy by reducing therapeutic doses and the conse-</span></p>
<p style="top:235.5pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">quent side effects.</span></p>
<p style="top:260.0pt;left:71.3pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">6.</span><span style="font-family:AdvP4B06EF,serif;font-size:11.0pt"> Expert opinion</span></p>
<p style="top:282.0pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">The CDs have mainly been used for many purposes, as com-</span></p>
<p style="top:294.0pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">plexing agents to increase aqueous solubility of poorly soluble</span></p>
<p style="top:305.9pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">drugs, to increase their bioavailability and stability and also to</span></p>
<p style="top:317.9pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">improve drug delivery from almost any type of drug formula-</span></p>
<p style="top:329.9pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">tion. Along with that, the relatively low cost and easy acquisi-</span></p>
<p style="top:341.8pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">tion are factors that place the CDs as continuously interesting</span></p>
<p style="top:353.8pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">drug delivery systems. Therefore, CDs continue to have</span></p>
<p style="top:365.7pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">different applications in different areas such as food and</span></p>
<p style="top:377.7pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">pharmaceutical industries.</span></p>
<p style="top:389.6pt;left:81.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">All these promising characteristics of CDs have motivated</span></p>
<p style="top:401.6pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the researchers to find a way to improve the effects of drugs</span></p>
<p style="top:413.5pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">with analgesic activity, which may also reduce the side effects</span></p>
<p style="top:425.5pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">and improve the pharmacological efficacy. Our systematic</span></p>
<p style="top:437.5pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">review found different clinical and preclinical studies that</span></p>
<p style="top:449.4pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">tested some drugs, with analgesic effect, complexed in differ-</span></p>
<p style="top:461.4pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">ent types of CDs. Therefore, it was possible to demonstrate</span></p>
<p style="top:473.3pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">that the use of these drug delivery systems was able to improve</span></p>
<p style="top:485.3pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the pharmacological effects of drugs, provide a more rapid</span></p>
<p style="top:497.2pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">onset of action and increase the duration of activity in</span></p>
<p style="top:509.2pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">humans.</span></p>
<p style="top:521.1pt;left:81.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">The preclinical studies demonstrated that the CD complex-</span></p>
<p style="top:533.1pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">ions were capable of producing analgesic profile in several</span></p>
<p style="top:545.1pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">animal models of nociception, having better effects than the</span></p>
<p style="top:557.0pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">drugs alone (non-complexed drug). The clinical studies</span></p>
<p style="top:568.9pt;left:71.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">showed that the CD complexation was able to increase the</span></p>
<p style="top:77.2pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">analgesic activity of compounds widely used nowadays, such</span></p>
<p style="top:89.2pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">as PX and DF.</span></p>
<p style="top:101.2pt;left:335.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Consequently, the use of new formulations with CDs is an</span></p>
<p style="top:113.1pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">important tool in the search for greater analgesic effect, and it</span></p>
<p style="top:125.1pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">may also be a way to reduce the therapeutic doses, increasing</span></p>
<p style="top:137.1pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the potential of the drug. On the other hand, it is necessary to</span></p>
<p style="top:149.1pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">investigate possible interactions between these agents and</span></p>
<p style="top:161.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">other formulations, once the interaction can adversely affect</span></p>
<p style="top:173.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">the performance of both.</span></p>
<p style="top:185.0pt;left:335.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">In summary, the use of CDs makes it possible to construct</span></p>
<p style="top:197.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">different pharmaceutical formulations, like capsules and gels,</span></p>
<p style="top:208.9pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">and optimize the chemical configuration of some drug mole-</span></p>
<p style="top:220.9pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">cules that can improve the pharmacokinetics and dynamic</span></p>
<p style="top:232.9pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">profiles, which can result in a better toxicity and side effect</span></p>
<p style="top:244.9pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">profiles. In this context, it is expected that the CDs can solve</span></p>
<p style="top:256.8pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">many problems associated with the delivery of different novel</span></p>
<p style="top:268.8pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">drugs through different delivery routes that may improve the</span></p>
<p style="top:280.8pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">prognosis of certain diseases, particularly those with severe</span></p>
<p style="top:292.8pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">pain as a symptom, like cancer, fibromyalgia, arthritis and</span></p>
<p style="top:304.7pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">neuropathy, offering a better quality of life to patients,</span></p>
<p style="top:316.8pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">caregivers and family members.</span></p>
<p style="top:341.3pt;left:325.3pt;line-height:11.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:11.0pt">Acknowledgments</span></p>
<p style="top:365.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">RG Brito is a doctoral student in a sandwich model and</span></p>
<p style="top:377.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">LJ Quintans-J</span><span style="font-family:AdvP4C4E59,serif;font-size:10.0pt">&#xfffd;</span><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">unior had a post-doctoral stage at the University</span></p>
<p style="top:388.9pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">of Iowa (UIOWA). We thank Emine O Bayman for the</span></p>
<p style="top:400.9pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">methodological support.</span></p>
<p style="top:425.5pt;left:325.3pt;line-height:11.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:11.0pt">Declaration of interest</span></p>
<p style="top:449.1pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">This work was supported by grants from the National Coun-</span></p>
<p style="top:461.2pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">cil of Technological and Scientific Development (CNPq/</span></p>
<p style="top:473.1pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Brazil), the Research Supporting Foundation of the State of</span></p>
<p style="top:485.1pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">Sergipe (FAPITEC-SE/Brazil) and Coordinating Develop-</span></p>
<p style="top:497.1pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">ment of Senior Staff (CAPES/Brazil). The authors have no</span></p>
<p style="top:509.1pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">other relevant affiliations or financial involvement with any</span></p>
<p style="top:521.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">organization or entity with a financial interest in or financial</span></p>
<p style="top:533.1pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">conflict with the subject matter or materials discussed in the</span></p>
<p style="top:545.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">manuscript. This includes employment, consultancies, hono-</span></p>
<p style="top:557.0pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">raria, stock ownership or options, expert testimony, grants</span></p>
<p style="top:568.9pt;left:325.3pt;line-height:10.0pt"><span style="font-family:AdvP5D8B,serif;font-size:10.0pt">or patents received or pending, or royalties.</span></p>
<p style="top:41.8pt;left:439.2pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">CDs improving analgesic drugs</span></p>
<p style="top:750.9pt;left:258.9pt;line-height:7.0pt"><span style="font-family:AdvP4194AB,serif;font-size:7.0pt">Expert Opin. Drug Deliv.</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt"> (2015)</span><span style="font-family:AdvP6A50,serif;font-size:7.0pt"> 12</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">(10)</span></p>
<p style="top:749.3pt;left:558.3pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">9</span></p>
<p style="top:558.4pt;left:-0.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Nandini Loganathan on 07/10/15</span></p>
<p style="top:426.0pt;left:7.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">For personal use only.</span></p>
<img style="position:absolute;transform:matrix(1.3333334,0,-0,1.3333334,674.7067,1021.9347)" src="data:image/png;base64,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">


<p style="top:77.2pt;left:49.0pt;line-height:10.0pt"><span style="font-family:AdvP93EE,serif;font-size:10.0pt">Bibliography</span></p>
<p style="top:89.7pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Papers of special note have been highlighted as</span></p>
<p style="top:100.7pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">either of interest (</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">) or of considerable interest</span></p>
<p style="top:111.7pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">(</span><span style="font-family:AdvP4C4E74,serif;font-size:8.0pt">&#xfffd;&#xfffd;</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">) to readers.</span></p>
<p style="top:125.6pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">1.</span></p>
<p style="top:125.6pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Azevedo LF, Costa-Pereira A,</span></p>
<p style="top:136.5pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Mendonc&#xb8;a L, et al. Epidemiology of</span></p>
<p style="top:147.5pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">chronic pain: a population-based</span></p>
<p style="top:158.5pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">nationwide study on its prevalence,</span></p>
<p style="top:169.4pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">characteristics and associated disability in</span></p>
<p style="top:180.4pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Portugal. J Pain 2012;13:773-83</span></p>
<p style="top:194.4pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2.</span></p>
<p style="top:194.4pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Manchikanti L, Ailinani H,</span></p>
<p style="top:205.3pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Koyyalagunta D, et al. A systematic</span></p>
<p style="top:216.3pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">review of randomized trials of long-term</span></p>
<p style="top:227.3pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">opioid management for chronic non-</span></p>
<p style="top:238.2pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">cancer pain. Pain Physician</span></p>
<p style="top:249.1pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2011;14:91-121</span></p>
<p style="top:263.1pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">3.</span></p>
<p style="top:263.1pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Harker J, Reid KJ, Bekkering GE, et al.</span></p>
<p style="top:274.0pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Epidemiology of chronic pain in</span></p>
<p style="top:285.0pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">denmark and sweden. Pain Res Treat</span></p>
<p style="top:296.0pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2012;2012:371248</span></p>
<p style="top:309.9pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">4.</span></p>
<p style="top:309.9pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Gaskin DJ, Richard P. The economic</span></p>
<p style="top:320.9pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">costs of pain in the United States. J Pain</span></p>
<p style="top:331.9pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2012;13:715-24</span></p>
<p style="top:345.8pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">5.</span></p>
<p style="top:345.8pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Dionne RA. Pharmacologic treatments</span></p>
<p style="top:356.7pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">for temporomandibular disorders.</span></p>
<p style="top:367.7pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Oral Surg Oral Med Oral Pathol Oral</span></p>
<p style="top:378.7pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Radiol Endod 1997;83:134-42</span></p>
<p style="top:392.6pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">6.</span></p>
<p style="top:392.6pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Becker DE. Pain management: Part 1:</span></p>
<p style="top:403.6pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Managing acute and postoperative dental</span></p>
<p style="top:414.5pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">pain. Anesth Prog 2010;57:67-78</span></p>
<p style="top:428.5pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">7.</span></p>
<p style="top:428.5pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Clauw DJ, Arnold LM, McCarberg BH.</span></p>
<p style="top:439.5pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">The science of fibromyalgia.</span></p>
<p style="top:450.4pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Mayo Clin Proc 2011;86:907-11</span></p>
<p style="top:464.3pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">8.</span></p>
<p style="top:464.3pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Xu B, Descalzi G, Ye H-R, et al.</span></p>
<p style="top:475.3pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Translational investigation and treatment</span></p>
<p style="top:486.3pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">of neuropathic pain. Mol Pain 2012;8:15</span></p>
<p style="top:500.2pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">9.</span></p>
<p style="top:500.2pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Abdel-Tawab M, Zettl H,</span></p>
<p style="top:511.2pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Schubert-Zsilavecz M. Nonsteroidal anti-</span></p>
<p style="top:522.1pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">inflammatory drugs: a critical review on</span></p>
<p style="top:533.1pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">current concepts applied to reduce</span></p>
<p style="top:544.0pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">gastrointestinal toxicity. Curr Med Chem</span></p>
<p style="top:555.0pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2009;16:2042-63</span></p>
<p style="top:568.9pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">10.</span></p>
<p style="top:568.9pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Laza-Knoerr AL, Gref R, Couvreur P.</span></p>
<p style="top:579.9pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Cyclodextrins for drug delivery.</span></p>
<p style="top:590.9pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">J Drug Target 2010;18:645-56</span></p>
<p style="top:602.7pt;left:49.0pt;line-height:5.6pt"><span style="font-family:AdvPi1,serif;font-size:5.6pt">..</span></p>
<p style="top:601.8pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP93EE,serif;font-size:8.0pt">Describes how useful is</span></p>
<p style="top:612.8pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP93EE,serif;font-size:8.0pt">the cyclodextrins.</span></p>
<p style="top:626.7pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">11.</span></p>
<p style="top:626.7pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Loftsson T, Brewster ME.</span></p>
<p style="top:637.7pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Pharmaceutical applications of</span></p>
<p style="top:648.7pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">cyclodextrins. 1. Drug solubilization and</span></p>
<p style="top:659.6pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">stabilization. J Pharm Sci</span></p>
<p style="top:670.6pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">1996;85:1017-25</span></p>
<p style="top:682.4pt;left:49.0pt;line-height:5.6pt"><span style="font-family:AdvPi1,serif;font-size:5.6pt">..</span></p>
<p style="top:681.5pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP93EE,serif;font-size:8.0pt">Describes the pharmaceutical</span></p>
<p style="top:692.5pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP93EE,serif;font-size:8.0pt">importance of cyclodextrins.</span></p>
<p style="top:87.1pt;left:218.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">12.</span></p>
<p style="top:87.1pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Scarpignato C. Piroxicam-</span><span style="font-family:AdvP697C,serif;font-size:8.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">-cyclodextrin:</span></p>
<p style="top:98.0pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">a GI safer piroxicam. Curr Med Chem</span></p>
<p style="top:109.0pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2013;20:2415-37</span></p>
<p style="top:122.9pt;left:218.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">13.</span></p>
<p style="top:122.9pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Del Valle EMM. Cyclodextrins and their</span></p>
<p style="top:133.9pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">uses: a review. Process Biochem</span></p>
<p style="top:144.8pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2004;39:1033-46</span></p>
<p style="top:156.7pt;left:218.3pt;line-height:5.6pt"><span style="font-family:AdvPi1,serif;font-size:5.6pt">..</span></p>
<p style="top:155.8pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP93EE,serif;font-size:8.0pt">Describes the different use</span></p>
<p style="top:166.8pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP93EE,serif;font-size:8.0pt">of cyclodextrins.</span></p>
<p style="top:180.7pt;left:218.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">14.</span></p>
<p style="top:180.7pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Quintans J de SS, Menezes PP,</span></p>
<p style="top:191.7pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Santos MRV, et al. Improvement of</span></p>
<p style="top:202.6pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">p-cymene antinociceptive and anti-</span></p>
<p style="top:213.6pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">inflammatory effects by inclusion in</span></p>
<p style="top:224.5pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP697C,serif;font-size:8.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">-cyclodextrin. Phytomedicine</span></p>
<p style="top:235.5pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2013;20:436-40</span></p>
<p style="top:249.4pt;left:218.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">15.</span></p>
<p style="top:249.4pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Tejashri G, Amrita B, Darshana J.</span></p>
<p style="top:260.4pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Cyclodextrin based nanosponges for</span></p>
<p style="top:271.4pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">pharmaceutical use: a review. Acta Pharm</span></p>
<p style="top:282.3pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Zagreb Croat 2013;63:335-58</span></p>
<p style="top:296.2pt;left:218.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">16.</span></p>
<p style="top:296.2pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Pinho E, Grootveld M, Soares G,</span></p>
<p style="top:307.2pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Henriques M. Cyclodextrins as</span></p>
<p style="top:318.2pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">encapsulation agents for plant bioactive</span></p>
<p style="top:329.1pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">compounds. Carbohydr Polym</span></p>
<p style="top:340.1pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2014;101:121-35</span></p>
<p style="top:354.1pt;left:218.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">17.</span></p>
<p style="top:354.1pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Stella VJ, He Q. Cyclodextrins.</span></p>
<p style="top:365.0pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Toxicol Pathol 2008;36:30-42</span></p>
<p style="top:376.9pt;left:218.3pt;line-height:5.6pt"><span style="font-family:AdvPi1,serif;font-size:5.6pt">.</span></p>
<p style="top:376.0pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP93EE,serif;font-size:8.0pt">Helps understand what is cyclodextrin.</span></p>
<p style="top:389.9pt;left:218.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">18.</span></p>
<p style="top:389.9pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Challa R, Ahuja A, Ali J, Khar RK.</span></p>
<p style="top:400.9pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Cyclodextrins in drug delivery: An</span></p>
<p style="top:411.8pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">updated review. AAPS PharmSciTech</span></p>
<p style="top:422.8pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2005;6:E329-57</span></p>
<p style="top:434.7pt;left:218.3pt;line-height:5.6pt"><span style="font-family:AdvPi1,serif;font-size:5.6pt">.</span></p>
<p style="top:433.7pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP93EE,serif;font-size:8.0pt">Helps to understand how cyclodextrin</span></p>
<p style="top:444.7pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP93EE,serif;font-size:8.0pt">is used in drug delivery.</span></p>
<p style="top:458.7pt;left:218.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">19.</span></p>
<p style="top:458.7pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Moher D, Liberati A, Tetzlaff J,</span></p>
<p style="top:469.6pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Altman DG. Preferred reporting items</span></p>
<p style="top:480.6pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">for systematic reviews and meta-analyses:</span></p>
<p style="top:491.6pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">the PRISMA statement. Ann Intern Med</span></p>
<p style="top:502.5pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2009;151:264-9; W64</span></p>
<p style="top:516.4pt;left:218.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">20.</span></p>
<p style="top:516.4pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Higgins JPT, Altman DG, G?tzsche PC,</span></p>
<p style="top:527.4pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">et al. The Cochrane Collaboration&#x2019;s tool</span></p>
<p style="top:538.4pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">for assessing risk of bias in randomised</span></p>
<p style="top:549.3pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">trials. BMJ 2011;343:d5928</span></p>
<p style="top:563.3pt;left:218.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">21.</span></p>
<p style="top:563.3pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Gan TJ, Daniels SE, Singla N, et al.</span></p>
<p style="top:574.2pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">A novel injectable formulation of</span></p>
<p style="top:585.2pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">diclofenac compared with intravenous</span></p>
<p style="top:596.2pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">ketorolac or placebo for acute</span></p>
<p style="top:607.1pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">moderate-to-severe pain after abdominal</span></p>
<p style="top:618.1pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">or pelvic surgery: a multicenter, double-</span></p>
<p style="top:629.0pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">blind, randomized, multiple-dose study.</span></p>
<p style="top:640.0pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Anesth Analg 2012;115:1212-20</span></p>
<p style="top:653.9pt;left:218.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">22.</span></p>
<p style="top:653.9pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Christensen K, Daniels S, Bandy D,</span></p>
<p style="top:664.9pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">et al. A double-blind placebo-controlled</span></p>
<p style="top:675.9pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">comparison of a novel formulation of</span></p>
<p style="top:686.8pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">intravenous diclofenac and ketorolac for</span></p>
<p style="top:697.7pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">postoperative third molar extraction pain.</span></p>
<p style="top:708.7pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Anesth Prog 2011;58:73-81</span></p>
<p style="top:87.0pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">23.</span></p>
<p style="top:87.0pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Keles</span><span style="font-family:AdvMT_RM,serif;font-size:8.0pt">&#xb8;</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt"> GT, Topc&#xb8;u I, Ekici Z, Yentu&#xa8;r A.</span></p>
<p style="top:98.0pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Evaluation of piroxicam-beta-cyclodextrin</span></p>
<p style="top:109.0pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">as a preemptive analgesic in functional</span></p>
<p style="top:119.9pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">endoscopic sinus surgery. Braz J Med</span></p>
<p style="top:130.9pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Biol Res 2010;43:806-11</span></p>
<p style="top:144.8pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">24.</span></p>
<p style="top:144.8pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Chang S-T, Chen L-C, Chang C-C,</span></p>
<p style="top:155.8pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">et al. Effects of</span></p>
<p style="top:166.8pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">piroxicam-beta-cyclodextrin sachets on</span></p>
<p style="top:177.7pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">abnormal postural sway in patients with</span></p>
<p style="top:188.6pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">chronic low back pain.</span></p>
<p style="top:199.6pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">J Clin Pharm Ther 2008;33:495-506</span></p>
<p style="top:213.6pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">25.</span></p>
<p style="top:213.6pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Shin-Tsu Chang L-CC. Efficacy and</span></p>
<p style="top:224.5pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">safety of piroxicam beta-cyclodextrin</span></p>
<p style="top:235.5pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">sachets for treating chronic low back</span></p>
<p style="top:246.5pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">pain: a randomized, parallel, active-</span></p>
<p style="top:257.4pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">controlled trial. J Med Sci 2008;28</span></p>
<p style="top:271.4pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">26.</span></p>
<p style="top:271.4pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Pijak MR, Turcani P, Turcaniova Z,</span></p>
<p style="top:282.3pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">et al. Efficacy and tolerability of</span></p>
<p style="top:293.3pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">piroxicam-beta-cyclodextrin in the</span></p>
<p style="top:304.2pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">outpatient management of chronic back</span></p>
<p style="top:315.2pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">pain. Bratisl Leka&#xb4;rske Listy</span></p>
<p style="top:326.2pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2002;103:467-72</span></p>
<p style="top:340.1pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">27.</span></p>
<p style="top:340.1pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Fioravanti A, Storri L, Di Martino S,</span></p>
<p style="top:351.1pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">et al. A randomized, double-blind,</span></p>
<p style="top:362.0pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">multicenter trial of</span></p>
<p style="top:372.9pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">nimesulide-beta-cyclodextrin versus</span></p>
<p style="top:383.9pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">naproxen in patients with osteoarthritis.</span></p>
<p style="top:394.9pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Clin Ther 2002;24:504-19</span></p>
<p style="top:408.8pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">28.</span></p>
<p style="top:408.8pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Siqueira-Lima PS, Ara</span><span style="font-family:AdvP4C4E59,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">ujo AAS,</span></p>
<p style="top:419.8pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Lucchese AM, et al.</span><span style="font-family:AdvP697C,serif;font-size:8.0pt"> b</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">-cyclodextrin</span></p>
<p style="top:430.8pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">complex containing lippia grata leaf</span></p>
<p style="top:441.7pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">essential oil reduces orofacial nociception</span></p>
<p style="top:452.7pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">in mice - evidence of possible</span></p>
<p style="top:463.7pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">involvement of descending inhibitory</span></p>
<p style="top:474.6pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">pain modulation pathway. Basic Clin</span></p>
<p style="top:485.5pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Pharmacol Toxicol 2014;114:188-96</span></p>
<p style="top:499.5pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">29.</span></p>
<p style="top:499.5pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Quintans-J</span><span style="font-family:AdvP4C4E59,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">unior LJ, Barreto RSS,</span></p>
<p style="top:510.5pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Menezes PP, et al.</span></p>
<p style="top:521.4pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP697C,serif;font-size:8.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">-Cyclodextrin-complexed (-)-linalool</span></p>
<p style="top:532.4pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">produces antinociceptive effect superior</span></p>
<p style="top:543.4pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">to that of (-)-linalool in experimental</span></p>
<p style="top:554.3pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">pain protocols. Basic Clin</span></p>
<p style="top:565.2pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Pharmacol Toxicol 2013;113:167-72</span></p>
<p style="top:579.2pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">30.</span></p>
<p style="top:579.2pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">El-Feky G, El-Banna S, Khalil S.</span></p>
<p style="top:590.1pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Preparation, in vitro and in vivo</span></p>
<p style="top:601.1pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">evaluation of oral indomethacin-HP-B-</span></p>
<p style="top:612.1pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Cyclodextrin loaded chitosan</span></p>
<p style="top:623.0pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">nanoparticules. Int J Pharm Pharm Sci</span></p>
<p style="top:634.0pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2013;5:638-45</span></p>
<p style="top:648.0pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">31.</span></p>
<p style="top:648.0pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Dolita K. Formulation and</span></p>
<p style="top:658.9pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">characterization of inclusion complex of</span></p>
<p style="top:669.8pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">acetyl salicylic acid (aspirin) and</span></p>
<p style="top:680.8pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">b-cyclodextrin vy solvent evaporation &amp;</span></p>
<p style="top:691.8pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">its comparatives study to aspirin alone.</span></p>
<p style="top:702.7pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Int J Pharm Sci Res 2012;3:2831-6</span></p>
<p style="top:41.8pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">R. G. Brito</span><span style="font-family:AdvP47DAD7,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:749.3pt;left:49.0pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">10</span></p>
<p style="top:750.9pt;left:236.6pt;line-height:7.0pt"><span style="font-family:AdvP4194AB,serif;font-size:7.0pt">Expert Opin. Drug Deliv.</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt"> (2015)</span><span style="font-family:AdvP6A50,serif;font-size:7.0pt"> 12</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">(10)</span></p>
<p style="top:558.4pt;left:-0.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Nandini Loganathan on 07/10/15</span></p>
<p style="top:426.0pt;left:7.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">For personal use only.</span></p>
<img style="position:absolute;transform:matrix(1.3333334,0,-0,1.3333334,674.7067,1021.9347)" src="data:image/png;base64,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">


<p style="top:72.1pt;left:71.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">32.</span></p>
<p style="top:72.1pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Singh I, Kumar P, Pahuja S, et al.</span></p>
<p style="top:83.1pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Development and pharmacological</span></p>
<p style="top:94.0pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">evaluation of cyclodextrin complexes of</span></p>
<p style="top:105.0pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">etoricoxib. Acta Pol Pharm</span></p>
<p style="top:116.0pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2011;68:279-84</span></p>
<p style="top:129.9pt;left:71.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">33.</span></p>
<p style="top:129.9pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Janovsky&#xb4; M, Dolezal T, Procha&#xb4;izkova&#xb4; M,</span></p>
<p style="top:140.9pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">et al. Influence on analgesic activity and</span></p>
<p style="top:151.8pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">serum levels after meloxicam</span></p>
<p style="top:162.8pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">complexation with beta-cyclodextrin in</span></p>
<p style="top:173.7pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">mice and rats. Arzneimittelforschung</span></p>
<p style="top:184.7pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2010;60:320-3</span></p>
<p style="top:198.6pt;left:71.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">34.</span></p>
<p style="top:198.6pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Sinha VR, Amita Goel H. In vivo</span></p>
<p style="top:209.6pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">bioavailability and therapeutic assessment</span></p>
<p style="top:220.6pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">of host-guest inclusion phenomena for</span></p>
<p style="top:231.5pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">the hydrophobic molecule etodolac:</span></p>
<p style="top:242.4pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">pharmacodynamic and pharmacokinetic</span></p>
<p style="top:253.4pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">evaluation. Sci Pharm 2010;78:103-15</span></p>
<p style="top:267.4pt;left:71.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">35.</span></p>
<p style="top:267.4pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Cappello B, di Maio C, Iervolino M,</span></p>
<p style="top:278.3pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">et al. Etodolac/cyclodextrin formulations:</span></p>
<p style="top:289.3pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">physicochemical characterization and</span></p>
<p style="top:300.3pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">in vivo pharmacological studies.</span></p>
<p style="top:311.2pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Drug Dev Ind Pharm 2009;35:877-86</span></p>
<p style="top:325.2pt;left:71.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">36.</span></p>
<p style="top:325.2pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Lu W-L, Zhang Q, Zheng L, et al.</span></p>
<p style="top:336.1pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Antipyretic, analgesic and anti-</span></p>
<p style="top:347.1pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">inflammatory activities of ketoprofen</span></p>
<p style="top:358.0pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">beta-cyclodextrin inclusion complexes in</span></p>
<p style="top:369.0pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">animals. Biol Pharm Bull</span></p>
<p style="top:380.0pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2004;27:1515-20</span></p>
<p style="top:393.9pt;left:71.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">37.</span></p>
<p style="top:393.9pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Astruc-Diaz F, McDaniel SW, Xu JJ,</span></p>
<p style="top:404.9pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">et al. In vivo efficacy of enabling</span></p>
<p style="top:415.8pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">formulations based on hydroxypropyl-</span><span style="font-family:AdvP697C,serif;font-size:8.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">-</span></p>
<p style="top:426.8pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">cyclodextrins, micellar preparation, and</span></p>
<p style="top:437.8pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">liposomes for the lipophilic cannabinoid</span></p>
<p style="top:448.7pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">CB2 agonist, MDA7. J Pharm Sci</span></p>
<p style="top:459.6pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2013;102:352-64</span></p>
<p style="top:473.6pt;left:71.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">38.</span></p>
<p style="top:473.6pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Svensson E, Persson J, Fitzsimmons B,</span></p>
<p style="top:484.6pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Yaksh TL. Intrathecal neurosteroids and</span></p>
<p style="top:495.5pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">a neurosteroid antagonist: effects on</span></p>
<p style="top:506.5pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">inflammation-evoked thermal</span></p>
<p style="top:517.5pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">hyperalgesia and tactile allodynia.</span></p>
<p style="top:528.4pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Neurosci Lett 2013;548:27-32</span></p>
<p style="top:542.3pt;left:71.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">39.</span></p>
<p style="top:542.3pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Franco de Lima RA, de Jesus MB,</span></p>
<p style="top:553.3pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Saia Cereda CM, et al. Improvement of</span></p>
<p style="top:564.3pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">tetracaine antinociceptive effect by</span></p>
<p style="top:575.2pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">inclusion in cyclodextrins. J Drug Target</span></p>
<p style="top:586.2pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2012;20:85-96</span></p>
<p style="top:600.1pt;left:71.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">40.</span></p>
<p style="top:600.1pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Volobuef C, Moraes CM, Nunes LAS,</span></p>
<p style="top:611.1pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">et al. Sufentanil-2-hydroxypropyl-</span><span style="font-family:AdvP697C,serif;font-size:8.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">-</span></p>
<p style="top:622.1pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">cyclodextrin inclusion complex for pain</span></p>
<p style="top:633.0pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">treatment: physicochemical, cytotoxicity,</span></p>
<p style="top:643.9pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">and pharmacological evaluation.</span></p>
<p style="top:654.9pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">J Pharm Sci 2012;101:3698-707</span></p>
<p style="top:668.9pt;left:71.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">41.</span></p>
<p style="top:668.9pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Sammeta SM, Vaka SRK, Murthy SN.</span></p>
<p style="top:679.8pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Transcutaneous electroporation mediated</span></p>
<p style="top:690.8pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">delivery of doxepin-HPCD complex:</span></p>
<p style="top:701.8pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">a sustained release approach for</span></p>
<p style="top:712.7pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">treatment of postherpetic neuralgia.</span></p>
<p style="top:723.6pt;left:93.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">J Control Release Off 2010;142:361-7</span></p>
<p style="top:72.1pt;left:240.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">42.</span></p>
<p style="top:72.1pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Gan TJ. Diclofenac: an update on its</span></p>
<p style="top:83.1pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">mechanism of action and safety profile.</span></p>
<p style="top:94.0pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Curr Med Res Opin 2010;26:1715-31</span></p>
<p style="top:108.0pt;left:240.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">43.</span></p>
<p style="top:108.0pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Marret E, Kurdi O, Zufferey P,</span></p>
<p style="top:118.9pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Bonnet F. Effects of nonsteroidal</span></p>
<p style="top:129.9pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">antiinflammatory drugs on patient-</span></p>
<p style="top:140.8pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">controlled analgesia morphine side</span></p>
<p style="top:151.8pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">effects: meta-analysis of randomized</span></p>
<p style="top:162.8pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">controlled trials. Anesthesiology</span></p>
<p style="top:173.7pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2005;102:1249-60</span></p>
<p style="top:187.7pt;left:240.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">44.</span></p>
<p style="top:187.7pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">McCormack K. Non-steroidal anti-</span></p>
<p style="top:198.6pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">inflammatory drugs and spinal</span></p>
<p style="top:209.6pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">nociceptive processing. Pain</span></p>
<p style="top:220.5pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">1994;59:9-43</span></p>
<p style="top:234.5pt;left:240.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">45.</span></p>
<p style="top:234.5pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Koes B, Scholten R, Mens J, Bouter L.</span></p>
<p style="top:245.4pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Efficacy of non-steroidal anti-</span></p>
<p style="top:256.4pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">inflammatory drugs for low back pain:</span></p>
<p style="top:267.4pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">a systematic review of randomised</span></p>
<p style="top:278.3pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">clinical trials. Ann Rheum Dis</span></p>
<p style="top:289.3pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">1997;56:214-23</span></p>
<p style="top:303.2pt;left:240.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">46.</span></p>
<p style="top:303.2pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Acerbi DD. Pharmacokinetic Profile of</span></p>
<p style="top:314.2pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Piroxicam-</span><span style="font-family:AdvP697C,serif;font-size:8.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">-Cyclodextrin. Drug Investig</span></p>
<p style="top:325.1pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">1990;2:42-9</span></p>
<p style="top:339.1pt;left:240.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">47.</span></p>
<p style="top:339.1pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Woodcock BG, Acerbi D, Merz PG,</span></p>
<p style="top:350.0pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">et al. Supermolecular inclusion of</span></p>
<p style="top:361.0pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">piroxicam with beta-cyclodextrin:</span></p>
<p style="top:372.0pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">pharmacokinetic properties in man. Eur J</span></p>
<p style="top:382.9pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Rheumatol Inflamm 1993;12:12-28</span></p>
<p style="top:396.9pt;left:240.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">48.</span></p>
<p style="top:396.9pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Lee CR, Balfour JA. Piroxicam-beta-</span></p>
<p style="top:407.9pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">cyclodextrin. A review of its</span></p>
<p style="top:418.8pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">pharmacodynamic and pharmacokinetic</span></p>
<p style="top:429.7pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">properties, and therapeutic potential in</span></p>
<p style="top:440.7pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">rheumatic diseases and pain states. Drugs</span></p>
<p style="top:451.7pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">1994;48:907-29</span></p>
<p style="top:465.6pt;left:240.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">49.</span></p>
<p style="top:465.6pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Davoli L, Ciotti G, Biondi M,</span></p>
<p style="top:476.6pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Passeri M. Piroxicam-beta-cyclodextrin in</span></p>
<p style="top:487.5pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">the treatment of low-back pain:</span></p>
<p style="top:498.5pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">controlled study vs etodolac.</span></p>
<p style="top:509.5pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Curr Ther Res 1989;46:940-7</span></p>
<p style="top:523.4pt;left:240.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">50.</span></p>
<p style="top:523.4pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Rainsford KD. Nimesulide &#x2013; a</span></p>
<p style="top:534.3pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">multifactorial approach to inflammation</span></p>
<p style="top:545.3pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">and pain: scientific and clinical</span></p>
<p style="top:556.3pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">consensus. Curr Med Res Opin</span></p>
<p style="top:567.2pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2006;22:1161-70</span></p>
<p style="top:581.2pt;left:240.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">51.</span></p>
<p style="top:581.2pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Batista PA, Werner MF de P,</span></p>
<p style="top:592.2pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Oliveira EC, et al. Evidence for the</span></p>
<p style="top:603.1pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">involvement of ionotropic glutamatergic</span></p>
<p style="top:614.0pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">receptors on the antinociceptive effect of</span></p>
<p style="top:625.0pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">(-)-linalool in mice. Neurosci Lett</span></p>
<p style="top:636.0pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2008;440:299-303</span></p>
<p style="top:649.9pt;left:240.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">52.</span></p>
<p style="top:649.9pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Elisabetsky E, Brum LF, Souza DO.</span></p>
<p style="top:660.9pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Anticonvulsant properties of linalool in</span></p>
<p style="top:671.8pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">glutamate-related seizure models.</span></p>
<p style="top:682.8pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Phytomedicine 1999;6:107-13</span></p>
<p style="top:696.8pt;left:240.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">53.</span></p>
<p style="top:696.8pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Vena&#x2c6;ncio AM, Marchioro M,</span></p>
<p style="top:707.7pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Estavam CS, et al. Ocimum basilicum</span></p>
<p style="top:718.7pt;left:262.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">leaf essential oil and (-)-linalool reduce</span></p>
<p style="top:72.1pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">orofacial nociception in rodents:</span></p>
<p style="top:83.1pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">a behavioral and electrophysiological</span></p>
<p style="top:94.0pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">approach. Rev Bras Farmacogn</span></p>
<p style="top:105.0pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2011;21:1043-51</span></p>
<p style="top:118.9pt;left:409.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">54.</span></p>
<p style="top:118.9pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Siani AC, Ramos MF, Menezes-de-</span></p>
<p style="top:129.9pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Lima O Jr, et al. Evaluation of</span></p>
<p style="top:140.9pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">anti-inflammatory-related activity of</span></p>
<p style="top:151.8pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">essential oils from the leaves and resin of</span></p>
<p style="top:162.8pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">species of Protium. J Ethnopharmacol</span></p>
<p style="top:173.7pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">1999;66:57-69</span></p>
<p style="top:187.7pt;left:409.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">55.</span></p>
<p style="top:187.7pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Bonjardim LR, Cunha ES,</span></p>
<p style="top:198.6pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Guimara&#x2dc;es AG, et al. Evaluation of the</span></p>
<p style="top:209.6pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">anti-inflammatory and antinociceptive</span></p>
<p style="top:220.6pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">properties of p-cymene in mice. Z Fu&#xa8;r</span></p>
<p style="top:231.5pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Naturforschung C J Biosci</span></p>
<p style="top:242.4pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2012;67:15-21</span></p>
<p style="top:256.4pt;left:409.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">56.</span></p>
<p style="top:256.4pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Xie G, Chen N, Soromou LW, et al.</span></p>
<p style="top:267.4pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">p-Cymene protects mice against</span></p>
<p style="top:278.3pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">lipopolysaccharide-induced acute lung</span></p>
<p style="top:289.3pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">injury by inhibiting inflammatory cell</span></p>
<p style="top:300.3pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">activation. Mol Basel Switz</span></p>
<p style="top:311.2pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2012;17:8159-73</span></p>
<p style="top:325.2pt;left:409.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">57.</span></p>
<p style="top:325.2pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Marreto RN, Almeida EECV, Alves PB,</span></p>
<p style="top:336.1pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">et al. Thermal analysis and gas</span></p>
<p style="top:347.1pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">chromatography coupled mass</span></p>
<p style="top:358.0pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">spectrometry analyses of</span></p>
<p style="top:369.0pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">hydroxypropyl-</span><span style="font-family:AdvP697C,serif;font-size:8.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">-cyclodextrin inclusion</span></p>
<p style="top:380.0pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">complex containing Lippia gracilis</span></p>
<p style="top:390.9pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">essential oil. Thermochim Acta</span></p>
<p style="top:401.9pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2008;475:53-8</span></p>
<p style="top:415.8pt;left:409.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">58.</span></p>
<p style="top:415.8pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Menezes PP, Serafini MR, Santana BV,</span></p>
<p style="top:426.7pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">et al. Solid-state</span><span style="font-family:AdvP697C,serif;font-size:8.0pt"> b</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">-cyclodextrin</span></p>
<p style="top:437.7pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">complexes containing geraniol.</span></p>
<p style="top:448.7pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Thermochim Acta 2012;548:45-50</span></p>
<p style="top:462.6pt;left:409.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">59.</span></p>
<p style="top:462.6pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Ciobanu A, Mallard I, Landy D, et al.</span></p>
<p style="top:473.6pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Inclusion interactions of cyclodextrins</span></p>
<p style="top:484.6pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">and crosslinked cyclodextrin polymers</span></p>
<p style="top:495.5pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">with linalool and camphor in Lavandula</span></p>
<p style="top:506.5pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">angustifolia essential oil.</span></p>
<p style="top:517.5pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Carbohydr Polym 2012;87:1963-70</span></p>
<p style="top:531.4pt;left:409.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">60.</span></p>
<p style="top:531.4pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Menezes PP, Serafini MR,</span></p>
<p style="top:542.3pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Quintans-J</span><span style="font-family:AdvP4C4E59,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">unior LJ, et al. Inclusion</span></p>
<p style="top:553.3pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">complex of (-)-linalool and</span></p>
<p style="top:564.3pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP697C,serif;font-size:8.0pt">b</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">-cyclodextrin. J Therm Anal Calorim</span></p>
<p style="top:575.2pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2014;115:2429-2437</span></p>
<p style="top:589.2pt;left:409.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">61.</span></p>
<p style="top:589.2pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Dillon CT, Hambley TW, Kennedy BJ,</span></p>
<p style="top:600.1pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">et al. Gastrointestinal toxicity,</span></p>
<p style="top:611.1pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">antiinflammatory activity, and superoxide</span></p>
<p style="top:622.1pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">dismutase activity of copper and zinc</span></p>
<p style="top:633.0pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">complexes of the antiinflammatory drug</span></p>
<p style="top:643.9pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">indomethacin. Chem Res Toxicol</span></p>
<p style="top:654.9pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2003;16:28-37</span></p>
<p style="top:668.9pt;left:409.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">62.</span></p>
<p style="top:668.9pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Moon H-G, Kang CS, Choi J-P, et al.</span></p>
<p style="top:679.8pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Acetyl salicylic acid inhibits Th17 airway</span></p>
<p style="top:690.8pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">inflammation via blockade of IL-6 and</span></p>
<p style="top:701.8pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">IL-17 positive feedback. Exp Mol Med</span></p>
<p style="top:712.7pt;left:431.8pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2013;45:e6</span></p>
<p style="top:41.8pt;left:439.2pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">CDs improving analgesic drugs</span></p>
<p style="top:750.9pt;left:258.9pt;line-height:7.0pt"><span style="font-family:AdvP4194AB,serif;font-size:7.0pt">Expert Opin. Drug Deliv.</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt"> (2015)</span><span style="font-family:AdvP6A50,serif;font-size:7.0pt"> 12</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">(10)</span></p>
<p style="top:749.3pt;left:553.4pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">11</span></p>
<p style="top:558.4pt;left:-0.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Nandini Loganathan on 07/10/15</span></p>
<p style="top:426.0pt;left:7.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">For personal use only.</span></p>
<img style="position:absolute;transform:matrix(1.3333334,0,-0,1.3333334,674.7067,1021.9347)" src="data:image/png;base64,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">


<p style="top:72.1pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">63.</span></p>
<p style="top:72.1pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Rubin BR, Burton R, Navarra S, et al.</span></p>
<p style="top:83.1pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Efficacy and safety profile of treatment</span></p>
<p style="top:94.0pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">with etoricoxib 120 mg once daily</span></p>
<p style="top:105.0pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">compared with indomethacin 50 mg</span></p>
<p style="top:116.0pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">three times daily in acute gout:</span></p>
<p style="top:126.9pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">A randomized controlled trial.</span></p>
<p style="top:137.8pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Arthritis Rheum 2004;50:598-606</span></p>
<p style="top:151.8pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">64.</span></p>
<p style="top:151.8pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Schnitzer TJ, Hochberg MC.</span></p>
<p style="top:162.8pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">COX-2-selective inhibitors in the</span></p>
<p style="top:173.7pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">treatment of arthritis. Cleve Clin J Med</span></p>
<p style="top:184.7pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2002;69:SI20</span></p>
<p style="top:198.6pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">65.</span></p>
<p style="top:198.6pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Akbulut N, Ustu&#xa8;ner E, Atakan C,</span></p>
<p style="top:209.6pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">C</span><span style="font-family:AdvP4C4E59,serif;font-size:8.0pt">&#x20ac;</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">olok G. Comparison of the effect of</span></p>
<p style="top:220.6pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">naproxen, etodolac and diclofenac on</span></p>
<p style="top:231.5pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">postoperative sequels following third</span></p>
<p style="top:242.4pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">molar surgery: A randomised, double-</span></p>
<p style="top:253.4pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">blind, crossover study. Med Oral Patol</span></p>
<p style="top:264.4pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2014;19:e149-56</span></p>
<p style="top:278.3pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">66.</span></p>
<p style="top:278.3pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Kaur N, Singh H, Gupta AC.</span></p>
<p style="top:289.3pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Randomized Controlled Trial of</span></p>
<p style="top:300.3pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Etodolac versus Combination of Etodolac</span></p>
<p style="top:311.2pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">and Eperisone in Patients of Knee</span></p>
<p style="top:322.2pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Osteoarthritis. Pain Res Treat</span></p>
<p style="top:333.2pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2013;2013:273695</span></p>
<p style="top:347.1pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">67.</span></p>
<p style="top:347.1pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Duangjit S, Obata Y, Sano H, et al.</span></p>
<p style="top:358.0pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Comparative study of novel</span></p>
<p style="top:369.0pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">ultradeformable liposomes: menthosomes,</span></p>
<p style="top:380.0pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">transfersomes and liposomes for</span></p>
<p style="top:390.9pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">enhancing skin permeation of</span></p>
<p style="top:401.9pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">meloxicam. Biol Pharm Bull</span></p>
<p style="top:412.8pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2014;37:239-47</span></p>
<p style="top:426.8pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">68.</span></p>
<p style="top:426.8pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Mas&#xb4;lanka T, Jaroszewski JJ. In vitro</span></p>
<p style="top:437.7pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">effects of meloxicam on the number,</span></p>
<p style="top:448.7pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Foxp3 expression, production of selected</span></p>
<p style="top:459.6pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">cytokines, and apoptosis of bovine CD25</span></p>
<p style="top:470.6pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">+CD4+ and CD25-CD4+ cells. J Vet Sci</span></p>
<p style="top:481.6pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2013;14:125-34</span></p>
<p style="top:495.5pt;left:49.0pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">69.</span></p>
<p style="top:495.5pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Carbone C, Rende P, Comberiati P,</span></p>
<p style="top:506.5pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">et al. The safety of ketoprofen in</span></p>
<p style="top:517.5pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">different ages. J Pharmacol Pharmacother</span></p>
<p style="top:528.4pt;left:70.9pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2013;4:S99-S103</span></p>
<p style="top:72.1pt;left:218.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">70.</span></p>
<p style="top:72.1pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Saleem MA, Bala S, Liyakat Aeajaz A.</span></p>
<p style="top:83.1pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Effect of Different Carriers on in vitro</span></p>
<p style="top:94.0pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Permeation of Meloxicam through Rat</span></p>
<p style="top:105.0pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Skin. Indian J Pharm Sci</span></p>
<p style="top:116.0pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2010;72:710-18</span></p>
<p style="top:129.9pt;left:218.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">71.</span></p>
<p style="top:129.9pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Ghorab MM, Abdel-Salam HM,</span></p>
<p style="top:140.8pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">El-Sayad MA, Mekhel MM. Tablet</span></p>
<p style="top:151.8pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">formulation containing meloxicam and</span></p>
<p style="top:162.8pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">beta-cyclodextrin: Mechanical</span></p>
<p style="top:173.7pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">characterization and bioavailability</span></p>
<p style="top:184.7pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">evaluation. AAPS PharmSciTech</span></p>
<p style="top:195.6pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2004;5:63-8</span></p>
<p style="top:209.6pt;left:218.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">72.</span></p>
<p style="top:209.6pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Naguib M, Diaz P, Xu JJ, et al. MDA7:</span></p>
<p style="top:220.6pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">a novel selective agonist for</span></p>
<p style="top:231.5pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">CB2 receptors that prevents allodynia in</span></p>
<p style="top:242.4pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">rat neuropathic pain models.</span></p>
<p style="top:253.4pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Br J Pharmacol 2008;155:1104-16</span></p>
<p style="top:267.4pt;left:218.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">73.</span></p>
<p style="top:267.4pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Naguib M, Xu JJ, Diaz P, et al.</span></p>
<p style="top:278.3pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Prevention of paclitaxel-induced</span></p>
<p style="top:289.3pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">neuropathy through activation of the</span></p>
<p style="top:300.3pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">central cannabinoid type 2 receptor</span></p>
<p style="top:311.2pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">system. Anesth Analg 2012;114:1104-20</span></p>
<p style="top:325.1pt;left:218.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">74.</span></p>
<p style="top:325.1pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Akk G, Covey DF, Evers AS, et al.</span></p>
<p style="top:336.1pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Mechanisms of neurosteroid interactions</span></p>
<p style="top:347.1pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">with GABAA receptors. Pharmacol Ther</span></p>
<p style="top:358.0pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2007;116:35-57</span></p>
<p style="top:372.0pt;left:218.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">75.</span></p>
<p style="top:372.0pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Jevtovic-Todorovic V, Covey DF,</span></p>
<p style="top:382.9pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Todorovic SM. Are neuroactive steroids</span></p>
<p style="top:393.9pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">promising therapeutic agents in the</span></p>
<p style="top:404.9pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">management of acute and chronic pain?</span></p>
<p style="top:415.8pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Psychoneuroendocrinology</span></p>
<p style="top:426.7pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2009;34:S178-85</span></p>
<p style="top:440.7pt;left:218.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">76.</span></p>
<p style="top:440.7pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Reddy DS. Neurosteroids: endogenous</span></p>
<p style="top:451.7pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">role in the human brain and therapeutic</span></p>
<p style="top:462.6pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">potentials. Prog Brain Res</span></p>
<p style="top:473.6pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">2010;186:113-37</span></p>
<p style="top:487.5pt;left:218.3pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">77.</span></p>
<p style="top:487.5pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Giannakopoulos H, Levin LM, Chou JC,</span></p>
<p style="top:498.5pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">et al. The cardiovascular effects and</span></p>
<p style="top:509.5pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">pharmacokinetics of intranasal tetracaine</span></p>
<p style="top:520.4pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">plus oxymetazoline Preliminary findings.</span></p>
<p style="top:531.4pt;left:240.2pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">J Am Dent Assoc 2012;143:872-80</span></p>
<p style="top:72.1pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">78.</span></p>
<p style="top:72.1pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Wilhelm W, Kreuer S. The place for</span></p>
<p style="top:83.1pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">short-acting opioids: special emphasis on</span></p>
<p style="top:94.0pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">remifentanil. Crit Care 2008;12:S5</span></p>
<p style="top:108.0pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">79.</span></p>
<p style="top:108.0pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Rajewski RA, Stella VJ. Pharmaceutical</span></p>
<p style="top:118.9pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">applications of cyclodextrins. 2. In vivo</span></p>
<p style="top:129.9pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">drug delivery. J Pharm Sci</span></p>
<p style="top:140.8pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">1996;85:1142-69</span></p>
<p style="top:154.8pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">80.</span></p>
<p style="top:154.8pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Irie T, Uekama K. Pharmaceutical</span></p>
<p style="top:165.7pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">applications of cyclodextrins. III.</span></p>
<p style="top:176.7pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Toxicological issues and safety evaluation.</span></p>
<p style="top:187.7pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">J Pharm Sci 1997;86:147-62</span></p>
<p style="top:201.6pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">81.</span></p>
<p style="top:201.6pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Hajak G, Rodenbeck A, Voderholzer U,</span></p>
<p style="top:212.6pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">et al. Doxepin in the treatment of</span></p>
<p style="top:223.5pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">primary insomnia: a placebo-controlled,</span></p>
<p style="top:234.5pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">double-blind, polysomnographic study.</span></p>
<p style="top:245.4pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">J Clin Psychiatry 2001;62:453-63</span></p>
<p style="top:259.4pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">82.</span></p>
<p style="top:259.4pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Drake LA, Fallon JD, Sober A. Relief of</span></p>
<p style="top:270.3pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">pruritus in patients with atopic dermatitis</span></p>
<p style="top:281.3pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">after treatment with topical doxepin</span></p>
<p style="top:292.3pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">cream. J Am Acad Dermatol</span></p>
<p style="top:303.2pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">1994;31:613-16</span></p>
<p style="top:317.1pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">83.</span></p>
<p style="top:317.1pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Gharzi M, Dolatabadi HRD, Reisi P,</span></p>
<p style="top:328.1pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Javanmard SH. Effects of different doses</span></p>
<p style="top:339.1pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">of doxepin on passive avoidance learning</span></p>
<p style="top:350.0pt;left:409.5pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">in rats. Adv Biomed Res 2013;2:66</span></p>
<p style="top:372.4pt;left:387.6pt;line-height:10.0pt"><span style="font-family:AdvP5D4A,serif;font-size:10.0pt">Affiliation</span></p>
<p style="top:384.9pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Renan G Brito</span><sup><span style="font-family:AdvP5D8B,serif;font-size:5.6pt">1,2</span></sup><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">, Adriano AS Ara</span><span style="font-family:AdvP4C4E59,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">ujo</span><sup><span style="font-family:AdvP5D8B,serif;font-size:5.6pt">3</span></sup><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">,</span></p>
<p style="top:395.9pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Jullyana SS Quintans</span><sup><span style="font-family:AdvP5D8B,serif;font-size:5.6pt">1</span></sup><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">,</span></p>
<p style="top:406.9pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Kathleen A Sluka</span><sup><span style="font-family:AdvP5D8B,serif;font-size:5.6pt">2</span></sup><sup><span style="font-family:AdvP5D8B,serif;font-size:8.0pt"> </span></sup><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">&amp;</span></p>
<p style="top:417.8pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Lucindo J Quintans-J</span><span style="font-family:AdvP4C4E59,serif;font-size:8.0pt">&#xfffd;</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">unior</span><sup><span style="font-family:AdvTIR,serif;font-size:5.6pt">&#x2020;</span></sup><sup><span style="font-family:AdvP5D8B,serif;font-size:5.6pt">1,2</span></sup></p>
<p style="top:427.1pt;left:387.6pt;line-height:5.6pt"><span style="font-family:AdvTIR,serif;font-size:5.6pt">&#x2020;</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Author for correspondence</span></p>
<p style="top:438.0pt;left:387.6pt;line-height:5.6pt"><span style="font-family:AdvP5D8B,serif;font-size:5.6pt">1</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Federal University of Sergipe, Department of</span></p>
<p style="top:450.7pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Physiology, Sa&#x2dc;o Cristo&#xb4;va&#x2dc;o, Sergipe, Brazil</span></p>
<p style="top:461.7pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Fax: +55 79 2105 6640;</span></p>
<p style="top:472.6pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">E-mail: lucindojr@gmail.com;</span></p>
<p style="top:483.6pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">lucindo@pq.cnpq.br</span></p>
<p style="top:492.9pt;left:387.6pt;line-height:5.6pt"><span style="font-family:AdvP5D8B,serif;font-size:5.6pt">2</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">University of Iowa, Carver College of Medicine,</span></p>
<p style="top:505.5pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Physical Therapy and Rehabilitation Science,</span></p>
<p style="top:516.4pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Iowa City, IA, USA</span></p>
<p style="top:525.7pt;left:387.6pt;line-height:5.6pt"><span style="font-family:AdvP5D8B,serif;font-size:5.6pt">3</span><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Federal University of Sergipe, Department of</span></p>
<p style="top:538.4pt;left:387.6pt;line-height:8.0pt"><span style="font-family:AdvP5D8B,serif;font-size:8.0pt">Pharmacy, Sa&#x2dc;o Cristo&#xb4;va&#x2dc;o, Sergipe, Brazil</span></p>
<p style="top:41.8pt;left:49.0pt;line-height:8.5pt"><span style="font-family:AdvP4B06EF,serif;font-size:8.5pt">R. G. Brito</span><span style="font-family:AdvP47DAD7,serif;font-size:8.5pt"> et al.</span></p>
<p style="top:749.3pt;left:49.0pt;line-height:9.0pt"><span style="font-family:AdvP4B06EF,serif;font-size:9.0pt">12</span></p>
<p style="top:750.9pt;left:236.6pt;line-height:7.0pt"><span style="font-family:AdvP4194AB,serif;font-size:7.0pt">Expert Opin. Drug Deliv.</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt"> (2015)</span><span style="font-family:AdvP6A50,serif;font-size:7.0pt"> 12</span><span style="font-family:AdvP45A506,serif;font-size:7.0pt">(10)</span></p>
<p style="top:558.4pt;left:-0.4pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">Expert Opin. Drug Deliv. Downloaded from informahealthcare.com by Nandini Loganathan on 07/10/15</span></p>
<p style="top:426.0pt;left:7.6pt;line-height:8.0pt"><span style="font-family:Times New Roman,serif;font-size:8.0pt">For personal use only.</span></p>
<img style="position:absolute;transform:matrix(1.3333334,0,-0,1.3333334,674.7067,1021.9347)" src="data:image/png;base64,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">
<p style="top:785.5pt;left:50.0pt;line-height:4.0pt"><span style="font-family:Arial,sans-serif;font-size:4.0pt;color:#b3b3b3">View publication stats</span></p>

</div>
